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Outline of the thesis
Essential hypertension is a common disorder, which affects 25-30% of the adult
population, and up to 60-70% of those beyond the seventh decade of life.'
Although seemingly symptomless it is in fact a silent killer, because it is by far the
most important risk factor worldwide for total mortality. Its impact on the global
burden of disease is higher than e.g. smoking, and alcohol.^
Although the clinical implications of hypertension are substantial our
understanding of the disorder is strikingly low. The majority of patients with
hypertension (*95%) suffers from primary or essential hypertension, which is an
euphemism for not knowing the exact cause of the increased pressure. It is widely
believed that essential hypertension is a multifactorial disorder caused by
heterogeneous genetic and environmental factors. Hypertension aggregates with
other cardiovascular risk factors, such as abdominal obesity, dyslipidemia, glucose
intolerance, hyperinsulinemia, and hyperuricemia, possibly because of a common
underlying cause.'
Already in 1831, Richard Bright stated that hypertension is a kidney disease.
Accumulating evidence indeed shows that the kidney plays a central role in the
pathophysiology of essential hypertension. Renal transplantation studies both in
rats and in men, showed that transplantation of a kidney from a normotensive
donor reduces the blood pressure in the recipient.^ Guyton and coworkers, in a
series of neat experiments, showed that long-term blood pressure control is
regulated by the pressure-natriuresis mechanism. Blood pressure rises when the
kidney requires a higher than usual blood pressure to maintain extracellular fluid
volume within normal limits.^ They demonstrated that in essential hypertension,
pressure-natriuresis is abnormal because sodium excretion is the same as in
normotension despite increased arterial pressure. Considerable evidence
indicates that this resetting of the pressure-natriuresis curve plays a key role in
causing hypertension, and is not merely an adaptation to increased blood
pressure. Because human essential hypertension is a heterogeneous disease, it is
likely that multiple neurohumoral and intrarenal defects contribute to abnormal
pressure-natriuresis and increased blood pressure.'
The renin-angiotensin system (RAS) is the principal hormonal system that
modulates both renal hemodynamics, i.e. glomerular filtration rate and renal
blood flow, as well as tubular function. In this way the RAS both directly and
indirectly regulates renal sodium handling. Secretion of renin is primarily
regulated within the kidney by changes in either perfusion pressure or the
delivery of sodium to the macula densa cells located in the distal tubules.
Increased RAS activity shifts the pressure-natriuresis curve to the right, which can
be reversed by blocking the RAS through angiotensin-converting enzyme (ACE)
13
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inhibition or angiotensin II type 1 receptor (AT1R) blockade. As in essential
hypertension the pressure-natriuresis curve is also shifted to the right, it is
tempting to assume that increased RAS activity is (at least partly) responsible for
the increase in blood pressure in essential hypertension/ However, increased RAS
activity is not a pathognomonic finding in essential hypertension as both high-
renin and low-renin forms of hypertension can be distinguished.
More and more evidence indicates that genetic factors play a prominent role in
essential hypertension, and the molecular revolution has initiated an extensive
search into these factors. This also was the major impetus for performing the
studies which are described in this thesis. In chapter 2, the genetic aspects of both
monogenic and essential hypertension are discussed. Furthermore, evolutionary
aspects of blood pressure regulation are highlighted, as these are important to
understand the contemporary epidemic outbreak of hypertension in the
developed and developing world. Lastly, because of the central role of the RAS in
blood pressure regulation, as indicated above, an overview of the RAS as we know
it today, is presented. Since angiotensin II (Angll) is the effector hormone of the
RAS, we were interested in polymorphisms that influence the generation and
effect of this hormone. The mutant D allele of the ACE insertion/deletion (I/D)
polymorphism is associated with higher circulating serum ACE levels^ and
therefore, at least in theory, generates more Angll causing higher blood pressures
and an increased incidence of cardiovascular disorders.' On the other hand, the
mutant T allelp of thp AT1R A1166C, oqlvmqrohism is associated with a hjaher
incidence of cardiovascular abnormalities""' and there is data to show that the
interaction of Angll with the AT1R is altered due to this polymorphism. Taking
these observations into account, our research has focused on the role of these
polymorphisms in modulating the effects of Angll on the kidney and, indirectly,
blood pressure. Chapter 3 addresses the effects of these polymorphisms on blood
pressure in healthy normotensives. As this study indicated that at least the ACE I/D
polymorphism is associated with higher blood pressures in normotensives, we
then became interested in the role of these polymorphisms on blood pressure in a
hypertensive population, which is discussed in chapter 4. Because phenotyping is
very important in studying genotype-phenotype relationships, we chose to use
high quality phenotyping of the blood pressure by means of 24 hour ambulatory
blood pressure monitoring. In chapter 5 the conversion of Angl to Angll was
studied to evaluate whether higher serum ACE levels in D allele carriers and their
increased cardiovascular risk can be explained by increased Angll generation.
Based on earlier studies which indicated that renal function is dependent upon
both RAS activity'' and genetic factors," we set out to assess, as described in
chapter 6, whether the ACE I/D and AT1R A1166C polymorphisms are associated
with impaired renal function in essential hypertension. This is followed, in chapter
7, by a study which investigated whether the AT1R A1166C polymorphism is
associated with altered renal sensitivity to Angll. Because these studies indeed
14
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revealed an increased Angll sensitivity in C allele carriers, two pharmacogenetic
studies were then initiated to study both the acute renal hemodynamic (Chapter
8) and long-term blood pressure (Chapter 9) effects of the AT1R antagonist
losartan in relation to this polymorphism. Finally, in chapter 10, we summarize
and discuss the different findings of our studies.
15
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Introduction
In developed and developing countries, hypertension affects 25-30% of the adult
population, and up to 60-70% of those beyond the seventh decade of life.' It is by
far the most important risk factor for total mortality.' It is now widely recognized
that hypertension is a multifactorial trait caused by a complex combination of
demographic, environmental, and genetic factors.'
There is substantial evidence for genetic influences on blood pressure. For
instance twin studies documented greater concordance of blood pressures of
monozygotic than dizygotic twins," and population studies demonstrate greater
similarity of blood pressure within families than between families.'' This familial
aggregation of blood pressure is not simply attributable to shared environmental
factors since adoption studies show greater concordance of blood pressure
among biological siblings than adoptive siblings living in the same household.*'
Genetic heritability in blood pressure resemblances varies between 25% in
pedigree studies to 65% in twin studies." Nevertheless, part of the familial
concordance can be explained by a shared environment, mostly dietary In
nature.'" Finally, single genes can impart large effects on blood pressure as
demonstrated by rare Mendelian forms of high and low blood pressure."
The inheritance of hypertension has been debated for many years ever since
Pickering and Platt clashed over the distribution of blood pressure in the
population. Pickering argued that blood pressure, like other traits such as height
or weight, was continuously distributed'^ whereas Platt believed that the
distribution was bimodal." Their views implied rather different inheritance
mechanisms: on the one hand multiple genes and on the other a single (or major)
gene controlling blood pressure. Pickering's polygenic model for blood pressure
in the general population has now been widely accepted. Indeed, the model of
multiple susceptibility genes with environmental interaction is one that can be
applied to many common complex diseases including asthma, diabetes and
ischemic heart disease. However, there are still some familial forms of
hypertension which are inherited as single-gene disorders, but they constitute
only a small proportion of all cases.
Although it is not well known which genes influence blood pressure variability
between individuals, family studies show that the 'inherited part' of blood
pressure ranges over the whole spectrum from low-normal blood pressure to
severe hypertension. Next to this, 'hypertensinogenic' factors like obesitas, insulin
resistance, alcohol, salt, etc. play a role. The actual blood pressure of a subject is
the sum of a more or less fixed, inherited part and a more variable part that is
influenced by the hypertensinogenic factors.
19
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Besides the independent effects of genetic and environmental factors on blood
pressure height, interactions between these factors are present. The outcome of
these effects influences intermediate phenotypes, like sympathetic activity, the
renin-angiotensin system (RAS), the kallikrein-kinin system, endothelial factors,
etc. These phenotypes influence, on their turn, other intermediate phenotypes
like sodium-excretion, vascular reactivity and cardial contractility. The sum of
these and many other intermediate phenotypes in the end defines total
peripheral resistance and cardiac output and as a resultant the actual blood
pressure (Figure 2.1). If we assume that every intermediate phenotype influencing
blood pressure is by itself dependent upon one or more genes, one can see the
enormous amount of genes involved in blood pressure regulation.
Genetic
factors
Environmental
factors
Intermediate
phenotype A
Intermediate
phenotype B
BIDOD
PRESSURE
Flgurt 2.1. Factors influencing blood pressure.
Evolutionary aspects
The common disease:common variant hypothesis speculates that the gene
variation underlying susceptibility to common heritable diseases existed within
the founding population of contemporary humans^'*^ As this population
expanded outwards from Africa, the ancient gene variation of these founders has
been distributed globally. The disease susceptibility alleles included among this
variation have persisted at moderate frequency, presumably because they have
been neutral during the natural selection process, at least until the recent
appearance of technological advancements creating the environment required
for disease manifestation. This hypothesis is supported by evidence that the
modern global population is the progeny of a recent (a 100,000 years) dispersal of
a single sub-Saharan African founding population of relatively small size that
replaced all other hominoids. The strongest genetic evidence in favor of this
recent African origin/replacement (RAOR) scenario arises from studies of sequence
variation in the mitochondrial DNA and in the non-recombining region of the Y
chromosome (NRY). Mitochondrial DNA reflects a matrilineal inheritance, whereas
the NRY reflects a patrilineal inheritance. Investigation of both mitochondrial DNA
and NRY variation indicates a single phylogenetic tree down which contemporary
20
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humans descended from common ancestors in Africa about 35 to 200,000 years
ago.'*" Because these 2 sources reflect separate genetic lineages, concordance
between them has provided high credibility for the RAOR model of contemporary
human origins.''' Estimates of the effective size of the ancestral population from
which contemporary humans are descended indicate a number of about
10,000.'* " This relatively small number fits well in the common diseasexommon
variant hypothesis, because recent expansion of the human population to its
current size of 6 billion from a small group of founders implies substantial sharing
of alleles, including those responsible for common diseases.'"'
Already forty years ago, Neel hypothesized that common complex genetic
diseases of 'civilization' including obesity, hypertension, and diabetes type 2
(DMII) result from the exposure of a thrifty genotype to a prodigal environment.'"'
According to this concept, diseases of civilization result from a discordance
between certain features of our present-day environment and our genetic make-
up which evolved over time to fit the life of Paleolithic humans. This lifestyle
involved a great deal of physical activity and a diet high in protein and potassium
and low in fat and sodium. Due to the irregular availability of food, short periods
of feast alternated with relatively longer periods of hunger. It is possible that many
metabolic features of modern humans originally evolved as adaptation to such a
lifestyle, and these features are now etiologic to modem diseases such as obesity,
hypertension, and DMII. Thus, individuals who are genetically predisposed to low
metabolic rates, sodium conservation, and rapid mobilization of insulin in
response to a carbohydrate challenge would be genetically predisposed to
obesity, salt-sensitive hypertension, and DMII when faced with a sedentary
lifestyle and a high salt, energy-dense diet.
The cultural changes that have occurred over the past 10,000 years have far
outpaced any possible genetic adaptations, especially since much of this cultural
change has occurred only recently following to the first industrial revolution 200
years ago.^' The extremely slow pace of genetic evolution is revealed by
biomolecular evidence indicating that humans and chimpanzees differ genetically
by only 1.6%, even though the hominoid-pongoid divergence occurred 7 million
years ago." If we assume that present-day hominoids are still faced with the same
selection pressures that applied to humans during the many millennia of
evolution, there are good reasons to believe that the genes relevant to the thrifty
genotype are highly conserved in these species and probably represent the
'original version' of these genes common to early hominoids. Thus, individuals or
populations in whom a large proportion of these ancestral thrifty genes remains
conserved are more likely to express the disease phenotype on exposure to a rich
environment than individuals or populations in whom less thrifty variants of these
genes have recently developed." The idea of the thrifty genotype has substantial
implications on our approach towards understanding and studying the genetic
basis of these complex diseases. Currently, most investigators are attempting to
21
Chapter 2
find the mutations or genetic defects responsible for obesity, hypertension, or
DMII. The thrifty-genotype hypothesis, however, implies that the genetic basis for
these diseases is not to be found in recent mutations or genetic defects but rather
lies in the conservation of the ancestral version of the relevant genes. Thus, while
the original version of the thrifty genotype may confer increased susceptibility to
hypertension or obesity, recent mutations resulting in a loss of thriftiness would
protect the carrier from the deleterious effects of the current Western diet, rich in
carbohydrates and salt. A fine example of this principle was recently provided by
the study of the angiotensinogen (AGT) gene in hypertension. Jeunemaitre et al.
reported a genetic variant of this gene, involving the substitution of threonine (T)
for methionine (M) at codon 235, to be more common in hypertensives than in
normotensive controls.'* Assuming that the rarer T allele associated with
hypertension was the novel form, they termed this variant M235T, suggesting that
M is the ancestral allele and T the mutation. However, subsequent studies in
Japanese" and African-Americans-"' have revealed that this mutation is much
more common in these populations than in whites, and other investigators have
found this variant to be even more common in Nigerians, in whom it approaches a
frequency above 90%/' Since the ancestors of present-day whites are believed to
have migrated from Africa, it soon became apparent that the T at codon 235,
associated with hypertension, is the wild type whereas the M allele, associated
with normotension, is the recent mutant. This idea was further supported by the
demonstration that the T at codon 235 is present in a variety of primates,
including man's closest relative, the chimpanzee.^ This would indeed be in line
with the concept that the original phylogenetically ancestral version of the AGT
gene is associated with hypertension, whereas the recent mutation somehow
decreases the risk for developing high blood pressure. It does not seem illogical to
assume that this concept also holds for the many other genes involved in
hypertension.
Genetic studies in hypertension
i
Three different approaches have been executed to investigate the genetic factors
that contribute to hypertension: studies on rare genetic syndromes, linkage
studies, and association studies.
Studies on rare genetic syndromes
With positional cloning disease genes are located using genome mapping
techniques with only minimal information about the function of the gene or the
basic biochemical defect. It uses genome-wide scans and linkage analyses in
families affected with a disease to define an initial candidate region, which then
may be narrowed considerably using fine mapping techniques. Screening for
22
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mutations in affected individuals may pinpoint the causative gene. With this
method the causative mutations that underlie several monogenic or Mendelian
disorders were identified. The advantage of this approach is that when a positive
result is obtained, it provides an unambiguous explanation of the cause of the
syndrome under investigation and often yields basic insights into patho-
physiology. While the number of individuals with these syndromes will always be
small, the implications of the findings can apply to much larger groups.
Linkage studies
In linkage studies statistical methods are used to locate genes contributing to
disease or other phenotypes to approximate chromosomal regions. Genetic
linkage analysis exploits the tendency of short chromosomal segments to be
inherited intact from parents to offspring. This means that if a marker locus and a
trait-influencing locus are physically close on a chromosome, the probability of a
recombination event occurring between them during meiosis is low, and the two
loci tend to be inherited together more often than would be expected from
independent segregation. Genome-wide linkage analyses have identified
chromosomal regions that influence interindividual variation in blood pressure
levels or risk for essential hypertension on almost all different chromosomes
(Table 2.1). Especially chromosomes 2,3,7,15 and 17 repeatedly showed evidence
for linkage with hypertension. Nevertheless, the specific genes and gene
variations responsible for the observed effects remain to be identified. Candidate
gene linkage analyses, in which the linkage of candidate genes with a specific
phenotype is studied, have suggested that the genes for AGT,^ a-adducin,"
angiotensin-converting enzyme (ACE),*"' and angiotensin II type 1 receptor
(ATlRp are involved in the pathogenesis of essential hypertension.
Association studies
Once their chromosomal position has been determined by linkage studies,
association (or case-control) studies are used for identifying genes implicated in
specific phenotypes. These are well suited to genetic studies of complex traits
because they can detect weak-to-moderate effects of genes on a trait."
Association methods test for differences in allele frequencies at a marker locus
between groups of individuals (e.g., cases and controls) to implicate specific
alleles of that locus in contributing to a specific phenotype. True association
between a marker locus and a disease locus may arise for two reasons: 1) the
marker itself directly contributes to the disease; and 2) alleles at the marker locus
are in linkage disequilibrium with alleles at the disease locus. Linkage
disequilibrium is said to be present when certain haplotypes (i.e., linear
arrangement of alleles at different loci on the same chromosome) occur more
frequently in a population than would be expected by chance, based on the
23
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assumption of independent occurrence of alleles at each locus. Loose linkage
between two loci will not result in an association in the population because
recombination will occur with a sufficiently high frequency in the population to
return alleles quickly to equilibrium. However, for tightly linked loci, linkage
disequilibrium can persist over many generations, when one assumes a low
mutation rate of both loci. The present-day population reflects the action of
recombination through many past generations, and linkage disequilibrium
mapping seeks to take advantage of this historical recombination to localize
genes that influence traits of interest.
Table 2.1. Chromosomes linked to Interindividual blood pressure variations or risk for essential
hypertension.
Chromosome
1
2
3
S
6
7
8
10
11
12
14
U
19
R«f«r*nc«(f)
196-198
198-204
200,201,205,206
198,201
197,207
197,198,201,208
198 - ; • • . -< i ; ;
2 0 1
200,206
197,200
199 •"•
197,206,209,210
206
70-72, 206
70,211
198,200,201
Polymorphisms
Approximately 90% of all variations in the human genome occur as single base
pair substitutions.''' These single nucleotide polymorphisms (SNPs) by definition
have a minor allele frequency greater than 1%. This variation arises through a
single mutation event in the history of the population. SNPs, as well as the less
frequently occurring insertions and deletions, generally have two alleles in the
population at large. Although in theory more than one substitution could occur at
any single nucleotide, resulting in the formation of more than two alleles, the
probability of such an event is extremely low. Consequently, SNPs are often
considered and referred to as di (or bi)-allelic markers, representing the ancestral
or wild type and the (mutant) variant form. The average number of nucleotide
differences between a random pair of chromosomes drawn from the population is
24
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estimated at 1/1000 base pairs.*"* However, this estimate is likely to vary
considerably across the genome. Indeed, a lower frequency of polymorphism is
observed in coding regions (exons) versus non-coding regions (introns). This is
presumably because of the effect of selection pressure to remove
disadvantageous alleles. The majority of DNA sequence variations between
human individuals is represented within populations.^ Comparisons among
populations result in the addition of only a fractional increase in SNP diversity,
although allele frequencies may differ across populations. This pattern reflects the
fact that all human populations share a relatively recent common genetic heritage
and that most common variation arose before the expansion of the human
species into distinct contemporary populations.
Mendelian forms of hypertension
Molecular genetic studies have identified mutations in several genes in 6
Mendelian forms of hypertension (Table 2.2). These genes typically impart very
large effects on blood pressure. Given the diversity of physiologic systems that
affect blood pressure, it is perhaps surprising that the mutated gene products in
almost all cases act in the same physiologic pathway in the kidney: altering net
renal salt reabsorption. Each of these conditions features salt sensitivity with
increased sodium and volume reabsorption by the kidney and low plasma renin
activity. Furthermore, Mendelian forms of hypotension (e.g., Gitelman and Bartter
syndrome) have been identified that increased our knowledge of blood pressure
regulation. These syndromes will not be discussed here.
Glucocorticoid-remediablealdosteronism
Glucocorticoid-remediable aldosteronism (GRA) is an autosomal dominant trait,
featuring early onset of hypertension with normal or elevated aldosterone levels
despite suppressed plasma renin activity.^ Hypokalemia and metabolic alkalosis
are variable associated findings," although normokalemia as a typical finding is
also reported.'"' High levels of the abnormal adrenal steroids 18-oxocortisol and
18-hydroxycortisol are a pathognomonic finding. The hallmark of this disease,
however, is that exogenous glucocorticoids completely suppress aldosterone
secretion.
GRA is caused by a gene duplication arising by unequal crossing over between
two closely related genes involved in adrenal steroid biosynthesis. These genes
encode aldosterone synthase (the rate limiting enzyme for aldosterone
biosynthesis in adrenal glomerulosa) and steroid 11(J-hydroxylase, an enzyme
involved in cortisol biosynthesis, in the adrenal fasciculata where their expression
is regulated by adrenocorticotropic hormone (ACTH)."'•« The resulting chimeric
gene encodes a protein with aldosterone synthase enzymatic activity, of which
25
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the expression is regulated by ACTH. Aldosterone synthase activity is thus
expressed ectopically in the adrenal fasciculata under control of ACTH rather than
angiotensin II (Angll), its normal hormonal regulator. As a consequence,
aldosterone secretion becomes inexorably linked to cortisol secretion, and
maintenance of normal cortisol levels results in constitutive aldosterone secretion,
which leads to an expanded plasma volume, hypertension, and suppression of
renin. Moreover, the increased lumen-negative potential resulting from increased
electrogenic Na* reabsorption increases the driving force for secretion of K* and
H\ accounting for the development of hypokalemia and metabolic alkalosis.
Table 2.2. Monogenic forms of hypertension.
Syndrome
Glucocorticoid remediable
•Idosteronism (GRA)
Apparent mlneralocortlcoid
txcass (AME)
Hypertension exacerbated by
Phonotyp#
HT, K*. alkalosis,
PRAi, aldo
suppressible by
dexamethasone
HT.K-l.aldoi,
alkalosis. PRAi,
suppressible by
spironolactone
HT,K-i,aldoi,
Liddle syndrome
Pseudohypoa Idosteronism
type 2 (Gordon's syndrome)
Hypertension with
brachydactyly
HT, K4,aldoi ,
alkalosis, PRAi
HT,K-t,PRAi,
normal renal
function
HT, brachydactyly
Mutation
Chimerical gene
containing promoter
area of aldo-synthase
and coding region
l i pH (dominant)
Absence of 11 |»HSD
(recessive)
Missense mutation
IMIIieldltM.UllK.UIU
receptor (dominant)
Mutations of p or y
subunit of ENaC
(dominant)
Mutations in either of
WNK1 orWNK4
(dominant)
Genes mapped to
12pl 1.2-12.2
(dominant)
Mechanism
Chimerical enzyme
regulated by ACTH
Impaired conversion
of cortisol (activates
MR) to cortisone
(inactive at MR)
Steroids without 21-
nyaroxyi group
(progesterone) and
spironolactone
stimulate mutant
mineralocorticoid
receptor
Increased ENaC
activity due to
reduced ENaC
clearance
Volume-expanded
HT, probably due to
increased renal
tubular sodium
reabsorption
Unknown
HT: hypertension; PRA: plasma renin activity; aldo: aldosterone; ENaC: epithelial sodium channel;
WNK1 /4: serine-threonine kinase 'with no lysine' type 1 /4; MR: mineralocorticoid receptor
A wide range of blood pressure levels (including normotension) is found in
affected GRA subjects.** However, these differences are not related to
environmental factors such as sodium intake or differences in steroid levels. It is
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hypothesized that chimeric gene expression is variable, with low blood pressure
subjects having reduced gene expression. Furthermore, it is likely that the wide
range in blood pressure levels in affected subjects involves interaction of other
systems which control blood pressure. This hypothesis is supported by studies in
two kindreds suggesting that blood pressure levels are reciprocally related to
levels of urinary kallikrein excretion.^
Syndrome of apparent mineralocorticoid excess
Patients with the apparent mineralocorticoid excess (AME) syndrome have the
same phenotypical findings as patients consuming large amounts of licorice:
volume expansion, low renin, low aldosterone, salt-sensitive (early onset)
hypertension, with sometimes metabolic alkalosis and hypokalemia. No abnormal
urinary steroid metabolites can be found. The hypertension can be well treated
with thiazide diuretics, or spironolactone. As aldosterone is low or sometimes
even undectable the response to the mineralocorticoid receptor (MR) antagonist
spironolactone suggests the presence of another circulating mineralocorticoid."
While biochemical investigation failed to identify an abnormal steroid in the
circulation, affected patients showed impaired conversion of cortisol to cortisone
due to absence of the enzyme 11|5-hydroxysteroid dehydrogenase (11|IHSD).**
The significance of this finding remained obscure until the cloning of the MR.**- /n
vivo, cortisol circulates at concentrations up to 1000-fold higher than aldosterone,
but almost all MR activation /'n v/vo is mediated by aldosterone. However, the
specificity of the MR for aldosterone /n wVo is mediated indirectly by 11J1HSD
which 'protects' the MR from cortisol by metabolizing it to cortisone, which does
not activate the MR."*"' In AME, the absence of this enzyme allows cortisol to
activate the MR, resulting in hypertension mediated by increased epithelial
sodium channel (ENaC) activity. Confirmation of the pathogenesis of AME came
with the cloning of 1ipHSD-2. This gene, expressed in the same cells of the
nephron that express ENaC, shows homozygous loss-of-function mutations in
AME patients."**
These findings explain the pathogenesis of hypertension in AME. Chronic
ingestion of large quantities of natural licorice results in hypertension with
suppressed renin and aldosterone due to the action of a licorice metabolite,
glycerrhetinic acid."' This compound is a potent inhibitor of 11 fiHSD, producing a
phenocopy of AME. Similarly, overproduction of cortisol due to adenomas of the
adrenal or pituitary glands, or due to inherited loss of the glucocorticoid
receptor" is also complicated by hypertension associated with low renin and
aldosterone levels. The hypertension in these settings may be explained by the
high circulating cortisol levels outstripping the ability of 1ipHSD to convert
cortisol to cortisone, resulting in cortisol-mediated activation of the MR.
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Hypertension exacerbated in pregnancy ;
A mutation in the ligand binding domain of the MR causes an autosomal
dominant form of hypertension that is markedly accelerated in pregnancy.*" The
missense mutation, MR S81OL, was found in a single patient during a systematic
screen of the MR in patients with early onset hypertension. Examination of the
patient's family demonstrated that 81OL carriers all developed hypertension
before age 20, a finding absent among their wild-type relatives. Biochemical
investigation of the mutant receptor demonstrated partial activation in the
absence of added steroid, but otherwise normal activation by aldosterone.
Surprisingly, however, compounds that normally bind, but do not activate the MR
are all potent agonists of the mutant receptor. This includes steroids lacking 21-
hydroxyl groups, such as progesterone, and clinically used antagonists of the MR,
such as spironolactone. Since progesterone levels rise 100-fold during pregnancy,
this observation suggested that patients harboring 81 OL might develop severe
hypertension in pregnancy. Indeed, all pregnancies among patients harboring this
mutation have been complicated by dramatic acceleration of hypertension
associated with complete suppression of the RAS.™
The mechanism by which 81 OL allows MR activation by steroids lacking 21-
hydroxyl groups has been examined by molecular modeling and site-directed
mutagenesis. The results demonstrate that the 81 OL residue in helix 5 of the
ligand binding domain makes a new Van der Waals interaction with A773 in helix
3, and that this interaction eliminates the requirement for the 21-hydroxyl group
of aldosterone to interact with N770 in helix 3. This helix 5-helix 3 interaction is
highly conserved among diverse nuclear hormone receptors, suggesting its
general role in receptor activation.™
Liddle syndrome
Liddle syndrome is characterized by autosomal dominant transmission of early
onset hypertension associated with hypokalemic alkalosis, suppressed plasma
renin activity, and low plasma aldosterone levels. Patients do not respond to
spironolactone, but are well treatable with thiazide diuretics and triamterene.
The disease is caused by mutations in either the p or the y subunit of the
amiloride- and triamterene-sensitive ENaC that delete their cytoplasmic C
termini.'''•" These mutations result in increased ENaC activity," largely
attributable to an increase in the number of channels at the cell surface.*" Rare
missense mutations in patients identified a segment in the C termini, PPPXY, that
when mutated gave the same phenotype." ** Systematic site-directed
mutagenesis of channel subunits indicates that mutations of any of these residues
yields an increased number of channels at the cell surface and hence, increased
channel activity." The increased number of channels is due to reduced clearance
of ENaC from the cell surface with a dramatically longer half-life.^
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Two lines of inquiry have suggested mechanisms for the prolonged half-life of
mutant channels. Inhibition of endocytosis via clathrin-coated pits by dominant-
negative dynamin induces a phenocopy of the electrophysiologic phenotype of
Liddle syndrome, increasing Na* current by markedly prolonging the half-life of
ENaC at the cell surface.** In parallel, two WW domain-containing proteins, Nedd4-
1 " and Nedd4-2*° have been identified that specifically interact with the PPPXY
sequence of ENaC subunits. These proteins have ubiquitin ligase domains,
suggesting that interaction with ENaC subunits leads to their ubiquitination,
targeting ENaC for degradation. Consistent with this proposal, expression of
dominant-negative Xenopus*' or mammalian Nedd4-2,<* containing the WW
domain without the ubiquitin ligase domain, also prolongs the half-life of wild-
type ENaC. These findings indicate that an increased number of ENaC at the cell
surface is sufficient to produce hypertension in humans.
Pseudohypoaldosteronism type II
Pseudohypoaldosteronism type II (PHAII), also known as Gordon hyperkalemia-
hypertension syndrome, is an autosomal dominant disease featuring
hypertension with hyperkalemia despite normal glomerular filtration rate. Mild
hyperchloremia, renal tubular acidosis, and suppressed plasma renin activity are
variable associated findings. The clinical features of this disease are chloride
dependent and completely corrected with thiazide diuretics, specific antagonists
of the Na-CI cotransporter (NCCT) of the distal convoluted tubule."*''
After this syndrome had been mapped to chromosome 1q31-42, 12p13, and
17p11-q21,"** it was shown that PHAII is caused by mutations in either of two
serine-threonine kinases, WNK1 and WNK4 (WNK: with / » lysine (/fl at a key
catalytic residue). PHAII-causing mutations in WNK1 are large deletions in the first
intron of the gene that appear to increase WNK1 expression. Mutations in WNK4
are missense mutations in highly conserved segments remote from the kinase
domain.*'
Both kinases are present in the kidney, with their expression being confined to the
distal convoluted tubule, connecting tubule, and collecting duct. These nephron
segments are known to play a key role in the regulation of salt, K\ and pH
homeostasis.^ These findings implicate WNK1 and WNK4 in a previously
unrecognized signaling pathway that regulates the balance between Cl
reabsorption versus K* and H* secretion.
The Cl dependence of PHAII phenotypes, their sensitivity to thiazide diuretics, and
the observation that they constitute a 'mirror image' of the phenotypes resulting
from loss-of-function mutations in the thiazide-sensitive NCCT causing Gitelman's
syndrome/* suggest that PHAII could result from increased activity of the NCCT
due either to loss of normal inhibition or constitutive activation by mutant WNK
kinases. Wild-type WNK4 inhibits NCCT-mediated Na'-influx by reducing
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membrane expression of the cotransporter and WNK4 mutations found in
patients with PHAII abrogate this inhibitory function.**
Linkage of PHAII to chromosome 1 in other families" as well as the absence of
mutations in WNK1 and WNK4 in many PHAII kindreds indicate that there must be
one or more yet unidentified PHAII genes.
Like patients with PHAII, many individuals with common, essential hypertension
have low plasma renin activity and respond well to thiazide diuretics, raising the
possibility that variants in WNK1 and WNK4 may underlie blood pressure variation
in the general population. Indeed, the WNK4 gene lies only 1 Mb from locus
D17S1299, the site showing the strongest linkage to blood pressure variation in
the Framingham Heart Study population.™ This same chromosome segment has
suggested linkage to hypertension in two other studies."" It will be of interest to
determine whether variants that alter WNK4 function account for this linkage.
Hypertension with brachydactyly
In 1973, Bilginturan described a Turkish family that suffered from brachydactyly
(type E) and severe hypertension/' The inheritance is autosomal dominant with
100% co-segregation of both phenotypes. The condition resembles essential
hypertension. Renin, aldosterone, and norepinephrine responses are normal and
no salt sensitivity is present.'* The response to antihypertensive drugs is
unremarkable." Another feature is diminished baroreflex sensitivity with
markedly impaired blood pressure buffering.'* Furthermore, the ventrolateral
medulla may be compromised in these patients, because neurovascular
anomalies are a regular finding." The gene(s) for this disease are mapped to
chromosome 12p11.2-12.2/" Interestingly, the same locus was recently mapped in
Chinese families with essential hypertension/'The 3-centimorgan region contains
three candidate genes: the ATP-dependent potassium channel Kir6.1, its regulator
the sulfonyl urea receptor SUR2, and the phosphodiesterase PDE3A.*° Screening
of the coding regions revealed that none of these candidate genes harbor obvious
mutations."' Gene expression and physiological studies did not yield convincing
results as well, making these genes unlikely to be the causative ones.*> Affected
subjects show a rearrangement on chromosome 12p. The rearrangement is
complex in that a deletion, reinsertion, and inversion have occurred.^ These
findings indicate that probably more than one gene is responsible for the complex
phenotype.
Other monogenic syndromes
Besides the syndromes discussed above in which hypertension is the most
prominent phenotype, several other familial syndromes have been described in
which hypertension is one of the phenotypes: pheochromocytoma due to
multiple endocrine neoplasia type MB (MEN-IIB) syndrome, Cushing syndrome.
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Conn syndrome, renal artery stenosis due to fibromuscular dysplasia, congenital
adrenal hyperplasia, and Bardet-Biedl syndrome.
Essential hypertension
In contrast with the Mendelian forms of hypertension discussed above, essential
hypertension is a polygenetic disorder. No major gene which could explain most
of the genetic component of the disorder seems to exist. On the contrary, several
genes have been found, which all play a minor role in the total genetic
component. These minor effects can probably be explained by the many
regulatory mechanisms that are involved in blood pressure regulation, whereby
the effects of a 'disturbing' gene can be easily compensated for by other
homeostatic systems. Association studies are the most frequently used tool in the
search for genes involved in essential hypertension. However, a positive
association of certain polymorphisms with (intermediate) phenotypes do not
mean that there is a causa/ explanation for the relation between gene and
phenotype, but rather indicate that there is a statististical re/af/on between them.
Further studies are then needed to exactly elucidate the pathophysiology
between the genetic mutation and the phenotype.
In this chapter we will mainly focus at polymorphisms of the RAS, but
polymorphisms in several other blood pressure regulating genes have been
described that showed associations with hypertension: u-adducin,-"' G-protein
beta3-subunit,^ endothelial nitric oxide synthase," beta2-adrenergic receptor,"
and beta-subunit of the epithelial sodium channel."
Renin-angiotensin system
The RAS, a complex cascade of proteases, is well known for its regulation of blood
pressure and fluid homeostasis. The enzymatic cascade by which Angll is
produced starts with renin, an aspartyl protease, secreted by myoepitheloid cells
of the glomerular afferent arteriole, which cleaves AGT to form the decapeptide
Angl (Figure 2.2). Angl is then further cleaved by ACE, a 170-kd dipeptidyl
carboxypeptidase, to produce the octapeptide Angll, the physiologically active
component of the system.
ACE is primarily attached to cell membranes and contains two catalytic domains,
which differ in their function. Whereas the C-terminal site is responsible for
approximately 75% of Angll-forming capacity, the N-terminal domain has major
functions in the processing of bradykinin, neurotensin, and substance P. In
addition, a testicular form (90 kd, with only one catalytic domain), which has an
important function in sperm differentiation, has been identified.'* In contrast to
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renin secretion, which is an endocrine process, ACE is largely responsible for Angl-
II conversion. The enzyme is expressed in high concentrations on the luminal
surface of vascular endothelial cells, from where it is shed into the plasma by
posttranslational proteolytic cleavage at such a high rate that in the systemic
circulation, renin, rather than ACE availability, is the rate-limiting factor for the
production of Angll.»"*> However, as shown by Danser et al., the greatest fraction
of Angll is formed within the tissues, where baseline ACE activity is much lower,
but where it can be increased by enhanced expression on smooth muscle or
inflammatory cells, as well as fibroblasts.*' ACE also inactivates bradykinin, a
peptide able to promote the release of important vascular mediators, including
nitric oxide, prostacyclin, and tissue plasminogen activator.* In this way, ACE has
broad-ranging effects for the entire vascular homeostasis.
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Figure 2.2. The renin-angiotensin system. The classic cascade of the renin-angiotensin system is
shown in bold. Alternative side roads of the system is indicated by dotted arrows. ACE:
angiotensin-converting enzyme. CAGE: chymostatin-sensitive angiotensin ll-generating
enzyme, t-PA: tissue plasminogen activator, AT1R: angiotensin II type 1 receptor, AT2R:
angiotensin II type 2 receptor, AT4R: angiotensin II type 4 receptor.
Angll, the final effector of the system, causes vasoconstriction directly by
stimulating the AT1R present on the vasculature and indirectly by increasing
sympathetic tone and arginine vasopressin release. Chronically, Angll regulates
blood pressure by modulating renal sodium and water reabsorption directly, by
stimulating AT1R in the kidney, or indirectly, by stimulating the production and
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release of aldosterone from the adrenal glands, or stimulating the sensation of
thirst in the central nervous system.
Further degradation (or processing) of Angll by aminopeptidase A and N produces
Anglll (Ang2-8), and AnglV (Ang3-8), respectively. All these peptides are effective
vasoconstrictors, though Anglll and AnglV are less potent than Ang l l . " "
The actions of Angll result from its binding to specific receptors (ATI R and AT2R),
which are classified by their differential affinities for various non-peptide
antagonists." Though belonging to the same 7-transmembrane domain, G-
protein coupled-receptor family, the functions and signalling mechanisms of
these receptor subtypes are quite different. While AT1R mediates the
vasoconstrictive, proliferative and hypertrophy-promoting effects of Angll, AT2R
stimulation promotes smooth muscle cell growth inhibition and phenotypic
differentiation, vasodilation, natriuresis, and a decrease in extracellular matrix
production.*''" The AT1R preferentially binds Angll, while the AT2R preferentially
binds Anglll.^ These receptors have a wide tissue-specific distribution, and are
both present in the kidney, brain and adrenal glands. In general, AT1Rs are
present in adult cardiovascular tissues, whereas AT2Rs are highly expressed in
fetal life and decline rapidly after birth."" AnglV preferentially interacts with
another ATR: the AT4R. In contrast to the other ATRs this receptor does not seem
to be a G-protein-coupled receptor.'"' It is widely distributed throughout the
body.'*''* Suggested function of the AT4R subtype is (renal) vasodilatation.''"''''
More recently, the presence of a renin receptor has been reported in the heart,
brain, placenta, kidney, and liver.'°° This receptor binds both renin and prorenin
and binding increases the catalytic activity of renin to cleave AGT while rendering
active prorenin.
Tissue RAS can be found in the brain, heart, vasculature, adipose tissue, gonads,
pancreas, placenta, and kidney."" The intrarenal RAS is hypothesized to regulate
systemic blood pressure and various aspects of renal function such as local blood
flow and sodium reabsorption,'^ whereas in the brain it may facilitate
neurotransmission and stimulate vasopressin release and sympathetic
outflow.'03 '04 The tissue RAS concept is strongly supported by observations that
hypertensive patients with normal or even low levels of systemic RAS activity can
be effectively treated with inhibitors of the RAS.'°s
The RAS plays a key role in blood pressure regulation. Genes that encode
components of the RAS are in turn thought to play a role in determining the
genetic susceptibility to hypertension. Up to now, however, consistent
associations between RAS genes and hypertension have been difficult to
demonstrate. The inconsistencies in the association studies may arise from the
inadequate power of small sample sizes, population structure, varying effects of
several disease-predisposing variants, gene-environment interactions, or poor
study design. Each of these factors can hinder the detection of a modest
contribution of an individual locus to hypertension.
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Angiotensinogen
Jeunemaitre et al. showed that the AGT gene locus on chromosome 1q42-q43 was
linked with hypertension in two large series of independently ascertained sibling
pairs.''' Because of this linkage the AGT gene was further scanned, and it was
found that in exon 2 of the gene a missense mutation exists, corresponding to a
change from methionine (M) to threonine (T) at residue 235 of mature AGT. This
M235T polymorphism was significantly associated with essential hypertension.
Also, AGT levels were significantly associated with the genotype, with TT
homozygotes exhibiting approximately 20% higher levels than MM
homozygotes.'* Other studies demonstrated that the 235T alleles are in linkage
disequilibrium with allelic variants in the AGT promoter region (A-6G and A-20G),
which may affect the basal rate of AGT transcription and could account for
phenotypic variation in plasma AGT concentrations.™"*"* In line with the ACE
insertion/deletion (I/D) polymorphism many linkage and association studies
followed which reported conflicting results.'*•'<>••"'
Three meta-analyses concluded that the 235T allele is associated with an
increased risk (20-31%) of hypertension.'" "« The meta-analysis of Staessen et al.
suggested ethnic differences in the overall role of the 235T allele as a
hypertension marker, with positive associations noted for white individuals, but
not for black individuals or Asians.'" In addition, the meta-analysis of Japanese
association studies reported considerable heterogeneity and a wide variation in
the 235T allele frequencies (60-83%) among control subjects.""
As discussed above it is plausible that not the T but the M allele is the mutant
allele and that this mutation somehow is an evolutionary adaptation that
decreases the risk for developing hypertension.
Renin
The human renin gene is located on 1q32, is 12.5 kb in length, and includes 10
exons and 9 introns."'' Renin is the rate-limiting factor of the RAS, plays a crucial
role in the regulation of blood pressure, and its gene may therefore be an
important candidate gene for hypertension. Strikingly enough several linkage
studies showed the opposite."*'^ Several polymorphisms have been found, of
which the Mbol dimorphism repeatedly showed associations with
hypertension.""" However, a Japanese study could not confirm this. '"
Fuchs et al. found a new SNP, C-5312T, located in the regulatory region of the
renin gene. The level of renin transcription was 45% greater with the -5312T
variant than with the -5312C variant.'" Further studies should investigate whether
this polymorphism is associated with plasma renin concentration, and/or
increased blood pressure.
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Angiotensin-converting enzyme
The human ACE gene contains 26 exons and is located on chromosome 17q23.
The structure of the gene suggests the duplication of an ancestral ACE gene.
Exons 4-11 and 17-24, which encode the two homologous domains of the ACE
molecule, are highly similar both in size and in sequence indicating a gene
duplication event during evolution that may have occurred more than 600 million
years ago. Both somatic and testicular ACE are derived from the same gene
through the use of alternative promoters and differential splicing.'-^ The somatic
ACE mRNA is transcribed from exons 1 to 26, but exon 13 is spliced out. The
testicular mRNA is transcribed from exons 13 to 26 using a testis-specific promoter
in intron 12.'" The evolutionary conservation of these two forms of ACE indicates
that both are functionally indispensable.'^
The ACE gene is linked to hypertension in salt-loaded stroke-prone spontaneously
hypertensive rats.'"'™ Using gene targeting, Krege et al. constructed ACE -/- (i.e.
homozygous null) mice and found that the blood pressure values of heterozygous
male mice were 15 to 20 mmHg less than normal.''''' These and other studies
focussed the attention to the human ACE gene as a potential candidate gene in
human hypertension. A total of 78 molecular variants were identified for the
human ACE gene."° Among the 78 polymorphisms, the most prominent one is
the insertion or deletion of a 287-basepair sequence in intron 16 of the gene. This
/A/u element was concluded to be an insertion (rather than a deletion) because its
sequence has closest similarity to other human-specific >4/u elements'" and PCR of
chimpanzee DNA revealed a fragment consistent with a lack of an /l/u."> These
data suggest that the /A/u insertion occurred after the human-chimpanzee split.'"
The intra-individual serum level of ACE is rather stable. However, the inter-
individual variation is high. The ACE I/D polymorphism accounts for 47% of the
total phenotypic variance of serum ACE."'' DD subjects have the highest, ID
subjects intermediate, and II subjects the lowest concentrations of serum ACE. At
least under some conditions, the genotype also is responsible for tissue ACE
activity. Mizuiri et al. determined ACE mRNA in renal biopsy specimens obtained
from healthy kidney donors. DD subjects had the highest number of ACE
transcripts in 100 ng of total RNA, compared to ID and II donors."'' The same
investigators were also able to show similar patterns with regard to intrarenal ACE
protein concentrations.'^ In another study, cardiac ACE activity in patients who
died of noncardiovascular disorders was significantly higher in DD subjects
compared to ID and II subjects.'" Similar data were obtained in lymphocytes."*
Since the I/D polymorphism is an intronic marker, it may be functionally neutral
but in strong linkage disequilibrium with another unidentified functional
mutation within the ACE gene. Zhu et a l . " ' revealed two potential ancestral
breakpoints in a 9-kb region of the 3'-region of the ACE gene that probably
harbours a functional variant. This study suggests that the ACE I/D polymorphism
may not be the functional quantitative trait locus (QTL) and the use of trans-ethnic
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mapping may help isolate the true functional QTL. The different degrees of
linkage disequilibrium between the QTL and I/D polymorphism in different ethnic
populations (e.g., Afro-Caribbeans, Caucasians, Chinese, Japanese) may account
for some negative results in studies of ACE I/D genotype and cardiovascular
disorders.''"'
The finding that serum ACE levels are (partly) genetically determined by the ACE
I/D polymorphism, generated an enormous amount of association studies in
which different cardiovascular phenotypes in different populations were
investigated. Blood pressure and/or hypertension are the best studied
phenotypes in relation to the ACE I/D polymorphism. Zee et al. were the first to
report a positive association of the ACE I/D polymorphism with essential
hypertension in Caucasians.'*' Hereafter, both positive"" and negative''" '**
findings in Caucasians were reported. Two large, population-based studies found
marginally significant linkage and association between blood pressure and the I/D
polymorphism that was restricted to males.™" A genome scan for blood pressure
from the Framingham Heart Study found strong evidence for a QTL on
chromosome 17, close to the ACE gene/" In patients of African descent, however,
the associations of the ACE I/D polymorphism with blood pressure are usually
positive.""' ""• In Asian populations lastly, borderline significant,''" as well as no
associations''*'"''' with hypertension are reported. Higaki et al. found significant
associations between the ACE I/D polymorphism and essential hypertension only
in Japanese men, '" as O'Donnell found in Caucasians."
On the whole, studies in different countries give divergent results. Nevertheless, it
appears that the association between the ACE I/D polymorphism and an increased
risk of hypertension is consistently present in populations of African descent,
while there might be a gender-specific association in Caucasians and Japanese.
Angiotensin II type 1 receptor
The human AT1R gene was cloned in 1992'" and is present as a single copy gene
on human chromosome 3q22.''"' The gene spans more than 55 kb and comprises
5 exons and 4 introns. The entire coding region is located within exon 5.'**.is5 The
gene is found to be highly polymorphic. Bonnardeaux et al. found 5 nonsense
polymorphisms, of which the A1166C polymorphism was associated with
hypertension.'''* No evidence of linkage could be found in this study. A Finnish
study, however, showed that of all the RAS genes as potential candidates, the
AT1R gene was the only one whose locus was linked with hypertension." They
also confirmed the previously described association of the Al 166C polymorphism
with hypertension, which others did as well.'"•'*• However, negative findings have
also been reported.'"'' '"
The AT1R A1166C polymorphism is located in the 3'-untranslated region (3'-UTR)
of the gene. In this part of a gene mRNA stability is regulated. It is hypothesized
that these regions play a role in changing gene expression in cardiovascular
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pathophysiology.'" The binding of AUF1, a protein that affects AT1R mRNA
stability through binding to AU-rich regions of the 3'-UTR, is not affected by this
polymorphism."** As the promoter of a gene is important in gene function
regulation, several studies searched for new polymorphisms in the promoter of
the AT1R gene.'" '** Several new polymorphisms have been found, mostly in
linkage disequilibrium with each other, but not with the A1166C polymorphism in
the 3'-UTR.'" '*' One study showed a weak linkage disequilibrium between the
mutant A allele of the G-2228A promoter polymorphism and the mutant C allele
of the A1166C polymorphism."* However, in this study no association of any of
the alleles with hypertension could be found. Takahashi et al. found an association
of the promoter C-535T polymorphism with hypertension in Japanese,""' that
could not be confirmed in Caucasians (described as C-521T).'"'**
Angiotensin II type 2 receptor
The human angiotensin II type 2 receptor (AT2R) gene is located on the X
chromosome (Xq22), spans about 5 kb and comprises two short noncoding exons,
2 introns and 1 coding exon (exon 3), which contains the entire protein coding
region."* Intron 1 contains transcriptional enhancers, and /n v/fro transcription is
highest in constructs containing both intron 1 and exon 3."° Animal studies
suggest that the AT2R plays an important role in the regulation of blood
pressure.'"•'" Three polymorphisms in the human AT2R gene, associated with
cardiovascular abnormalities, have been described: the T1334C polymorphism in
the promoter region,'" the G1675A polymorphism within intron 1 near the region
important for gene transcriptional activity,"" and the C3123A polymorphism
within the 3'-UTR of exon 3. '" The G1675A polymorphism is associated with left
ventricular structure in young males with early structural changes of the heart due
to hypertension,'™ whereas the C3123A polymorphism is associated with left
ventricular structure in women with hypertrophic cardiomyopathy, but not in
men, independently of the circulating RAS.'™ Only 1 study focussed at
hypertension as phenotype and described an association of the promoter T1334C
polymorphism with hypertension in Chinese males.'"
Aldosterone
The aldosterone synthase gene (CYP11B2) is located on 8q21. The sequence of
this gene is about 95% identical to its neighboring gene CYP11 Bl, encoding 11 [}-
hydroxylase, in coding regions and 90% identical in introns. Both genes contain 9
exons and 8 introns and are arranged in tandem, 40 kb apart. The enzyme
aldosterone synthase is the key rate-limiting enzyme in the final steps of
aldosterone biosynthesis.
With respect to essential hypertension, studies have concentrated on 2
polymorphisms in the CYP11B2 gene. The C-344T SNP in the 5'-promoter region of
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the gene alters a putative recognition site for the transcription factor SF1.'^' The
immediate biologic importance of this is unclear: whereas binding of SF1 is
reduced 4-fold by the change from C to T, there is no discernible effect on gene
transcription studied in /n wfro systems.'®^ Mutant T allele carriers have higher
blood pressures,'""83 iw. but this could not be confirmed in other studies.'®' '*'
Aldosterone levels are increased in T allele carriers compared to C allele
carriers,'**'" whereas Davies et al. found that the T allele was associated with
higher urinary aldosterone excretion.'*' Inappropriate aldosterone production for
the prevailing renin level might be an intermediate phenotypic expression of
genetic variation at this locus. Lim et al. showed that more than 90% of
hypertensives with an increased aldosterone-to-renin ratio (ARR) fail to suppress
plasma aldosterone with salt loading and fludrocortisone.'*> An increased
frequency of the T allele was reported in patients with raised ARR,'" "* but
Tamaki et al. found that homozygosity for the C allele was associated with a
higher ARR.'^
The second polymorphism involves intron 2 of CYP11B2, which is replaced, in part,
by the corresponding intron from CYP11B1."" The C-344T and intron 2
polymorphisms are in linkage disequilibrium.'*'"' Therefore positive associations
of the intron 2 polymorphism with essential hypertension,'""-''' and with an
increased ARR"'•''" are in line with the findings with respect to the C-344T
polymorphism.
Summary
As twin and adoption studies in the past already indicated, the genetic heritability
in blood pressure resemblances is substantial: between 25-65%. Growing
evidence indicates that multiple genes are involved in blood pressure regulation,
each having a modest effect on blood pressure. Although the genetic component
of blood pressure heritability is substantial, environmental factors cannot be ruled
out. The actual blood pressure of a subject is the resultant of a very complex play
between many genetic, environmental and interacting factors. The thrifty-
genotype hypothesis implies that the genetic basis of contemporary modern
diseases such as obesity, hypertension and diabetes mellitus is not to be found in
recent mutations or genetic defects, but rather lies in the conservation of the
ancestral version of the relevant genes. These genes are so-called thrifty genes
that stem from African founders and that are needed to survive in a world with
irregular availability of food (i.e. glucose) and sodium. In the last years, most
progress in the study of genetic aspects of hypertension has been made by
meticulously studying the several monogenic or Mendelian forms of
hypertension. These findings also increased our knowledge of blood pressure
regulation in the general population. Although the genes involved in these
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syndromes typically impart very large effects on blood pressure, the genes
involved in essential hypertension mostly show modest effects. The extensive
search for these genes revealed linkages with QTLs on almost all chromosomes.
Candidate genes that showed significant linkage with hypertension are AGT, a-
adducin, ACE, and AT1R. Association studies are frequently hindered by aspects as
underpoweredness, inhomogenously selected populations, publication bias, etc.
Still, we may conclude that the following RAS polymorphisms are associated with
hypertension: the M235T polymorphism in AGT, the insertion/deletion (I/D)
polymorphism in ACE, the A1166C polymorphism in AT1R, and the C-344T
polymorphism in aldosterone synthase.
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Chapter 3
Abstract
Several studies have assessed the relationship between the angiotensin-converting
enzyme (ACE) insertion/deletion (I/D) or angiotensin II type 1 receptor (AT1R) A1166C
polymorphisms and blood pressure. Since most data have been obtained in selected
populations, the present study was performed in a healthy normotensive primary care
population. The objective was to investigate the individual effects of the aforementioned
polymorphisms and their interaction on blood pressure.
This cross-sectional study included 203 healthy subjects. Office blood pressure was
measured and polymorphisms were genotyped. Polymorphism interaction was tested
using the following model: systolic blood pressure (SBP) (or diastolic blood pressure (DBP))
= bo + btX + b?Y + bjXY, in which X and Y represent the polymorphisms' risk alleles.
The ACE I/D polymorphism was associated with SBP (P=0.002) and DBP (P=0.004); highest
pressures tracked with the DD genotype. Furthermore, in multiple linear regression analysis
the ACE D allele was associated with SBP (P=0.005) and DBP (/>=0.001), when adjusted for
body mass index and age. With respect to the AT1R A1166C polymorphism, SBP was
highest in the CC genotype (P=O.O25). In linear regression analysis the C allele was not
associated with SBP. No synergistic effect of ACE D and AT1R C alleles on blood pressure
was found. Nevertheless, highest DBP tracked with the DDCC combination in comparison
with other homozygous allele combinations (P=0.030).
This study confirmed an association of the ACE I/D and ATI R A1166C polymorphisms with
blood pressure in a healthy normotensive primary care population. Although synergistic
effect of both polymorphisms on blood pressure does not seem to be present, an additive
effect on DBP is likely.
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Introduction
Hypertension is a multifactorial complex trait.' Twin and family studies suggest
that approximately 25% to 65% of blood pressure variations arise from genes.^
Since multiple transplantation studies in animals and in humans have shown that
the inherited tendency to hypertension predominantly resides in the kidney,**
and because the renin-angiotensin system (RAS) plays a central role in the
regulation of kidney function and blood pressure, the search for genes associated
with hypertension has predominantly focused on the RAS. Two well studied
genetic polymorphisms of the RAS are the angiotensin-converting enzyme (ACE)
insertion/deletion (I/D) polymorphism and the angiotensin II (Angll) type 1
receptor (AT1R) AT 166C polymorphism. The D allele of the ACE I/D polymorphism
correlates with a higher plasma ACE activity and behaves as a marker of
atherosclerotic cardiovascular complications, in particular myocardial infarction.''
" Its association with hypertension, however, is not beyond dispute."" On the
other hand, the presence of the C allele of the AT1R A1166C polymorphism is
associated with aortic stiffness'*'* and essential hypertension.'*" Our group has
shown that patients with the CC genotype exhibit increased sensitivity to Angll,'*
a finding which has been corroborated by other observations."
A synergistic relationship between the presence of the D allele of the ACE I/D
polymorphism and one or two C alleles of the AT1R A1166C polymorphism has
been observed in terms of blood pressure variation and myocardial infarction,™ "
but again, results are conflicting."^ However, most data with regard to the
potential hypertensive effect of genetic polymorphisms, alone or in combination,
have been obtained in selected populations, which are potentially confounded by
referral bias. Furthermore, in most studies dealing with the effect of genetic
polymorphisms on blood pressure, results may have been influenced by pre-
existing cardiovascular morbidity and antihypertensive treatment. Therefore, the
present study aimed to assess the effect of the two aforementioned
polymorphisms and their interaction on blood pressure in healthy normotensive
subjects who were drawn from a primary care practice.
Methods
Subjects
Enrollment of subjects for this cross-sectional study started in October 1997 and
lasted until January 2001. All participants were recruited from a General Practice in
Kerkrade, The Netherlands. This academic group practice takes part in the
Registration Network Family Practices^ which provides an interregional long-term
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and thorough recording of morbidity based on the International Classification of
Primary Care. The practice has a list of 4200 subjects, among which more than 300
patients with hypertension. All subjects included were healthy normotensive
controls of an ongoing study on cardiovascular risk. Before entering the study,
subjects were matched for age and sex with a chronically treated hypertensive
cohort, and inclusion was validated by thorough analysis of the subjects' records
combined with additional measurements of blood pressure and risk indicators.
Reasons for exclusion were the presence of hypertension, diabetes mellitus,
myocardial infarction, angina pectoris, cerebrovascular disease, intermittent
claudication and use of cardiovascular medication.
Blood pressure was measured after 10 minutes of rest in sitting position, using a
sphygmomanometer. All measurements were performed in the office by one of
the authors (L.H.). Hypertension was defined as systolic blood pressure (SBP)>160
mmHg and/or diastolic blood pressure (DBP)>95 mmHg according to the
Guidelines on Hypertension for Dutch General Practitioners.™ Blood samples were
drawn for serum creatinine, uric acid, total cholesterol and glucose levels.
Creatinine clearance was calculated using Cockcroft's formula."
Participants gave informed consent and the study was approved by the Medical
Ethics Committee of the University Hospital Maastricht.
Genetic analysis
DNA was extracted from whole blood using the QIAamp" Blood Kit (Qiagen Inc.,
Valencia, CA, USA). The ACE I/D polymorphism was detected using the technique
described by Rigat era/.*' A second PCR was performed to avoid misidentification
of ID as DD." The AT1R A1166C polymorphism was genotyped by means of
mutagenically separated PCR, as described earlier.'**
Statistical analysis
Differences between genotype groups were tested with One-Way analysis of
variance (ANOVA), using Bonferroni's method for post hoc multiple comparisons
between genotype classes. Genotype frequencies between groups were
compared using a Chi-Square test and tests for Hardy-Weinberg equilibrium were
carried out using standard methods.'" With linear regression analysis
determinants of blood pressure were investigated. Effects of the genotypes,
represented by dummy-variables, were assessed using the deviation from mean
coding approach.''' The interaction between both polymorphisms on blood
pressure was tested using the following model: SBP (or DBP) = bo + b,X + bjY+
btXY, in which b represents a constant variable, X the risk allele of polymorphism
X, Y the risk allele of polymorphism Y, and XY the interaction between the two. A
post hoc analysis, in which subjects were divided in a true normotensive group
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(SBP<130 mmHg and DBP<85 mmHg) and a borderline hypertensive group
(SBP>130 mmHg and DBP>85 mmHg), was carried out to assess whether
associations were similar or not in both groups. The study had a power of 0.8 to
detect a difference between groups of 10 and 5 mmHg in mean SBP and DBP,
respectively. Unless indicated otherwise, data are expressed as means t standard
error of the mean (SEM). A P-value less than 0.05 was considered statistically
significant. Statistical analyses were performed using SPSS 11.0 for Windows (SPSS
Inc.. Chicago, IL, USA).
Results
General characteristics
Altogether, 203 subjects were included in the study. Characteristics of the study
population genotyped for the ACE I/D and the AT1R A1166C polymorphisms are
summarized in Table 3.1 and Table 3.2, respectively. The determination of the
genotypes failed in 6 subjects for the ACE I/D polymorphism and in 5 subjects for
the AT1R A1166C polymorphism. So, in 197 subjects both polymorphisms were
successfully determined. With respect to the ACE I/D polymorphism no significant
differences between the three different genotypes were found, with the exception
of uric acid concentration, which was higher in DD subjects compared to ID
subjects (P<0.05; Table 3.1). With respect to the AT1R A1166C polymorphism,
cholesterol levels were higher in AA subjects compared to AC subjects (P<0.05),
but otherwise no significant differences between genotypes were found (Table
3.2). Genotype frequencies of both polymorphisms were in Hardy-Weinberg
equilibrium.
Blood pressure and separate polymorphisms
For the ACE I/D polymorphism SBP and DBP were significantly different between
the genotype groups, P=0.002 and P=0.004, respectively (Table 3.1). Post hoc
comparison of the ACE genotype classes showed a significantly higher SBP in DD
homozygotes (138±2 mmHg) compared to both ID heterozygotes (130±1 mmHg,
P=0.002). The difference between DD and II homozygotes (132±2 mmHg) was
borderline significant: P=0.08. DBP was significantly higher in DD homozygotes
(81 ±1 mmHg) compared to both ID heterozygotes (77±1 mmHg, P=0.006) and II
homozygotes (77±1 mmHg, P=0.015). In simple linear regression analysis body
mass index (BMI) and age proved to be independent predictors of blood pressure.
Multiple linear regression analysis confirmed the association of the ACE D allele
with SBP (R?=0.048; P=0.005) and DBP (R^=0.058; P=0.001) when adjusted for BMI
and age. This was also true for both SBP (0=0.291; P<0.001) and DBP (|i=0.238;
P=0.001) when using the deviation from mean coding approach. No association
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between the ACE D allele and BMI or age was found. In the post hoc analysis these
associations were found in both the normotensive group and in the group of
subjects with borderline hypertension.
Table 3.1. Characteristics of the study population genotyped for the ACE I/D polymorphism.
Parameter N ID DO Ava lu* * *
Number, n (%)
Males/females, n
Age, yeors
BMI, kg/m'
Waist/hip ratio
SBP, mmHg
DBP, mmHg
Heart rate, beofs/m/n
Smoking, poefcyeorj
CC, mt/m/n
Uric acid, mmoW
Cholesterol, mmo//l
Glucose, mmoW
46 (23.4)
17/ 29
63 ±2
27.3 ± 0.6
0.92 ± 0.01
132 ±2
77 ± 1
75 ±2
21.3 ±4.2
81.2 ±3.6
0.30 ± 0.01
5.54 ±0.16
5.85 ± 0.26
98 (49.7)
46 /52
65 ± 1
26.9 ± 0.5
0.92 ± 0.01
130 ± 1
77 ±1
75 ± 1
26.9 ± 3.3
74.9 ± 2.7
0.29 ± 0.01
5.69 ±0.13
5.51 ±0.09
53 (26.9)
30/23
62 ± 2
27.4 ± 0.7
0.92 ± 0.01
138 ± 2 '
81 ± 1 "
75 ± 1
25.9 ± 5.1
79.3 ± 3.5
0.33 ±0.01 '
5.72 ±0.15
5.72 ±0.14
0.999"
0.148"
0.291
0.765
0.993
0.002
0.004
0.997
0.646
0.328
0.011
0.701
0.224
n: number; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure;
packyears: one package of cigarettes a day a year; CC: creatinine clearance; One-Way ANOVA unless
Indicated otherwise; '"Chi-Square test; *P<0.05 vs. II (Bonferroni); 'P<0.05 vs. ID (BonferroniV
Subjects with the CC genotype of the AT1R A1166C polymorphism had a
significantly higher SBP compared to AC subjects (141 ±3 mmHg vs. 131 ±2 mmHg,
P=0.02, Table 3.2). However, after adjustment for BMI and age no association was
found between the AT1R C allele and SBP. This was also true when the
normotensive and borderline hypertensive group were considered respectively.
Interaction of both polymorphisms
Table 3.3 shows the interaction of the ACE I/D and the AT1R A1166C alleles on
blood pressure in this population. No interaction of the ACE D and the AT1R C
alleles on SBP (P=0.475) or DBP (P=0.688) was found in the linear regression model
for interaction as described above. Since this finding does not exclude an additive
effect of both alleles and because there is uncertainty with respect to the pattern
of inheritance (recessive, co-dominant or dominant), we decided to re-analyse
these data using homozygous allele combinations only, i.e. IIAA, IICC, DDAA and
DDCC. With this approach, we found that the highest DBP tracked with the
homozygous DDCC allele combination (Figure 3.1) when compared to the other
homozygous allele combinations (P=0.03).
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Table 3.2. Characteristics of the study population genotyped for the AT 1R A1166C polymorphism.
Parameter
Number, n (%)
Males/females, n
Age. yeon
BMI. *g/m-'
Waist/hip ratio
SBP, mmHg
DBP, mmHg
Heart rate, beofs/min
Smoking, podcyeors
CC mi/min
Urk acid. mmo//l
Cholesterol, mmo//l
Glucose. mmo//l
AC CC lvalue*
104(52.5)
53/51
65 ±1
26.8 ±0.5
0.92 ± 0.01
13311
7 8 * 1
76±1
30.4 ± 3.9
76.0 ± 2.8
0.30 ±0.01
5.83 ±0.11
5.61 ±0.11
77(38.9)
33/44
63±1
27.0 ± 0.5
0.91 ±0.01
131 ±2
78 ±1
74 ±1
21.3 ±3.1
78.0 ± 2.8
0.29 ±0.01
5.36 ±0.14*
5.64 ±0.16
17(8.6)
8 / 9
62 ±3
28.6 ± 0.9
0.95 ±0.02
141 ±3 '
78 ±2
73 ±3
24.5 ± 4.2
83.1 ±4.6
0.33 ±0.02
5.94 ±0.27
5.85 ±0.11
0.879*
0.558"
0.312
0.303
0.395
0.025
0.963
0.551
0.172
0.524
0.324
0.016
0.709
n: number; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure;
packyears: one package of cigarettes a day a year; CC: creatinine clearance; One-Way ANOVA unless
indicated otherwise; "Chi-Square test; *P<0.05 vs. AA (Bonferroni); 'P<0.05 vs. AC (Bonferronl).
Table 3.3. Interaction of ACE I/D and ATI R A1166C polymorphisms on blood pressure.
ACE I/D
N
ID
DD
SBP
DBP
SBP
DBP
SBP
DBP
AA
133± 4
76± 1
130 ± 2
78 ± 1
140± 2
81 ± 1
AT1RA1166C
AC
128 ± 3
77 ± 2
129 ± 3
77 ± 1
135 ± 3
80 ± 2
CC
145 ± 5
78 ± 3
138 ± 6
73 ± 3
141 ± 5
82 ± 3
SBP: systolic blood pressure; DBP: diastolic blood pressure. All pressures expressed in mmHg.
^•0238
150,
125-
100-
75-
50
I IIAA
CZ3ICC
fflP DBP
Figure3.1. Effects of homozygous allele combinations of the ACE I/D and ATIR A1166C
polymorphisms on blood pressure.
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Discussion
In the present study we investigated the individual and interactive influences of
two polymorphisms of the RAS in normotensive healthy subjects drawn from a
primary care setting. Our data show an association of the ACE I/D polymorphism
with both SBP and DBP and a relation of the AT1R A1166C polymorphism with SBP
only. Whereas there does not seem to be synergy between both polymorphisms,
our results indicate an additive effect on DBP, as the highest pressure tracked with
the presence of two D alleles of the ACE gene in combination with two AT1R C
alleles.
Several studies Investigated the association between the ACE I/D polymorphism
and blood pressure, yielding conflicting results.'-'"-'*"*' However, most negative
studies assessed the association by taking hypertension as a qualitative trait,
rather than using blood pressure as a continuous, quantitative trait. '""*'
Furthermore, results could have been influenced by pre-existing cardiovascular
morbidity and medication influencing blood pressure (since the majority of
studies was conducted in hypertensive populations) and, potentially, by referral
bias. The association between ACE genotype and blood pressure in the present
study is in agreement with the findings by Uemura et a l . " and data from the
Framingham Heart Study.'* Recently, a Japanese study'* reported identical results,
suggesting that the action of the polymorphism may be homogeneous
throughout ethnic groups. Since it has been shown that the D allele is associated
with higher levels of ACE,"^  an association of the ACE I/D polymorphism with
blood pressure could be explained by an increase in local Angll levels. So far,
however, no study has provided evidence to support this notion.
Although in the present study highest SBP tracked with CC homozygosity for the
AT1R A1166C polymorphism, the C allele was not significantly associated with SBP
in linear regression analysis. Nevertheless, Hingorani et al.*' observed a
significantly higher SBP and DBP in the presence of two AT1R C alleles. Others also
found an association of the AT1R A1166C polymorphism with essential
hypertension and aortic stiffness, particularly in the face of increased SBP.'*"
Moreover, our group" found that the CC genotype is associated with increased
sensitivity to Angll. This may contribute to the increased incidence of
cardiovascular abnormalities found in subjects with one or two C alleles.
Several studies have shown an interaction between ACE D and AT1R C alleles with
respect to the risk of myocardial infarction.^"** Since blood pressure also may be
related to multiple genes, we investigated whether there is a synergistic effect of
the ACE D and AT1R C alleles on blood pressure. An interaction in the sense of
synergy, however, was not present in our population. Nevertheless, an additive
effect was found. Analysing only homozygous allele combinations, we found an
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effect of both genes on DBP with the highest pressure in subjects with the DDCC
allele combination. The effect was most pronounced when adding an ACE D allele
(IIAA vs. DDAA and IICC vs. DDCC), but, also the addition of an ATI R C allele (IIAA
vs. IICC and DDAA vs. DDCC) seemed to increase DBP. This is more or less in line
with a recently published prospective study*"" that found an 'epistatic' interaction
of the ACE I/D polymorphism with both the aldosterone synthase and u-adducin
polymorphisms on the development of hypertension. Particularly in the case of
homozygosity of the ACE D allele, the risk of developing hypertension during 12
years of follow-up increased significantly.
In conclusion, this study confirmed an association of the ACE I/D polymorphism
on blood pressure in a healthy normotensive primary care population. A
synergistic effect between the ACE I/D and the AT1R AT 166C polymorphisms on
blood pressure could not be shown, though an additive effect on DBP is very
likely. This study supports the notion that further research is necessary to explore
the role of multiple genetic markers with respect to cardiovascular risk in a general
population.
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Abstract
Data on the association of the angiotensin-converting enzyme (ACE) insertion/deletion
(I/D) and angiotensin II type 1 receptor (ATIR) A1166C polymorphisms with hypertension
are conflicting. In most studies, however, the qua//fafive phenotype (hypertension), rather
than the quonf/fof/Ve phenotype (the level of blood pressure (BP)) was used. Furthermore,
most studies have focused on office BP only. The objective was to investigate the
association of BP with the ACE I/D and ATIR A1166C polymorphisms by means of both
office and ambulatory blood pressure monitoring (ABPM).
From 348 hypertensive patients in whom 24 hour BP profiles were measured with a
SpaceLabs 90207 device, BP data were analysed. The ACE I/D and ATIR A1166C
polymorphism were determined using PCR.
Office BP did not differ between the various ACE or AT1R genotype groups. However,
ambulatory BP (systolic, diastolic, and mean) and BP load were positively associated with
the ACE I/D polymorphism. This was true for values obtained during the initial hour, as well
as for those during daytime (9:00 AM-9:00 PM), nighttime (1:00 AM-6:00 AM) and 24 hours.
An 'allele dose effect' for both BP and BP load was found. There were no differences in heart
rate, BP variability, and amount of dipping. The ATIR A1166C polymorphism showed no
consistent association with blood pressure (load).
From these data we conclude that frequent measuring of blood pressure by ABPM is crucial
to find an association of the ACE D allele with various aspects of blood pressure.
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Introduction
Given the pivotal role of angiotensin II (Angll) in blood pressure regulation, the
genes coding for angiotensin-converting enzyme (ACE) and the angiotensin II
type 1 receptor (AT1R) are among the prime candidates to determine the severity
of hypertension. Indeed, some studies have found a positive association between
the ACE insertion/deletion (I/D) polymorphism and hypertension." Other studies,
however, failed to confirm this association.'* A meta-analysis by Staessen et al. led
to the conclusion that the D allele of this polymorphism is not associated with
hypertension per se, but rather behaves as a marker of atherosclerotic
cardiovascular complications.'' Fewer studies have addressed the association
between the AT1R A1166C polymorphism with blood pressure, and these also
showed conflicting results.**
However, most of these studies assessed associations by taking hypertension as a
qualitative trait, rather than using blood pressure as a continuous quantitative
trait. Moreover, in almost all studies office blood pressure measurements were
used, instead of more informative 24 hour ambulatory blood pressure
measurements (ABPM).
Since ABPM data correlate better with target organ damage than does blood
pressure determined in the examiners office,'' " one could hypothesize that ABPM
data are also superior to office measurements for evaluating the possible
association between blood pressure and the ACE I/D and AT1R A1166C
polymorphisms. ABPM has the additional advantage of providing detailed
information about blood pressure load, variability, and dipping. Therefore, in the
present study we investigated the association of the ACE I/D and AT1R A1166C
polymorphisms with both office and ambulatory blood pressure measurements in
treated and untreated essential hypertensive patients. We also assessed the
association of other ABPM derivatives like blood pressure load, variability, and
dipping with these polymorphisms. Finally, we tested whether such associations
are gender dependent, as was suggested by some recent studies.'^•'*
Methods
Patients
Patients were selected from our outpatient department in a 14 months period.
They were drawn from a larger group of patients, all of whom had been referred
to our clinic for evaluation of their hypertension. As part of the work-up we
routinely perform 24 hour ABPM in such patients to exclude 'white coat'
hypertension. To be eligible for the present study, patients had to have
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uncomplicated essential hypertension without comorbid conditions. Patients with
proven renal artery stenosis on renal angiography were excluded. Altogether, 348
patients qualified for inclusion in the study and all gave written informed consent
to participate. ABPM measurements were performed in 144 untreated patients
and 204 patients who used blood pressure modifying drugs (BPMD, i.e. either
antihypertensives or other agents that could potentially influence blood pressure
such as non-steroidal anti-inflammatory drugs). The study was approved by the
Medical Ethics Committee of the University Hospital Maastricht.
Blood pressure measurements
Office blood pressure measurements as used in this study were based on the
average of three duplicate readings obtained during the last three visits to the
clinic prior to ABPM. Patients were always seen by their own doctor.
Measurements were performed in the seating position after 10 minutes of rest.
After these three visits ABPM was performed using the SpaceLabs 90207 device
(SpaceLabs'", Redmond, WA, USA). Patients were always monitored during normal
daily activity. For calibration, the device was connected to a mercury
sphygmomanometer with an Y-tube. Three consecutive measurements were
taken, 2 to 3 minutes apart, in a seated position, and calibrated to the monitor
readings. The device was used only if measurements differed by <LS mrnHp frr»p?
the sphygmomanometer. Ambulatory blood pressure recordings were obtained
every 15 minutes during daytime (7:00 AM-11:00 PM) and every 30 minutes during
nighttime (11:00 PM-7:00 AM). Blood pressure data were transferred into a
personal computer and analysed by the dabl' ABPM program (ECF Medical Ltd.,
Dublin, Ireland) for the following derivatives: time weighted mean blood pressure,
load, leese, blood pressure variability (standard deviation of mean blood pressure,
coefficient of variation, root mean square of successive deviations), number of
load events, number of leese events, maximum load duration, and maximum leese
duration. All these variables were calculated for the initial hour, daytime (defined
as the period from 9:00 AM to 9:00 PM less the initial hour), and nighttime (defined
as the period from 1:00 AM to 6:00 AM). Mean, load, and leese were also
determined for the entire 24 hour period. Lastly, the percentage dipping was
calculated. All analyses were applied to systolic blood pressure (SBP), diastolic
blood pressure (DBP), mean blood pressure (MBP), pulse pressure (PP), and heart
rate (HR), but only when data were valid (i.e. when MBP>0 and SBP>MBP>DBP).
For definition of these variables see appendix.
Genetic analysis
DNA was extracted from whole blood using the QIAamp' Blood Kit (Qiagen Inc.,
Valencia, CA, USA). The ACE I/D polymorphism was detected using the technique
described by Rigat et al.'* A second PCR was performed to avoid misidentification
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of ID as DD.'* The AT1R A1166C polymorphism was genotyped by means of
mutagenically separated PCR, as described earlier." *
Statistical analysis
The calculation of allele frequencies to test for Hardy-Weinberg equilibrium was
carried out using standard methods" and Chi-Square test was used to compare
expected with observed frequencies. One-Way analysis of variance (ANOVA) was
used to compare differences between the genotype groups of each
polymorphism. When this revealed significant differences, data were further
tested by post hoc comparisons with Bonferroni correction for multiple testing to
assess between which groups significant differences existed. To explore the
possible inheritance model, data were analysed assuming either a recessive (II+ID
vs. DD or AA+AC vs. CC), an additive (II vs. ID vs. DD or AA vs. AC vs. CC), or a
dominant (II vs. ID+DD or AA vs. AC+CC) effect of the D allele and C allele,
respectively. The study had a power of 0.9 to detect a difference in mean 24 hour
blood pressure of 3 mmHg between groups. Results are expressed as means +
standard error of the mean (SEM). A P-value of less than 0.05 was considered to be
statistically significant. Statistical analyses were performed using SPSS 11.0 for
Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
The baseline characteristics of the genotype groups of the ACE I/D and the ATI R
A1166C polymorphisms are summarized in Table 4.1 and 4.2, respectively. The
genotype groups of both polymorphisms were in Hardy-Weinberg equilibrium.
With respect to both polymorphisms patients in the various genotype groups
were comparable for age, gender, treatment status, and renal function (as
assessed by serum creatinine). Body mass index (BMI), however, was significantly
higher in the DD patients compared to the other groups. Importantly, systolic and
diastolic office blood pressures did not differ between the various genotype
groups.
ACE I/D polymorphism and ABPM data
/n/f/'a/ hour
During the first hour of blood pressure registration, a significant effect of
genotype was demonstrable on DBP (Figure 4.1 B), a borderline significant effect
on SBP (P=0.09; Figure 4.1 A) and MBP (P=0.06), and not on PP and HR. In the post
hoc comparison DBP was significantly higher in DD patients than in ID (104±1 vs.
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100±l mmHg; P<0.05; Figure 4.1B), and than in II patients (104±1 vs. 99±2 mmHg;
P<0.05; Figure 4.1 B). Diastolic blood pressure load as well as maximum diastolic
load duration were also significantly higher in DD as compared to ID and II
patients.
Table 4.1. Characteristics of the study population with respect to ACE I/D polymorphism.
Total H ID DO J
Number, n (%) 348(100) 72(20.7) 168(48.3) 108(31.0)
Males/females, n 125/223 24/48 56/112 45/63
Treated/untreated, n 204 / 144 39/33 105 / 63 60/48
Age,yeor$ 53 ± 1 51 ±2 54±1 53±1
BMI,lcg/m> 27.7 ±0.3 26.6 ±0.4 27.2 ± 0.5 29.5 ±0.7"
Creatinlne,^mo//I 86 ± 1 84 ±3 86 ±2 86 ±2
Off Ice SBP, mmHg 168 ±2 165 ±3 171 ±2 166 ±3
Office DBP, mmHg 98 ± 1 97 ± 1 97 ± 1 99 ± 2
n: number; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; j
•P<0.05 vs. II; 'P<0.05 vs. ID. i
Table 4.2. Characteristics of the study population with respect to AT1R A1166C polymorphism.
Number, n (%)
Males/females, n
Treated/untreated, n
Age, yeorj
BMI, fcg/nr'
Creatinine, ymoM.
Office SBP, mmHg
Office DBP, mmHg
Total
348(100)
125/223
204/144
53 ± 1
27.7 ± 0.3
86±1
168 ±2
98±1
AA
176 (50.6)
58/118
107/69
54 ± 1
27.5 ± 0.5
86±2
167 ± 2
98± 1
AC
144(41.4)
54/90
78/66
52 ± 1
27.8 ± 0.5
84±2
169 ±3
97 ± 1
cc
28 (8.0)
13/15
19/9
53 ±3
28.3 ±1.3
92 ±5
173 ±5
100±3
n: number; BMI: body mass Index; SBP: systolic blood pressure; DBP: diastolic blood pressure.
Doyr/me (9:00 -AM-9.-00 P/W
For daytime pressures, significant relationships existed between genotype and
SBP (Figure 4.1A), DBP (Figure 4.1B), and MBP. SBP was markedly higher in DD
patients than in ID and II patients (155±2 vs. 149±2 and 146±2 mmHg,
respectively; P<0.05). The same was true for DBP (97±1 vs. 92±1 and 92±2 mmHg,
respectively; P<0.05) and MBP (117±1 vs. 112±1 and 110±2 mmHg, respectively;
P<0.05). PP and HR did not differ between groups. Systolic, diastolic and mean
blood pressure load (Figure 4.1 C), as well as maximum systolic and mean load
duration were significantly higher in DD patients compared to II patients. Systolic
load events were significantly higher in DD patients in comparison to II patients.
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Figure 4.1 A. SBP during Initial hour, daytime, nighttime, and 24 hours with respect to ACE I/D
polymorphism.
B. OBP during initial hour, daytime, nighttime, and 24 hours with respect to ACE I/O
polymorphism.
C. Blood pressure load during initial hour, daytime, nighttime, and 24 hours with respect to
ACE I/D polymorphism.
Daytime (9:00 AM-9:00 PM, less initial hour), nighttime (1:00 AM-6:00 AM). P-values
between groups as tested by One-Way ANOVA.
Mghrr/me (7.00 4M-6.0
During nighttime, only tendencies for higher systolic (Figure 4.1 A), diastolic
(Figure 4.1 B), and mean blood pressures in DD individuals compared to II patients
were found, but these were not significant. The same was found for systolic,
diastolic, and mean blood pressure load (higher in DD individuals compared to II
patients).
24 hours
As shown in Figure 4.1, twenty-four hour blood pressure and load were also
significantly related to genotype, no matter whether systolic, diastolic or mean
blood pressure (load) was taken as variable, with again higher values in DD
patients compared to II patients. The systolic, diastolic and mean blood pressures
in DD patients were also significantly higher compared to ID patients. Blood
pressure variability over 24 hours and the degree of nocturnal dipping were not
different between the genotype groups.
Since BMI appeared to be significantly higher in DD patients compared to II and ID
patients (Table 4.2), we evaluated the relationship between blood pressure and
ACE I/D genotype again in a multivariate regression model with genotype and BMI
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as independent variables and blood pressure data as dependent variable. All
associations as described above remained, however, statistically significant.
ATI R A1166C polymorphism and ABPM data
In general no significant effect of AT1R A1166C genotype on any of the ABPM
variables was found. Only during 24 hours systolic, diastolic and mean leese were
significantly lower in CC patients compared to AA and AC patients (Figure 4.2).
A 17».« »*0 77 »0S» W)2» »0 59
dayim ngnninw 24t»
Figure 4.2 A. DBP during initial hour, daytime, nighttime, and 24 hours with respect to AT1R Al 166C
polymorphism.
B. SBP during initial hour, daytime, nighttime, and 24 hours with respect to AT1R Al 166C
polymorphism.
C. Blood pressure load during initial hour, daytime, nighttime, and 24 hours with respect to
AT 1R A1166C polymorphism.
Daytime (9:00 AM-9:00 PM, less initial hour), nighttime (1:00 AM-6:00 AM). P-values
between groups as tested by One-way ANOVA.
Effect of treatment status and gender
When ABPM data were analysed separately for those using or not using BPMD
(BPMD+ and BPMD-, respectively), the associations as described above were
apparent in both groups. When broken down by gender, there was a tendency for
males to show more positive associations of the ACE I/D polymorphism with
ABPM derivatives than females (Table 4.3).
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Table 4.3. P-valuev according to gender, of associations of different ABPM derivatives with ACE I/D
polymorphism.
24 hours
SBP
06P
MBP
Systolic load
Oiastolk load
Mean load
SBP
DBP
MBP
Systolic load
Diastolic load
Mean load
SBP
DBP
MBP
Systolic load
Diastolic load
Mean load
0 146'
0.042
0.053'
0.109'
0.031'
0.02 V
0.021'
0.023'
0.016'
0.067
0066
0 126
0.093
0.033'
0.039'
0.138
0.019-
0 A M '
0.010
0.123
0.029
0.020
0.240
0.059
0.644
0.818
0.892
0.307
0.867
0.650
0.050
0.235
0.102
0.058
0.471
0.171
P-values are based on comparing II vs. DD subjects (largest genetic contrast) for each gender. SBP:
systolic blood pressure; DBP: diastolic blood pressure; MBP; mean blood pressure; 'significant
difference only present in males; 'significant difference only present in females.
Inheritance model
The positive associations of the ACE I/D polymorphism on blood pressure and
blood pressure load were significant in all three models, but the most significant
results were found in the recessive inheritance model.
Discussion
The present study shows that, when blood pressure is measured by means of
ABPM, a clear, allele-dependent, association of the ACE I/D polymorphism with
blood pressure can be found in patients with uncomplicated essential
hypertension. The AT1R A1166C polymorphism, on the other hand, shows no
consistent relationship with ABPM data.
The absence of an association between office blood pressure and the ACE I/D
polymorphism is in agreement with the meta-analysis by Staessen et al. who
concluded that the D allele of the ACE I/D polymorphism is not associated with
hypertension, but behaves as a marker of atherosclerotic cardiovascular
complications and diabetic nephropathyJ> In almost all studies included in this
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meta-analysis office blood pressures were used instead of ABPM. Only a few
studies addressed the association of the ACE I/D polymorphism with ambulatory
measured blood pressure with both negative"*" and positive findings." " All
these studies were relatively small and used 'standard' 24 hour ABPM parameters
like daytime, nighttime and 24 hour blood pressure, rather than the more
sophisticated ABPM derivatives like load, leese, variability, dipping, etc.
Recently, Matsubara et al. published data of a large Japanese general population
cohort.'* In this cohort, 803 subjects were phenotyped for their blood pressures
by means of the fully automatic device ABPM-630. The association of ambulatory
blood pressure values with the ACE I/D polymorphism could not be confirmed.
The conclusions of this study should be interpretated carefully. Firstly, the ABPM-
630 device, used in this study, is not validated by the British Hypertension Society.
So, whether blood pressures values of this study are reliable is disputable.
Secondly, although there was a Hardy-Weinberg equilibrium of this population,
the allelic frequency of the D allele was low: 31.5% (compared to 55.2% in our
study). Although this is a common finding in Japanese studies, this frequency is
even lower than in other Japanese population studies.***" This in combination
with an unvalidated ambulatory blood pressure measuring device could
theoretically harm the power (which is not mentioned) to find statistical
differences. On the contrary, an even larger Japanese general population cohort
afti tfnd the association ot the ACE I/D polymorphism with hypertension, but only
in men and not in females.'" Interestingly, gender-specific analyses of the study of
Matsubara revealed a tendency of a higher prevalence of hypertension and a high
odds ratio for the male DD genotype.
The maximal differences in blood pressure are to be expected between II and DD
patients (largest genetic contrast). In the present study the differences in blood
pressure between II and DD patients were 8-11 mmHg for SBP and 5-7 mmHg for
DBP. Given this relatively small difference, earlier studies probably did not have
enough power to find the association. Still, this small genotype effect may be of
importance since, for instance, the Syst-Eur Trial recently showed that a 10 mmHg
higher 24 hour SBP is associated with an increased risk for various cardiovascular
outcome measures (23% for total mortality; 47% for stroke) in older patients with
systolic hypertension." So, such differences in blood pressure between genotypes
as measured in the present study may have a major impact on cardiovascular
morbidity and mortality.
Although we were able to show strong associations of ABPM derived blood
pressure data with the ACE I/D polymorphism, it should be emphasized that these
data were obtained in a rather selected cohort of hypertensive patients with,
consequently, a narrow range of blood pressure at higher levels. Therefore, our
results cannot simply be extrapolated to other patient groups or to
normotensives. Further studies in subjects from a general population are needed
to establish whether our findings also apply to the population at large.
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Several studies indicated that the association of the ACE gene locus with blood
pressure is gender-dependent.'^"•" Although in our group of untreated patients
the subgroups of males (n=58) and females (n=86) were relatively small, our data
confirm that there is a gender difference in the association of blood pressure with
the ACE I/D polymorphism: in males the association was more prominent than in
women. As for now, one can only speculate how the gender-specific impact of a
polymorphism located on an autosomal chromosome can be explained. It could
be that the ACE I/D polymorphism is in linkage disequilibrium with a functional
mutation nearby which has a close interaction with a specific locus on
chromosome Y. The latter was suggested by Kreutz et al. to explain the sex-
differences in salt-loaded blood pressure levels among spontaneously
hypertensive rats." Another explanation could be gender-specific regulation of
the renin-angiotensin system (RAS), as proposed by Danser and Schunkert." For
instance, in males renin and prorenin are *30% and 50% higher, respectively, than
in women.''' As a corollary, males with the DO genotype (with higher circulating
levels of ACE) may generate more AngI and Angll than females with the same
genotype. It is also possible that androgens potentiate the contribution of the RAS
to blood pressure." Finally, it may be that estrogens (during the premenopausal
period) protect women against the negative effects of the ACE DD genotype, thus
masking any gene-related blood pressure increase. If the latter is true, this
protective effect should disappear after menopause. Although this study was not
designed to address this issue, it was found that indeed in premenopausal women
the relation between ACE I/D genotype and blood pressure (load) was absent, in
contrary to postmenopausal women in which this association was prominent.
Larger studies, especially designed to address this issue are needed to confirm this
finding.
Our data further indicate that the effect of the ACE I/D polymorphism on blood
pressure is more prominent for diastolic blood pressure than for systolic or pulse
pressure. This is in agreement with the Framingham Heart Study data, where in a
large cohort (n=3095) associations with the ACE I/D polymorphism were even
absent for systolic and pulse pressure.'*
It is controversial whether the AT1R A1166C polymorphism is associated with
blood pressure. After the first publication of Bonnardeaux et al.* both positive" •"
and negative™'".'13 studies have been published. All of these addressed the
relation with office blood pressure. Although we had expected to find higher
blood pressure levels in patients with the CC genotype, we could not confirm this.
Only during 24 hours systolic, diastolic and mean leese were significantly lower in
CC patients compared to AA and AC patients. As these were the only associations
with the AT1R A1166C polymorphism it should be concluded from this study that
this polymorphism is not associated with ABPM derived blood pressure values.
Earlier work of our group has shown that the C allele of this polymorphism is
associated with an increased sensitivity for Angll."* Probably the effects of the
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AT1R Al 166C polymorphism on cardiovascular function is (partly) blood pressure
independent.
In summary, this study shows that ABPM is an useful tool to investigate the
association of blood pressure with genetic polymorphisms. A positive association
of the ACE I/D polymorphism with blood pressure and blood pressure load can be
found. These associations are most prominent for DBP and for males. The AT1R
A1166C polymorphism shows no allele-dependent association with blood
pressure. Our data further illustrate once more that 'high-fidelity' phenotyping
(ABPM instead of casual measurements) is an absolute prerequisite in studies on
the genotype-phenotype relationships in hypertension.
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Appendix
Time weighted mean blood pressure:
ABPMs consist of samples taken over 24 hours. However they are not always taken
at regular intervals (e.g. a patient might accidentally or deliberately take an extra
reading or a reading might be missed). To calculate the relevant mean over a
certain timeframe this must be taken into account. Each reading therefore
represents a timeframe from halfway from its preceding reading to halfway to its
succeeding reading. As for the first and last readings of each timeperiod this will
give errors, the software program uses a frequency of one reading every 30
minutes (0.556 kHz) to also calculate these timeframes. Missed readings are dealt
with by allowing compensation for singletons. The maximum weight for one side
(to preceding or succeeding reading) is therefore the period.
Load:
Area of the curve above an upper limit of normality (daytime: 135/90, nighttime;
120/70) expressed as a percentage of the area of the curve above an average of
normality (daytime: 122/78, nighttime: 105/60) where values below the upper
limit are regarded as being at that limit.
Leese:
Area of the curve below a lower limit of normality (daytime: 110/66, nighttime:
90/50) expressed as a percentage of the area of the curve below an average of
normality (daytime: 122/78, nighttime: 105/60) where values above the lower limit
are regarded as being at that limit.
Number of load events:
Distinct occasions when curve goes above normal.
Number of leese events:
Distinct occasions when curve goes below normal.
Maximum load duration:
Longest period when curve is continuously above normal.
Maximum leese duration:
Longest period when curve is continuously below normal.
Percentage dipping:
(daytime value less nighttime value)/(daytime value)-!00.
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Abstract
It is still unknown whether D allele carriers of the angiotensin-converting enzyme (ACE)
insertion/deletion (I/D) polymorphism exhibit enhanced conversion of angiotensin I (AngI).
Therefore, we conducted an ;n wfro study in which the plasmatic conversion of AngI over
time in relation to the ACE I/D polymorphism was investigated. Both the immediate and the
long-term conversion were studied.
In 14 II, 16 ID, and 16 DD hypertensives, changes in AngI and Angll concentrations were
measured at 0, 60, 120 and 180 min after blood withdrawal. Similar experiments were
performed after adding either excess AngI or enalaprilate to the plasma at baseline.
Over a period of three hours, II and ID subjects showed a significant decline in AngI levels
compared to baseline (at maximum 16% and 19%, respectively; P<0.05), whereas DD
subjects showed no significant change. After adding exogenous AngI, all genotype groups
Immediately metabolized more than 90% of the peptide, but continued to show significant
decreases of about 50% in AngI as compared to baseline over the next few hours. No
changes in AngI were observed in enalaprilate-treated plasma. Angll levels decreased in DD
subjects both with (at maximum -18%; P<0.05) and without (at maximum -37%; P<0.05)
exogenous AngI but not in the others. No changes in any group were seen in the
enalaprilate experiments.
CO/IC/l/5/O/l
Our data show that following the immediate conversion of AngI, a secondary phase of slow
conversion is demonstrable. While the initial phase does not differ between the three
genotype groups, the slow conversion of AngI does with the lowest conversion occurring
in DD patients. The difference can be overcome at higher prevailing concentrations of AngI.
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Introduction •<
Since individuals who are homozygous for the deletion variant (DD) of the
angiotensin-converting enzyme (ACE) gene express about 50% higher levels of
the enzyme than II subjects,' it is tempting to hypothesize that they also have
increased conversion of angiotensin I (Angl). Indirect support for this hypothesis
comes from epidemiologicai studies which show that a number of hypertensive
and atherosclerotic complications occur more frequently in DD patients.''' This
would at least be compatible with enhanced formation of Angll, a peptide with
known deleterious effects on the cardiovascular system. However, studies which
compared the vasoconstrictor responses to Angl in subjects with the different
genotypes have produced conflicting results. While some investigators reported
enhanced pressor responses to Angl in DD subjects,'* '"> others failed to confirm
this.'*'" The fact that D allele carriers do not exhibit a compensatory suppression
of circulating r en in " even argues against increased generation of Angll from Angl.
Since the results of /n wVo studies may be confounded by many variables that
cannot be adequately controlled, it seems preferable in this respect to assess
potential differences in Angl conversion between individuals with different
genotypes under ;n v/fro conditions. Of note, some investigators have reported
that ACE itself is functionally similar in the three genotypes,''"'' but they all used
artifical substrates. Because kinetic parameters for ACE may be somewhat
different with Angl as substrate, there is a case for studying the spontaneous
plasmatic conversion of Angl into Angll. However, given the low concentrations of
angiotensins in plasma which are well below the KM value for the enzymatic
reaction between ACE and Angl, the rate of conversion in normal plasma must be
independent of Angl levels. This, together with the fact that metabolization of
Angl into Angll is a fast process taking place within seconds to minutes, would
make it unlikely to see major differences in plasmatic Angl conversion in relation
to genotype. Consequently, if there are differences in the degree of Angl
conversion between individuals, one would have to invoke another mechanism of
conversion, possibly occurring at a slower pace. This led us to hypothesize that
there might be a secondary, slower, conversion phase which either or not is
related to ACE itself and which could lead to differences between patient groups.
To put this to the test, we followed changes in Angl concentrations over a
prolonged period of time in plasma which was maintained in a waterbath at a
constant temperature of 37°C and to which a renin-inhibitor had been added.
Plasma samples were either untreated or spiked with an excess of exogenous
Angl. Although changes in the concentration of Angl were taken as the primary
outcome variable, we also measured Angll concentrations at the various time
points.
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Methods
Patients
Patients were randomly selected from a genetic database of hypertensive patients
genotyped for the ACE insertion/deletion (I/D) polymorphism. All selected
patients (14 II, 16 ID, 16 DD) gave written informed consent (both genotyping and
blood withdrawal) to participate in the study. Antihypertensive medication had
been stopped 3 weeks prior to blood withdrawal. Patients refrained from nicotine,
alcohol, caffeine and caffeine-like substances from 8:00 PM the evening before
blood withdrawal. The study was approved by the Medical Ethics Committee of
the University Hospital Maastricht.
Genetic analysis
DNA was extracted from whole blood using the QIAamp" Blood Kit (Qiagen Inc.,
Valencia, CA, USA). The ACE I/D polymorphism was detected using the technique
described by Rigat et al." A second PCR was performed to avoid misidentification
of ID as DD."
Biochemical measurements
Venous blood (40 mL) was collected into polystyrene tubes containing 2 mL of
sampling buffer (composition: 7% w/v trisodium citrate, 35 mmol/L o-
phenanthroline (Sigma P9375), 0.04 mmol/L renin-inhibitor (Sigma C9415)). After
withdrawal, blood was rapidly centrifuged at 37°C at 3000 rpm for 15 min. The
supernatant was then distributed in 4 parts (t=0, t=60, t=120 and t=180 min) and
incubated at 37°C. The conversion from Angl to Angll was stopped in different
tubes at baseline (t=0) and at 60, 120 and 180 min by adding enalaprilate (0.5 mL,
0.25 mmol/L). Subsequently, plasma was quickly frozen in liquid nitrogen and
stored until assay. A second series had the same work up, but contained 150 pg
Angl per mL blood (=115.7 pmol/L) that was added at baseline. Angl and Angll
were determined by standard radioimmunoassay (Peninsula Laboratories Europe,
St. Helens, UK) following C-18 Sep-Pak (Waters-Millipore) extraction of the
peptides. Intra- and intercoefficients of variation of all assays were <10%. Cross-
reactivity of antibodies for Angl and Angll assays were <0.2%. All samples from the
same individual were assayed in a single run. To assess whether changes in Angl
were dependent on ACE, a control experiment was performed as follows. Venous
blood samples from 8 II, 10 ID, and 11 DD subjects were collected in sampling
buffers to which enalaprilate (0.5 mL, 0.25 mmol/L) had been added. After
isolating plasma, Angl and Angll were again measured at 0,120, and 180 min.
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Statistical analysis
Data are shown as medians and interquartile ranges (IQR). Both absolute and
relative changes of Angl conversion are shown. Relative changes are expressed as
the percentage change compared to baseline. Because of small samples sizes
(n<20) non-parametric tests were used. The Chi-Square test was applied to
compare categorical data (e.g. gender) between genotype groups. Wilcoxon
Signed Rank test was used for differences within groups. To compare data
between groups (II, ID, and DD) a two step approach was taken. First, overall
differences between groups were evaluated by means of Kruskall-Watlis analysis
of variance. When these analyses revealed a significant effect of genotype, data
were further tested by pairwise comparisons using the Mann-Whitney 17 test. A P-
value of less than 0.05 was considered to be statistically significant. Statistical
analyses were performed using SPSS 11.0 for Windows (SPSS Inc., Chicago, IL,
USA).
Results
Subjects
A total of 46 subjects (17 males and 29 females) were selected: 14 II, 16 ID, and 16
DD. The overall median age was 53 (IQR 49, 63) years. There were no significant
differences in gender and age between the groups.
Conversion of endogenous Angl
At baseline, plasma Angl levels were comparable between the genotype groups
(II: 7.28 pmol/L; ID: 9.78 pmol/L; DD: 8.66 pmol/L; P=0.66), and so were plasma
Angll levels (II: 7.27 pmol/L; ID: 6.80 pmol/L; DD: 6.17 pmol/L; P=0.85). However, II
and ID subjects showed a significant decline in Angl levels at 120 and 180 min
compared to baseline (P<0.05), whereas in DD subjects only small changes were
found which were not statistically significant (Figure 5.1).
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FigureS.l. Relative change in Angl levels without exogenous Angl. *P<0.05 vs. baseline; 'P<0.05 vs.
DD.
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At 120 and 180 min AngI levels were significantly lower in II subjects (5.97 and 6.79
pmol/L, respectively) than in DD subjects (8.51 and 9.27 pmol/L, respectively;
P<0.05 vs. II). No significant differences for AngI levels were found between II and
ID. The maximum decreases in AngI concentrations in II and ID subjects were
reached at 120 min (16 and 19%, respectively; Figure 5.1). DD subjects showed a
significant decrease in Angll at 60 (-19.7%), 120 (-17.4%) and 180 (-37.4%) min
compared to baseline (all: P<0.05; Figure 5.2). In II and ID subjects, on the other
hand, no significant changes in Angll occurred (Figure 5.2). The control
experiment, in which the effect of inhibition of converting enzyme was tested,
showed no significant changes in either AngI or Angll levels during the 180 min of
the experiment in any of the genotype groups (Figures 5.3 and 5.4), suggesting
that under the conditions of study the decreases in AngI concentrations were
related to conversion by ACE.
• D
DO
Figure 5.2. Relative change in Angll levels without exogenous AngI. 'P<0.05 vs. baseline.
•*•• D
• 00
Figure 5.3. Relative change In AngI levels without exogenous AngI and with enalaprilate.
Conversion of AngI in the presence of added peptide
Baseline AngI levels after adding the exogenous AngI were about 15 pmol/L in all
genotype groups. Since 150 pg/mL (=115.6 pmol/L) had been added to the tubes,
all groups had immediately converted more than 87% of the excess AngI within
the first few seconds during which the plasma was processed. All genotype
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groups showed a significant decrease of about 50% in AngI at 60.120 and 180 mln
as compared to baseline (Figure 5.5). This decrease was not significantly different
between the groups. DD subjects showed a significant decrease in Angll at 180
min (-182%) compared to baseline (P<0.05, Figure 5.6). Angll did not significantly
change in II and ID subjects.
Figure S.4. Relative change in Angll levels without exogenous Angt and with •nalaprltatt.
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Figure 5.5. Relative change in AngI levels with exogenous AngI. "P<0.05 vs. baseline.
• • • • * • • • D
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-20-I
Figure 5.6. Relative change in Angll levels with exogenous AngI. *P<0.05 vs. baseline.
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Discussion
This study investigated spontaneous changes in AngI concentrations in plasma in
relation to the ACE I/D polymorphism. Baseline plasma levels of AngI and Angll
were comparable in the three genotype groups which is in line with earlier studies
demonstrating that the higher ACE levels in D allele carriers do not lead to higher
circulating plasma Angll concentrations.'* ' * " * * Moreover, the comparable AngI
levels indirectly suggest that no compensatory suppression of renin occurs in D
allele carriers, as was earlier concluded by Danser et al.'* Finally, when plasma was
spiked with exogenous AngI during the process of blood sampling, the excess
peptide was rapidly metabolized as less than 13% was recovered after one hour.
All these observations suggest that classical conversion of AngI as it is known to
us, occurred normally without demonstrable differences between genotype
groups.
The results of our experiments further show that over a prolonged period of time
additional changes in peptide levels occur. Although such changes could, in
theory, be non-specific they could be prevented by adding enalaprilate to the test
medium. This suggests that ACE is, at least partly, involved in the slow conversion
of AngI. Interestingly enough, the rate of conversion was dependent on genotype.
While AngI significantly decreased during the 3 hours of the experiment in II and
ID carriers, it hardly changed in DD subjects. This is a remarkable finding and
indicates that under the conditions of our study ACE in DD subjects, if anything, is
working at a s/ower rate. At first sight, our findings seem to be in contrast with the
results of two studies which showed an increased Angl-ll conversion."'" For
instance, Ueda et al. studied Angll generation and systemic pressor responses in
normotensive men. They provided evidence for enhanced Angl-ll conversion in
DD subjects as compared to subjects with the II genotype. However, statistical
significance for the difference between II and DD subjects was obtained only at
the highest AngI dose (20 ng/kg/min) that was tested, leading the authors to
conclude that D allele-related effects on conversion will only be observed under
conditions in which the renin-angiotensin system is stimulated.''' Another group
of investigators focused on vascular, rather than circulating or systemic Angl-ll
conversion, by studying contractile responses to AngI and Angll in preparations of
human internal mammary arteries /n w'fro. Combining ID and DD patients, they
found increased Angl-ll conversion in this group compared to II patients.
However, other studies, using the systemic,'* forearm'^* and isolated arteries"
model failed to find increased Angl-ll conversion. Interestingly, when we added an
extra amount of AngI to obtain high normal levels (*15 pmol/L), plasma samples
of DD subjects showed the same decline in AngI as II and ID subjects. A possible
explanation for this phenomenon could be that plasma of DD subjects contains a
factor which blocks the slow conversion phase of AngI at relatively low
concentrations of this peptide but loses its power when AngI rise. This could be
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the case when the unknown factor is a weak competitive inhibitor of the binding
ofAngltoACE.
The plasma levels of Angl that we obtained after adding exogenous Angl were
well within the range that one could expect during sodium restriction or after
diuretic treatment. Conversely, baseline levels were as one would expect on a
liberal salt intake. Since conversion of Angl in DO subjects seems to be slower at
low plasma concentrations, one could hypothesize that the balance between
volume status and Angll generation is slightly disturbed in II subjects as compared
to 0 0 subjects during high salt intake. Indeed, some studies have shown that II
individuals display a greater degree of sodium sensitivity than DD subjects.*-"
In enzyme kinetic studies, following substrate decrease (=Angl conversion) has the
same meaning as measuring product increase (=Angll generation). In this study,
we deliberately chose to use Angl conversion, rather than Angll generation as the
primary outcome because it is easier to measure Angl and because we cannot
exclude generation of other angiotensins, which would escape our assay system.
However, for the sake of completeness we also followed changes in Angll
concentrations and, surprisingly, found these to remain unchanged in II and ID
subjects but to decrease in DD patients, at least when ACE was not blocked. In the
enalaprilate experiments no changes in Angll whatsoever were apparent in any of
the groups. This suggests that any new formation of Angll is immediately followed
by removal of the octapeptide. While this latter process may be slow in persons
carrying the II or ID genotype, it apparently occurs much more quickly in DD
individuals. Our data further indicate that this process is dependent upon
normally functioning ACE and raises the question whether ACE itself is not
responsible for enhanced degradation of Angll. Further experiments are needed,
however, to explore this issue in greater detail.
As any ;n wfro study, the present one also has its limitations. We only focussed on
soluble ACE activity and, hence, the role of membrane-bound ACE in Angl-ll
conversion remains unclear, /n wVo, membrane-bound ACE is probably more
important for Angl-ll conversion than soluble ACE. Accordingly, the rate of the
slow Angl conversion may be different at the tissue level.
In conclusion, this study shows that the DD genotype of the ACE I/D
polymorphism, at least at low plasma concentrations of Angl, is associated with a
slower secondary conversion of this peptide. This could mean that the increased
plasma ACE levels that are seen in D allele carriers serve as a compensatory
mechanism to allow for sufficient ongoing conversion of Angl into Angll.
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Abstract
A consistent finding in hypertensive patients is a reduced renal blood flow, which declines
progressively with age. The pathophysiological background of this phenomenon has not
been fully elucidated but likely includes the renin-angiotensin system. The present study
was conducted to investigate whether renal hemodynamics in essential hypertensive
patients depend on genetic factors related to the generation (angiotensin-converting
enzyme (ACE) insertion/deletion (I/D) polymorphism) and effect (angiotensin II (Angll) type
1 receptor (AT1R) A1166C polymorphism) of Angll.
Effective renal plasma flow (ERPF), glomerular filtration rate (GFR), filtration fraction (FF),
blood pressure, as well as renin, Angll, aldosterone, and ACE were studied in 212 essential
hypertensives on a standardized low salt diet genotyped for the AT1R A1166C and ACE I/D
polymorphisms.
Mean age was 50±1 years and comparable in all genotype groups. ERPF in AT1R CC
patients (338±17 ml_/min/1.73 nr') was significantly lower compared to AA patients
(400±11 ml7min/1.73 m>; P<0.05) and so was GFR (105±4 mL/min/1.73 nV vs. 111±2
mL/min/1.73 m'; P<0.05). FF was significantly higher in CC patients (0.32 ± 0.01) compared
to AA patients (0.30±0.01; P<0.05). The ACE I/D polymorphism showed no association with
renal function, as well as no significant interaction with the AT1R A1166C polymorphism.
Besides the association of the ACE I/D polymorphism with ACE levels, no genotype effects
on hormonal characteristics were found. The age-related decline in ERPF was comparable
in all genotype groups but with a significantly lower intercept in CC patients.
The C allele of the AT1R A1166C polymorphism is associated with impaired renal function.
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Introduction
One of the most consistent findings in hypertensive patients is a reduced renal
blood flow (RBF).' Moreover, compared to normotensives, the age-related decline
in RBF is markedly exaggerated in hypertension.'*' Although the mechanisms
which are responsible for these abnormalities have not been fully elucidated,
several lines of evidence point towards increased intrarenal activity of the renin-
angiotensin system (RAS)." Recently, we demonstrated that in hypertensive
patients with the CC genotype of the angiotensin II (Angll) type 1 receptor (ATI R)
A1166C polymorphism, an increased renal sensitivity to Angll'' and blunted (renal)
responses to an AT1R antagonist*' can be found. Other studies have shown that
this polymorphism is associated with diabetic nephropathy" and the time from
onset to end-stage renal disease."" Except for increased sensitivity to Angll,
enhanced production of this peptide may also be involved. In this respect it is
noteworthy that the D allele of the angiotensin-converting enzyme (ACE)
insertion/deletion (I/D) polymorphism has also been found to be associated with
diabetic" and hypertensive nephropathy," and progression to chronic renal
failure in (mainly) glomerular diseases.'*•'« Moreover, it was found that both
polymorphisms work synergistically as blood pressure variation and the risk for
myocardial infarction is concerned.'^ These findings prompted us to study renal
hemodynamics, and in particular their relationship with age, in essential
hypertensives in relation to these two polymorphisms. We hypothesized that both
the ATI R C allele and ACE D allele are associated with impaired renal function.
Methods
Patients
All hypertensive patients who were referred for evaluation of their hypertension
to the Hypertension Research Unit of the University Hospital Maastricht
(secondary/tertiary referral center) between 1996 to 2002 underwent a detailed
history and physical examination by an internist, followed by several laboratory
assessments which included evaluation of renal plasma flow and glomerular
filtration rate by means of para-aminohippurate (PAH) and inulin respectively. In
addition, they were genotyped for the AT1R A1166C and ACE I/D polymorphisms.
Patients entered the study if they fulfilled all the inclusion criteria: age between 18
and 80 years, Caucasian, hypertension according to World Health Organization-
International Society of Hypertension criteria''', able to stop antihypertensive
medication for 3 weeks. Exclusion criteria were secondary hypertension,
congestive heart failure (New York Heart Association classes II through IV), hepatic
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(> Child-Pugh B) or renal insufficiency (creatinine clearance <60 mL/min). In case
of clinical suspicion of renal artery stenosis, renal angiography was performed.
Detailed hormonal evaluation was conducted if clinical or biochemical signs
suggested an endocrine form of hypertension. The protocol was approved by the
Hospital Ethics Committee and all patients gave written informed consent. A total
of 253 patients were studied during this time period.
Genetic analysis
DNA was extracted from whole blood using the QIAamp' Blood Kit (Qiagen Inc.,
Valencia, CA, USA). The ACE I/D polymorphism was detected using the technique
described by Rigat et al.'* A second PCR was performed to avoid misidentification
of ID as DD." The AT1R A1166C polymorphism was genotyped by means of
mutagenically separated PCR, as described earlier.*
Renal function measurements
Renal hemodynamics, i.e. effective renal plasma flow (ERPF) and glomerular
filtration rate (GFR) were measured as the clearance of PAH (Merck Sharp &
Dohme, West Point, PA, USA) and inulin (Inutest, Laevosan Gesellschaft, Linz,
Austria) respectively, usinp the continuous infusion method ™ Roth variahlps wprp
corrected for body surface area and expressed as mL/min/1.73 nV. Effective renal
blood flow (ERBF) was calculated using the formula: ERPF/O -hematocrit). Filtration
fraction (FF) was calculated as GFR/ERPF. Renal vascular resistance (RVR) was
calculated according to the formula: (mean blood pressure/ERBF)-80,000 and
expressed in dynes-sec-cm \ Patients were investigated after a standardized low
(55 mmol Na7day) salt diet for 7 days, with a fixed potassium intake of 80
mmol/day. Compliance with the diet was checked by measuring sodium,
potassium and creatinine output in a 24 hour urine collection obtained during the
last day of the dietary period. A standardized low salt diet was chosen to: a)
minimize the interindividual effects of sodium concentration on renal function,
and b) obtain a situation of 'Angll dependent' renal function due to increased
endogenous Angll levels. Antihypertensive medication had been stopped two
weeks prior to the start of dietary intervention. Patients refrained from nicotine,
alcohol, caffeine and caffeine-like substances from 8:00 PM the evening before the
measurements. Clearance studies started at 8:30 AM after an overnight fast and
patients remained supine during the entire session. In both arms an antecubital
vein was cannulated with a 20G cannula. The one in the right arm was used for the
infusion of PAH and inulin, whereas the cannula in the left arm was used for blood
sampling. To ensure diuresis, subjects consumed 200 mL of water every hour until
the last blood samples had been drawn. After a two-hour equilibration period,
necessary to reach steady state plasma concentrations of PAH and inulin, 4 blood
samples were taken with 15 minutes interval for the measurements of PAH, inulin,
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and hematocrit. Systolic blood pressure (SBP), diastolic blood pressure (DBP),
mean blood pressure (MBP) and heart rate (HR) were measured at a 3-minute time
interval by a semi-automatic oscillometric device (Dinamap Vital Signs Monitor
1846, Critikon, Tampa, FL, USA). In a subset of patients (n=93) blood samples were
drawn for determination of active plasma renin concentration (APRC), Angll,
aldosterone, and ACE. All samples were stored at -80" C until assay.
Assay methods
APRC was measured by a two-site direct immunoassay (Nichols Institute
Diagnostics, San Juan Capistrano, CA, USA)." For measuring Angll, blood samples
were collected in tubes containing an inhibitor solution to prevent /n wfro
generation and degradation of this peptide,-' and spun immediately in a cooled
centrifuge. Subsequently, the plasma was quickly frozen in liquid nitrogen.
Hereafter, Angll was determined by ' " I radioimmunoassay (RIA) following
extraction from plasma. Aldosterone was assayed by means of a solid-phase
protein binding RIA (Diagnostic Products Corporation, Los Angeles, CA, USA)."
ACE, PAH and inulin levels were measured spectrophotometrically.*"* Intra- and
interassay coefficients of variation of all assays were <10%. All samples from the
same individual were assayed in a single run.
Statistical analysis
For each variable, normality in each genotype group was tested using
Kolmogorov-Smirnov (with Lilliefors significance correction) or Shapiro-Wilk's test
(n<50) when applicable. When these tests indicated that data were not normally
distributed, natural logarithmic transformation was applied. When after this
transformation data were still not normally distributed, non-parametric tests were
used for analysis. Comparisons of means were performed using One-Way analysis
of variance or Kruskal-Wallis when appropriate. When these analyses yielded
significant differences, further testing between genotype groups was done with
Student's f-test or Mann-Whitney L/ test with Bonferroni correction for multiple
testing. The Chi-Square test was used for comparison of proportions. With simple
linear regression analysis, determinants of renal function (i.e. ERPF, GFR and FF)
were investigated. Effects of the genotypes, represented by dummy-variables,
were assessed using the deviation from mean coding approach," which does not
imply any genetic hypothesis. The interaction between both polymorphisms on
renal function was tested using the following model: ERPF (or GFR, or FF) = bo +
biX + b2Y + b3XY, in which bo represents a constant variable, X the risk allele of
polymorphism X, Y the risk allele of polymorphism Y, and XY the interaction
between the two. The study had a power of >0.75 to detect a difference between
the different genotype groups of 63 and 13 mL/min/1.73 m* in mean ERPF and
GFR, respectively. Results are expressed as means ± standard error of the mean
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(SEM). A P-value of less than 0.05 was considered to be statistically significant
Statistical analyses were performed using SPSS 11.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
Results
Characteristics of the patients
Forty-one of the 253 patients exhibited some degree of renal artery stenosis and
were, therefore, excluded for further analysis. The remaining 212 patients
included 114 men (54%) and were comparable for sex, age, body mass index
(BMI), blood pressure, HR and plasma creatinine with respect to both
polymorphisms (Tables 6.1 and 6.2).
Table 6.1. Characteristics of the study population with respect to ATI R A1166C polymorphism.
AA AC CC
Number, n (%)
Males/females, n
Age, years
BMI, kg/m-'
SBP, mmHg
DBP, mmHg
Heart rate, b«ofs/m/n
Serum creatinine, umoW
114(53.8)
58/ 56
50 ± 1
27.0 ± 0.4
159±5
91 ± 2
66±2
84 ± 2
72 (34.0)
41/31
50±1
27.4 ± 0.5
173±6
95 ±3
68±2
83 ±2
26(12.3)
15/ 11
52 ±3
26.6 ± 0.9
160 ±5
93 ±3
65 ±2
86 ±4
n: number; BMI: body mass index; SBP: systolic blood pressure; OBP: diastolic blood pressure.
Table 6.2. Characteristics of the study population with respect to ACE I/D polymorphism.
II » DO
Number, n (%)
Males/females, n
Age, yeorj
BMI, fcg/rrr'
SBP, mmHg
DBP, mmHg
Heart rate, bears/mm
Serum creatinine, >/moML
28(13.2)
12/16
S1± 3
27.3 ± 0.8
155± 7
90±4
65 ± 2
82 ± 4
115(54.2)
57/ 58
49 ± 1
26.8 ± 0.4
166 ± 4
94± 2
65 ± 2
82 ± 2
69(32.5)
45/24
53 ±1
27.6 ±0.5
165±6
94 ±2
6812
88±2
n; number; BMI: body mass index; SBP: systolic blood pressure; OBP: dUstolic blood pressure.
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Renal hemodynamics and hormonal characteristics
Who/epopu/af/on
Mean ERPF for the whole population was 384±8 mL/min/1.73 nV. Independent
determinants of ERPF were age (R'=0.142; P<0.001), gender (R-=0.022; P=0.032),
BMI (R-=0.039; P=0.004). SBP (R'=0.068; P=0.037), and AT1R C allele (R-=0.028;
P=0.014). Mean GFR for the whole population was 110±2 mL/min/1.73 m>.
Independent determinants of GFR (after logarithmic transformation) were age
(R'=0.16; P<0.001), gender (R^O.027; P=0.018), BMI (R>=0.042; P=0.003), and AT1R
C allele (R'=0.03; P=0.012). Mean FF for the whole population was 0.30±0.01.
Independent determinants of FF (after logarithmic transformation) were age
(R>=0.16; P<0.001), gender (R'=0.027; P=0.018), BMI (R->=0.042; P=0.003), and AT1R
C allele (R'=0.03; P=0.012).
A 7" / ff d n 66C po/ymorph/'sm
As shown in Table 6.3, ERPF in CC patients (338±17 mL/min/1.73 m') was
significantly lower compared to AA patients (400±11 mL/min/1.73 m'; P<0.05).
The association of the AT1R C allele with ERPF remained significant after
adjustment for age, gender, and BMI. No significant interaction between the AT1R
C allele and the major determinant of ERPF, age, was present (Figure 6.1). Also no
significant interactions between the AT1R C allele and gender or BMI on ERPF
were found. GFR was significantly lower in CC patients (105±4 mL/min/1.73 m?)
compared to AA patients (111 ±2 mL/min/1.73 m ;^ P<0.05). The association of the
AT1R C allele with GFR also remained significant after adjustment for age, gender,
and BMI, again without a significant interaction between the AT1R C allele and
age, gender, or BMI on GFR. Finally, FF was significantly higher in CC patients
(0.32±0.01) compared to AA patients (0.30±0.01; P<0.05) with the association of
the AT1R C allele with FF remaining significant after adjustment for age, gender,
and BMI. No significant interaction between the AT1R C allele and age, gender, or
BMI on FF was present. Angll concentrations in AC patients (21.9±2.9 pmol/L) were
significantly higher compared to those in AA patients (19.2±5.4 pmol/L; P<0.05;
Table 6.3), but comparable to those in CC patients (18.4±4.6 pmol/L; P=0.09; Table
6.3). Aldosterone in AA (0.32±0.03 nmol/L) and CC (0.25±0.03 nmol/L) were both
signifcantly lower compared to AC patients (0.37±0.03 nmol/L; P<0.05 vs. AA and
CC; Table 6.3). No significant differences between genotype groups were found
for APRC and ACE (Table 6.3).
dC£ //D po/ymorpWsm
No differences in renal hemodynamics, APRC, and Angll were found between the
genotype groups (Table 6.4). Aldosterone in DD patients (0.37±0.04 nmol/L) was
slightly higher compared to II patients (O.3O±O.O5 nmol/L; P=0.08) and ID patients
(0.31 ±0.03 nmol/L; P=0.06; Table 6.3). As would be expected, ACE levels in DD
(19±1 U/L; P<0.05 vs. II and ID) and ID (16±1 U/L; P<0.05 vs. II and DD) patients
were significantly higher compared to those in II patients (11±1 U/L; Table 6.4).
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Table 6.3. Renal hemodynamics and hormonal characteristics with respect to AT1R A1166C
polymorphism.
AA AC CC
Urinary Na\ mnK>//?4/v
ERPF, ml/m/n/J. 73 nr>
GFR, ml/m/n/;.73nr'
FF :
RVR, dynes j e c - c / n ' - ••- .
APRC, mU/t
Angll, p/no//l
Aldosterone, nmo//t
Aldosterone/APRC ratio
ACE, (M.
80± 5
400 ± 11
111 ± 2
0.30 ± 0.01
13484 ±626
20.1 ± 1.6
19.2 ±5.4
0.32 ± 0.03
0.022 ± 0.003
18± 1
80 ± 8
376± 15
111 ±3
0.30 ± 0.01
13049 ±920
22.3 ± 2.3
21.9 ±2.9*
0.37 ± 0.03'
0.024 ± 0.004
15± 1
62 ± 9
337 ±17*
105 ±4'
0.32 ±0.01'
15082 ±767
17.6 ±2.0
18.4 ±4.6
0.25 ± 0.03"
0.016 ±0.002
18±1
ERPF: effective renal plasma flow; GFR: glomerular Filtration rate; FF: filtration fraction; RVR: renal
vascular resistance; APRC: active plasma renin concentration; Angll: angiotensin II; ACE: angiotensin-
converting enzyme; *P<0.05 vs. AA;; 'P<0.05 vs. AA after logarithmic transformation; "P<0.05 vs. AC.
800 T
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Figure 6.1. Relationship between ERPF and age with respect to ATI R A1166C polymorphism.
Table 6.4. Renal hemodynamlcs and hormonal characteristics with respect to ACE I/D polymorphism.
AC CC
Urinary Na*. mmo//74nr
ERPF, ml/m/n/i. 73 m^
GFR. ml/m/n/!.73 n^
FF
RVR, dynesseC'Cm'
APRC. mlV/l
Angll. pmo//l
Aldosterone, nmof/L
Aldosterone/APRC ratio
ACE, U/L
78 ± 8
401 ± 25
114±5
0.31 ± 0.02
12837± 1078
21.1 ± 3J
13.9± 3.7
0.30 ± 0.05
0.023 ± 0.007
11 ± 1
75 ± 6
383 ± 11
109 ± 2
0.30 ±0.01
14021 ±665
19.7 ±1.5
19.7 ±2.9
0.31 ± 0.03
0.020 ± 0.002
16± 1*
81 ± 8
378±15
109±3
0.31 ± 0.01
14037 ±663
20.9 ± 2.2
21.7 ±5.6
0.37 ± 0.04
0.024 ± 0.003
19± 1 "
ERPF: effective renal plasma flow; GFR: glomerular filtration rate; FF: filtration fraction; RVR: renal
vascular resistance; APRC: active plasma renin concentration; Angll: angiotensin II; ACE: angiotensin-
converting enzyme; *P<0.05 vs. II;'P<0.05 vs. ID.
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/nreracr/on befween A 7 J /? A f; 66C and dCF //D po/ymorph/sm
Table 6.5 shows the interaction of the ATI R C and ACE D alleles on ERPF and GFR.
No interaction of both risk alleles on ERPF (P=0.918) and GFR (P=0.824) was found.
Table 6.5. Interaction of ATI R A1166C and ACE I/D polymorphisms on ERPF and GFR.
ACE I/O
ERPF
GFR
ERP
GFR
ERPF
GFR
AA
436137
11318
389114
11013
405 ±21
11215
AT1RA1166C
AC
393144
11518
393 1 22
11315
347124
10814
CC
30S 1 20
1141 IS
347 1 22
10214
327131
112110
DO
ERPF: effective renal plasma flow; GFR: gtomemlar filtration rate. All variables expressed In
mL/mln/1.73nV.
Discussion
This study investigated renal hemodynamics and hormonal characteristics with
respect to the AT1R A1166C and ACE I/D polymorphisms. The results show that
the AT1R C allele is independently associated with reduced ERPF and GFR, and
increased FF. No significant interactions between the AT1R C allele and known
determinants of renal function (age, gender, BMI, blood pressure) were present.
On the other hand, no differences in renal hemodynamics with respect to the ACE
I/D polymorphism were found. Lastly, interactions of the AT1R C and ACE D alleles
which have previously been reported could not be confirmed for the phenotypes
studied here.
As far as we know this is the first, large sample size study that investigated renal
hemodynamics, using clearance techniques, with respect to both the AT1R
A1166C and ACE I/D polymorphisms. The gold standard in renal function
assessment still are clearance studies of inulin to estimate GFR and PAH (or
analogue) to estimate RPF.
One study found that the average time from the onset of renal disease to end-
stage renal failure in patients with the AT1R C allele was significantly shorter than
in those with the AA genotype (6.3 vs. 13 years).' In line with our data, Miller et al.
showed in a small study of 66 healthy patients (of which 7 had the CC genotype)
that the combined AC/CC genotype group had a lower GFR and ERPF, and an
increased FF and RVR compared to AA subjects.^ However, a comparable study
by Hilgers et al. in male normotensives or mildly hypertensives could not confirm
this." These two studies both investigated normotensives on a high salt diet,
whereas we studied hypertensives on a low salt diet. As the frequency of the C
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allele is higher in hypertensives^ we were able to collect more CC patients. Both
Miller et al. and Hilgers et al. chose to combine AC and CC subjects in one group.
This however, is incorrect as the inheritance is recessive.* This could be a possible
explanation for the negative finding of Hilgers et al. The decreased ERPF and GFR
in the study of Miller et al. that was found in subjects on a high salt diet, a finding
that we could confirm,'' refutes a (major) confounding effect of salt intake on the
association of the AT1R A1166C polymorphism with impaired renal function.
Urinary sodium excretion was not different between the AT1R genotype groups
and adding this variable in the regression model did not change the positive
association of the ATI R C allele with ERPF.
Our findings of a negative association of the ACE I/D polymorphism with renal
function is corroborated by two other studies. One study in a general population
showed that overall renal function, estimated by means of measured and
calculated creatinine clearance, was not significantly different between the
different ACE I/D genotypes.™ Further subgroup analyses revealed that the risk for
mild renal dysfunction (<60 mL/min/1.73 m') was increased in D allele carriers, but
only when the u-adducin Trp allele was present. As creatinine clearance is a fallible
index of GFR,"' especially in the lower ranges, the significance of these findings is
debatable. A second study used radioisotopes for measuring ERPF and GFR and
could also not find a positive association of the ACE I/D polymorphism with renal
function." If anything, the single gene effects on renal function of the ACE D allele
seem to be minor.
By constricting the efferent arteriole of the glomerulus, Angll increases glomerular
pressure to maintain GFR. As a result, ERPF decreases while FF increases. Our
observation of a reduced ERPF and GFR and increased FF in AT1R C allele carriers
fits well in the hypothesis of increased Angll sensitivity that we and others showed
earlier.'"'•" '" Besides increased Angll sensitivity in the acute situation,''<• we
recently showed that the AT1R A1166C polymorphism was associated with
blunted blood pressure responses to losartan-based treatment in a 12 week trial.'
Others showed increased vascular responsiveness of coronary and internal
mammarian arteries to different stimuli in patients carrying the C allele." ^ Thus,
we now have growing evidence that the C allele of the AT1R A1166C
polymorphism is indeed associated with increased Angll sensitivity. Furthermore,
our data suggest that the genetic effect of the C allelle is a recessive one since AC
carriers behave rather similarly as AA subjects.
Regression analysis showed that apart from known determinants of renal function
(age, gender, BMI, and blood pressure), the AT1R C allele is an independent factor
determining ERPF, GFR and FF. Also after adjusting for these covariates the
associations remained. Of these covariates, age is still the major factor
determining renal function. The effect of the AT1R C allele on renal function is
comparable with gender, BMI and blood pressure. Since in our regression model
these determinants together only explained about 20% of the variation in renal
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function, there must be other influences on the kidney that still have to be
elucidated. More studies are needed to unravel other genetic factors involved in
renal function regulation but like in other complex traits (e.g. blood pressure) one
major gene effect is not to be expected.
Although the slope of the regression line of the relationship between ERPF and
age in CC patients compared to AA and AC patients seemed to be less steep, no
significant interaction between the C allele and age was present. We suspect that
CC subjects already have impaired renal function at birth, but that the age-
dependent decline is not accelerated by this allele. Taking this a step further, one
could even hypothesize that due to the increased Angll sensitivity, this
polymorphism leads to impaired intra-uterine renal development and, therefore,
that these subjects start their lives with impaired renal reserve. On the other hand,
however, it cannot be ruled out that subjects with a lower GFR experience a more
stable renal function in the long term as compared with those with a higher GFR
(and probably higher glomerular pressure). Of course, other studies are necessary
to explore these possibilities in greater detail.
Earlier studies reported that the AT1R A1166C and ACE I/D polymorphisms work
synergistically on blood pressure variation and the risk for myocardial
infarction,''"'* and for this reason we were interested in the interaction of both
polymorphisms on renal function. However, we could not confirm such an
interaction, just as we failed to do so with respect to blood pressure."
It remains elusive, why the C allele of the AT1R A1166C polymorphism is
associated with increased sensitivity to Angll and, in the end, an increased
incidence of cardiovascular disease.'""**-** AS we* and others** did not find
differences in the number of platelet AT1R binding sites (Bm^ x) and Angll affinity
(KD), differences probably cannot be explained by the number and function of the
AT1R. On the other hand, one should realize that the platelet model is just a
surrogate model for the RAS in the systemic circulation, as well as in the kidneys
and adrenals. With a low number of ATlRs**'*' per platelet (about 4 to 6) the
limitations of this model in showing prominent differences in AT1R number and
function are clear. Because this polymorphism is located in the uncoding 3'-region
of the AT1R gene it could be in linkage disequilibrium with a coding mutation
nearby. However, Poirier et al. rescanned the AT1R gene, but did not find new
variants which could affect the regulation of the gene in response to Angll.'"'
Furthermore, the binding of AUF1, a protein that affects AT1R mRNA stability
through binding to AU-rich regions of the uncoding 3'-untranslated region of the
mRNA, is not affected by this polymorphism."'
In conclusion, the present study shows that the C allele of the AT1R A1166C
polymorphism is associated with reduced ERPF and GFR, and increased FF. As the
presence of the AT1R C allele and age are both independent factors determining
ERPF, it is conceivable that CC subjects are prone to develop hypertension at an
earlier stage than those carrying one or two A alleles.
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Abstract
Several investigations have shown heterogeneity in the functional responses to
angiotensin II (Angll) in patients with essential hypertension. The present study was
initiated to evaluate whether the A1166C polymorphism of the Angll type 1 receptor (AT1R)
gene contributes to this variability in Angll responses.
After 7 days high sodium diet (220 mmol Na7day) we measured in 42 essential
hypertensive patients blood pressure, heart rate (HR), effective renal plasma flow (ERPF),
glomerular filtration rate (GFR), active plasma renin concentration (APRC), aldosterone, and
atrial natriuretic peptide (ANP) before and during Angll infusion (increasing doses of 0.3,1.0
and 3.0 ng/kg/min). Calculated variables were filtration fraction (FF) and renal vascular
resistance (RVR). Patients in the three genotype groups (AA: n=14; AC: n=17;CC:n=11) were
matched for sex, age, and body mass index.
*#*<//**
At baseline, CC patients had decreased GFR (P=0.06) and aldosterone (P<0.05), and
increased ANP (P<0.05) as compared to AA patients. Moreover, responses of ERPF, GFR and
RVR to the lowest concentration of Angll (0.3 ng/kg/min) were more pronounced in CC
patients compared to AA patients (ERPF/GFR: P<0.05; RVR: P=0.07), whereas maximal
responses were all comparable between the groups. HR was decreased at all levels of Angll
infusion in CC patients, while it did not change in AA or AC patients. There were no
differences in responses of APRC, aldosterone, and ANP to Angll between the three groups.
From these data we conclude that the C allele of the AT1R A1166C polymorphism is
associated with increased sensitivity, but not reactivity to Angll.
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Introduction
One of the striking features of essential hypertension is the heterogeneity of
patients' responses to angiotensin II (Angll).' This is not only apparent in situations
where the formation or action of endogenous Angll is blocked, but also when
exogenous Angll is administered. Besides interindividual differences in responses
to Angll, there is marked variability in tissue sensitivity to this peptide. For
instance, we and others have shown that the kidney is more sensitive to Angll
than the systemic vasculature and that an enhanced responsiveness cannot be
explained satisfactorily from differences in plasma levels of Angll.-'' Ultimately,
however, it is the Angll type 1 receptor (AT1R) which translates angiotensin
stimulation into a (patho)physiological response. Recently, it was found that the
A1166C polymorphism of the AT1R gene is associated with essential
hypertension* and myocardial infarction."" The C allele of this polymorphism even
shows a synergistical interaction with the D allele of the angiotensin-converting
enzyme (ACE) insertion/deletion polymorphism with respect to the risk of
myocardial infarction.* In addition, the C allele seems to be an independent
determinant of aortic stiffness/ Although these studies suggest that the A1166C
AT1R polymorphism contributes to cardiovascular disease, the exact role of this
polymorphism in the pathophysiology of hypertension is as yet unclear.
Moreover, no unequivocal data exist to show that this polymorphism may account
for (part of) the variability in responsiveness to exogenous Angll, especially with
regard to renal hemodynamics. Therefore, we conducted a study in which we
investigated the possible influence of the A1166C polymorphism of the AT1R on
the reactivity to Angll in hypertensive patients. To this end, we measured systemic
and renal hemodynamic responses as well as humoral changes during infusion of
graded doses of Angll. Studies were performed under conditions of high salt
intake, since this augments the responsiveness to exogenous Angll."' Since
patients with the CC genotype run an increased risk of cardiovascular
complications, we hypothesized that C allele carriers exhibit an increased
responsiveness to Angll.
Methods
Patients
A genetic database of hypertensive patients was screened for those with the
relatively rare CC genotype of the AT1R A1166C polymorphism. Eleven patients
with this genotype were selected. Subsequently, the database was searched for
patients with the AA and AC genotype to match with the selected CC patients for
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age, sex, and body mass index (BMI). Secondary hypertension was excluded on
the basis of clinical and laboratory evalutation, as well as renal angiography if
necessary. All 42 selected patients (14 AA, 17 AC, 11 CC) gave written informed
consent to participate in the study. The study was approved by the Medical Ethics
Committee of the University Hospital Maastricht.
Genetic analysis
DNA was extracted from whole blood with the use of the QIAamp' Blood Kit
(Qiagen Inc., Valencia, CA, USA). We adopted the mutagenically separated PCR
technique'" to determine the genotype of the AT1R A1166C mutation. Briefly, two
allele-specific primers and their nonselective complementary strand primer were
mixed and used for the PCR amplification in a single reaction. In addition to the
base substitution, deliberate differences were introduced into the allele-specific
primers. In that way we were able to drastically reduce cross-reactions between
two allelic PCRs in a mixed reaction. The following primers were used:
• FP1166A, 5'-CTC TGC AGC ACT TCA CTA CCA AAT GAT. CA-3'
• FP1166C, 5'-GAA GGA GCA AGA GAA CAT TCG ACT GCA GCA CTT CAC TAC
CAAATGAGAC.-3'
• RP1166, 5'-TGC CGA CGA GCT TCT TGT TAC AGT CTT T-3'
(deliberated differences and base substitutions are underlined). The size of PCR
products were 190 bp and 210 bp for the 1166A and 1166C alleles, respectively.
These products were resolved on a 3% agarose gel.
Angll infusion protocol
Patients were investigated after 7 days of high salt diet (220 mmol Na7day), with a
fixed potassium intake of 80 mmol/day. The rationale for a high salt intake is that
under these circumstances, the endogenous Angll level is low, and therefore a
response to exogenous Ang II is more pronounced and can be detected better
than under low salt conditions." Compliance with the diet was checked by
measuring sodium, potassium and creatinine output in 24 hour urine collections
obtained during the last day of the dietary period. Antihypertensive medication
had been stopped two weeks prior to the start of dietary intervention. Patients
refrained from nicotine, alcohol, caffeine and caffeine-like substances from 8:00
PM the evening before the measurements. Experiments started at 8:30 AM after
an overnight fast and patients remained supine during the entire session. In both
arms an antecubital vein was cannulated with a 20G cannula. The cannula in the
right arm was connected to a 3-way tap for the infusion of Angll and para-
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aminohippurate (PAH)/inulin (for measuring renal hemodynamics), whereas the
cannula in the left arm was used for blood sampling. To ensure diuresis, subjects
consumed 200 m l of water every hour until the last blood samples had been
drawn. After a two-hour equilibration period, necessary to reach steady state
plasma concentrations of PAH and inulin, stepwise increasing doses (0.3, 1.0 and
3.0 ng/kg/min) of human Angll (Clinalpha AG, Laufelfingen, Switserland) were
administered. Each infusion step was continued for 30 minutes to allow renal
clearances to reach a new steady state. Blood pressure and heart rate (HR) were
measured at a 3-minute time interval and after each infusion period blood
samples were drawn for measurement of PAH, inulin, hematocrit and plasma
levels of Angll, active plasma renin concentration (APRC), aldosterone and atrial
natriuretic peptide (ANP). Blood samples for measurement of ACE were drawn
only at baseline. All samples were stored at -80" C until assay. For each
determination, all samples from the same individual were assayed in a single run.
Hemodynamic methods
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) and HR were
measured by a semi-automatic oscillometric device (Dinamap Vital Signs Monitor
1846, Critikon, Tampa, FL, USA). Renal hemodynamics, i.e. effective renal plasma
flow (ERPF) and glomerular filtration rate (GFR) were measured as the clearance of
PAH (Merck Sharp & Dohme, West Point, PA, USA) and inulin (Inutest, Laevosan
Gesellschaft, Linz, Austria) respectively, using the continuous infusion method.'^
Both variables were corrected for body surface area and expressed as
mL/min/1.73 m .^ Effective renal blood flow (ERBF) was calculated using the
formula: ERPF/(1 -hematocrit). Filtration fraction (FF) was calculated as GFR/ERPF.
Renal vascular resistance (RVR) was calculated according to the formula: (mean
blood pressure/ERBF)-80,000 and expressed in dynes-sec-cm •*.
Assay methods
APRC was measured by a two-site direct immunoassay {Nichols Institute
Diagnostics, San Juan Capistrano, CA, USA)." For measuring Angll, blood samples
were collected in tubes containing an inhibitor solution to prevent /n v/fro
generation and degradation of this peptide,''' and spun immediately in a cooled
centrifuge. Subsequently, the plasma was quickly frozen in liquid nitrogen.
Hereafter, Angll was determined by ' " I radioimmunoassay (RIA) following ethanol
extraction (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA).
Aldosterone was assayed by means of a solid-phase protein binding RIA
(Diagnostic Products Corporation, Los Angeles, CA, USA).'^  ANP was measured by
a ' " | RIA (DiaSorin Inc., Stillwater, MN, USA). ACE, PAH and inulin levels were
measured by means of a spectrophotometer.'^•'« Intra- and intercoefficients of
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variation of all assays were <10%. All samples from the same individual were
assayed in a single run.
Statistical analysis
Sample size was estimated on the basis of the variability of the assay methods as
derived from earlier studies. Of all measurements, assessment of ERPF has been
shown to be the one with the highest standard deviation (in our hands 6.4%). A
difference in ERPF >10% can be detected in this study with a power of 0.8. Results
are expressed as means ± standard error of the mean (SEM). Because of small
samples sizes (n<20) non-parametric tests were used. To compare data between
groups (AA, AC, and CC) a two step approach was used. First, overall differences
between groups were evaluated by means of Kruskall-Wallis analysis of variance.
When these analyses revealed a significant effect of genotype, data were further
tested by pairwise comparisons using the Mann-Whitney f test. To compare the
effect of Angll infusion w/f/i/n groups, data were analysed by the Friedman test.
Furthermore, results were analysed according to a recessive C allele model (AA/AC
patients versus CC patients) and to a dominant C allele model (AA patients versus
AC/CC patients). A P-value of less than 0.05 was considered to be statistically
significant. Statistical analyses were performed using SPSS 11.0 for Windows (SPSS
Inc., Chicago, IL, UbA).
Results
Baseline characteristics
The baseline characteristics of the three genotype groups are summarized in
Table 7.1. There were no significant differences in age, BMI, and 24 hour urinary
sodium excretion (UN..V) between the groups. Systolic blood pressure (SBP) was
higher in AC patients compared to AA patients (P<0.05). HR was lower in CC
patients compared to AA patients (P<0.05). GFR in CC patients was slightly lower
compared to AA patients (P=0.06). Also, plasma aldosterone was lower in CC
patients both when compared to AA and when compared to AC patients (P<0.05).
Plasma ANP was significantly higher in CC patients compared to AA patients
(P<0.05). RVR, ERPF, ERBF, FF, APRC, Angll and ACE were comparable in the three
groups.
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Table 7.1. Baseline characteristics.
Number (male/female)
Age, years
BMI. Jtg/m-'
SBP, mmHj
DBP. mmHg
Heart rate, bears/rrv'n
UN.V. mmo//^4/ir
ERPF. mi/min/l.7Jm'
GfR.mL'rn/n/).73nT'
FF
RVR rfynes sec-cm'
APRC. my/t
Angll, pmo//l
Aldosterone, nmot l
ACE, IM.
ANP, ng/l
14 (8/6)
45 ± 3
27.0 ± 0.9
150 ±8
9015
68±3
214122
415123
12815
0.32 1 0.01
1369411258
16.713.7
16.31 2.7
0.25 1 0.06
17.21 1.2
42.118.3
17(9/8)
4913
26.711.1
17217*
9414
6613
218119
407122
12516
0.3110.01
1527211324
10.911.2
12.611.5
0.2110.03
14.610.9
58.617.4
4814
25.41 1.1
15517
8913
6013*
236126
391 ±36
11415
0.31 1 0.02
149461 1369
10.51 1.4
14.21 3.0
0.11 10.02"*
17.01 1.2
82.21 13 1 "
BMI: body mass index; SBP: systolic blood pressure; D8P: diastollc blood pressure; UN,.V urinary
sodium excretion; ERPF: effective renal plasma flow; ERBF: effective renal blood flow; GFR: glomerular
filtration rate; FF: filtration fraction; RVR: renal vascular resistance; APRC: active plasma renln
concentration; Angll: angiotensin II; ACE: angiotensin-converting enzyme; ANP: atrlal natriuretlc
peptide; »P<0.05 vs. AA; 'P<0.05 vs. AC.
Responses to Angll
Plasma Angll levels were comparable for all genotype groups during the different
infusion doses of Angll. A significant increase during Angll infusion within all
groups was found for SBP, diastolic blood pressure (DBP), RVR, Angll, aldosterone,
and ANP, whereas a significant decrease during Angll infusion within all groups
was found for ERPF, ERBF, and APRC. No differences were found between the
genotype groups for both SBP and DBP at any dose of Angll. During infusion of all
doses of Angll, HR showed a decrease in CC patients, while it did not change in AA
and AC patients (Figure 7.1). (Borderline) significant differences in HR were found
between AC and CC patients at 0.3 and 1.0 ng/kg/min, and between AA and CC at
0.3 and 3.0 ng/kg/min. At the lowest dose of Angll, GFR showed a small increase in
AA patients, in contrast to a small decrease in CC patients (P<0.05; Figure 7.2). No
differences between the genotype groups were found at the higher doses. ERPF in
AA and AC patients did not change at the lowest dose, whereas CC patients
showed a marked decrease which was significantly different from the response in
AA patients (P<0.05; Figure 7.3). No differences between the genotype groups
were found at the higher doses. The increase in RVR during the lowest dose was
more pronounced also in CC patients compared to AA patients, although not
significantly (P=0.07; Figure 7.4). Again no differences between the genotype
groups were found at the higher doses. There were no differences between the
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genotype groups with respect to changes in FF, APRC, aldosterone, and ANP
during the three doses of Angll.
Genetic model
Comparing a recessive C allele model (AA/AC patients versus CC patients) with a
dominant C allele model (AA patients versus AC/CC patients) showed that the
differences as described above remained only significant in the recessive model.
-10-1 0 3 10 3 0 ng AnglVkg/min
Figure 7.1. Responses of HR to increasing doses of continuously infused Angll.
0 3 10 3 0 ng AnglVkg/min
Figure 7.2. Responses of GFR to increasing doses of continuously infused Angll.
5-,
0-
0 3 10 3 0 ng AngVkg/mn
Figure 7.3. Responses of ERPF to increasing doses of continuously infused Angll.
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0 3 10 30 ng AngWkgtaw
Figure 7.4. Responses of RVR to increasing doses of continuously infused Angll.
Discussion
This study investigated the potential role of the AT1R A1166C polymorphism in
the renal hemodynamic and humoral responses to Angll in essential hypertensive
patients during high sodium diet. Our data show that patients with the CC
genotype display an exaggerated response of GFR, ERPF and RVR to Angll at a low
dose of 0.3 ng/kg/min, but not at the higher doses employed. In addition, we
found that CC patients, in contrast to the others, respond to Angll with an overall
decrease in HR. Thus, except for the changes in HR, phenotypic differences
between the groups were observed only at the lowest dose when plasma levels of
Angll remain within the physiological range. Because responses to Angll during
the supraphysiological doses of 1.0 and 3.0 ng/kg/min were comparable between
the genotype groups, our data indicate that sensitivity, but not reactivity to Angll
is increased in CC patients. These findings are in line with observations by others
showing increased vascular responsiveness of coronary and internal mammarian
arteries, to different stimuli in patients carrying the C allele.'-' '^
We did not find any differences between the genotype groups with respect to
their humoral responses to Angll. This is in agreement with the data of Giacche et
al. who measured the aldosterone response to Angll in Caucasian hypertensives
after a low salt diet and found no differences between the genotype groups."
Unfortunately, they only infused 3.0 ng/kg/min and they did not study their
patients after a high salt diet, when the effects of exogenous Angll are likely to be
more pronounced."'
Recently, after we had completed our investigation, a study like ours was
published in which no differences in response to Angll between the 3 genotypes
were found.™ However, the authors of that study used a higher initial dose of
Angll: 0.5 ng/kg/min. This dose may already be too high to find the increased
sensitivity to Angll. Furthermore, the data they presented were based on 15 min
infusions, which could be too short to attain a steady state effect of Angll. Finally,
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the heterogeneous population of normo- and hypertensive subjects in that study
could also explain the discrepancies with the results we found.
Although it is not readily apparent why CC patients exhibit an exaggerated renal
hemodynamic response to a low dose of Angll, it may be related to an altered
renal sodium handling. Normally, when an individual switches from a low to a
high sodium diet, (renal) vascular responsiveness to Angll increases with a
concurrent decline in adrenal responsiveness."" In our study, all patients adhered
to the same diet, yet CC patients seemed to respond as if they were more salt
repleted than the others. In this respect it is striking that already at baseline,
patients with the CC genotype had lower plasma aldosterone and higher plasma
ANP levels as compared to the AA genotype. Although we did not measure body
fluid volumes, the latter combination strongly suggests that, at least after one
week of high sodium intake, CC patients are relatively hypervolemic. Since we did
not study our patients at low salt intake, we do not know whether this relative
hypervolemia is an intrinsic abnormality of CC patients or that it becomes evident
only at a high salt intake. Whatever the case may be, we can only speculate why
CC patients apparently fail to adjust their (circulating) volume in response to a
high salt diet. As tubular reabsorption of sodium is partly regulated by Angll, it is
possible that the responses of renal tubular cells to Angll are enhanced as well in
patients with the CC genotype. Indeed, the fact that CC patients had comparable
Angll levels as the other genotype groups, but tended to have a lower GFR and
ERPF and a higher RVR even before the Angll infusion was started, suggests that
these patients may also be hyperresponsive to endogenous Angll.
A remarkable finding in our data concerns HR which not only was significantly
lower in CC patients as compared to AA patients before the infusion, but also
slowed down at all levels of Angll infusion in CC patients while it did not change
appreciably in the others. All these differences occurred in the face of comparable
blood pressures. Therefore, it seems as if baroreceptor sensitivity is enhanced in
CC patients which would be in line with our 'hypervolemia hypothesis'. Indeed, if
we assume that circulating volume is increased in CC patients, then a
baroreceptor-mediated decline in HR would be one mechanism to prevent too
much of a rise in blood pressure.
Although several of our data suggest an 'allele dose effect', further analysis in
which combinations of genotypes were compared (AA versus AC/CC and AA/AC
versus CC), points towards a recessive effect of the C allele. This indicates that it is
highly probable that the significant results found in CC patients have to be
explained by the genotype of the AT1R A1166C polymorphism rather than by
chance.
It remains elusive, why the C allele of the AT1R A1166C polymorphism is
associated with increased sensitivity to Angll and, in the end, an increased
incidence of cardiovascular disease.*-'-*'-" As w e " and others" did not find
differences in the number of platelet AT1R binding sites (Bm*») and Angll affinity
1 14
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). differences probably cannot be explained by the number and function of the
AT1R. On the other hand, one should realize that the platelet model is just a
surrogate model for the renin-angiotensin system in the systemic circulation, as
well as in the kidneys and adrenals. With a low number of ATlRs"*' per platelet
(about 4 to 6) the limitations of this model in showing prominent differences in
AT1R number and function are clear. Because this polymorphism is located in the
uncoding 3'-region of the AT1R gene it could be in linkage disequilibrium with a
coding mutation nearby. However, Poirier et al. rescanned the AT1R gene, but did
not find new variants which could affect the regulation of the gene in response to
Angll.'•> Furthermore, the binding of AUF1, a protein that affects AT1R mRNA
stability through binding to AU-rich regions of the uncoding 3-untranslated
region of the mRNA, is not affected by this polymorphism."
In conclusion, we have found that the genotype of the AT1R A1166C
polymorphism is yet another factor that needs to be taken into account when
assessing the effects of Angll on the kidney. Increased sensitivity to Angll may well
be associated with a tendency for volume expansion and hence volume-
dependent hypertension. ......
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Abstract
Clinical observations point towards heterogeneity in patients' responses to
antihypertensive drugs. In all likelihood, this is at least in part genetically determined. As
our earlier work showed that angiotensin II (Angll) sensitivity is associated with the A1166C
polymorphism of the Angll type 1 receptor (AT1R) gene, we conducted the present study in
which the responses to acute ATI R blockade were studied.
After both 7 days of low (55 mmol NaVday) and high (220 mmol NaVday) sodium diet, the
systemic and renal hemodynamic as well as humoral effects of acute AT1R blockade with
EXP3174 (active metabolite of losartan) were studied in 29 essential hypertensive patients
genotyped for the AT1R A1166C polymorphism (15 AA and 14 CC). By means of platelet-
binding studies the baseline ATI R density (B™«) and affinity (KD) was tested.
During low and high salt diet, baseline Bm« and KD were comparable between both
genotype groups. At baseline, during low salt diet, CC patients had significantly lower
glomerular filtration rate and nearly significantly lower effective renal plasma flow (ERPF)
compared to AA patients. Blood pressure responses to EXP3174 during high salt were
significantly blunted in CC patients compared to AA patients (mean arterial pressure: 1.8%
vs. 7.5%). During low salt the increase in ERPF (12.9% vs. 16.1%), as well as the decrease in
filtration fraction (9.0% vs. 14.0%) and renal vascular resistance (7.5% vs. 15.1%) were
blunted in CC patients compared to AA patients. Humoral effects were not different
between the groups.
This study shows that the systemic and renal hemodynamic responses to acute AT1R
blockade are at least in part genetically determined.
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Introduction
One of the striking features of essential hypertension is the heterogeneity of
patients' responses to antihypertensive drugs. Recent data indicate that this is. at
least partly, genetically determined and that genetic polymorphisms in effector
systems may predict the responsiveness to pharmacological agents.*' An
outstanding example where this supposition could be tested is the interaction
between the polymorphisms of the angiotensin II (Angll) type 1 receptor (AT1R)
and the response to AT1R blockade. The gene coding for the AT1R has a
polymorphism (A1166C) in the 3'-untranslated region, which was found to be
associated with myocardial infarction,' hypertension/"• pregnancy-induced
hypertension,* lacunar infarction,' and faster deterioration of renal function." We
recently found that Angll sensitivity is also associated with this polymorphism,'
with C allele carriers showing an increased renovascular sensitivity to Angll,
Whether responsiveness to AT1R blockade is also different in relation to this
polymorphism is not well known. In one study, Miller et al. found blunted humoral
and renal hemodynamic responses in AA subjects compared to AC/CC subjects
after a single oral dose of losartan.'" However, since the acute effects of AT1R
blockade were not assessed by intravenous administration of the antagonist,
differences in biological availability could have contributed at least partially to the
variation in response. Moreover, only 7 CC subjects were studied who were
pooled with the AC patients for analysis. This prompted us to conduct a study on
the systemic and renal hemodynamic as well as humoral effects of intravenously
infused EXP3174 (the active metabolite of losartan) in hypertensive subjects with
either the AA or the CC genotype. By selecting patients who were homozygous for
either the wild type or the mutant receptor gene, we aimed to maximize the
contrast between groups. For this reason, we also refrained from including a
heterozygous group of patients. Based on our earlier finding of increased Angll
sensitivity in CC subjects, we anticipated that C allele carriers would exhibit a
potentiated response as compared to AA patients.
Methods
Patients
A genetic database of hypertensive patients from the Hypertension Research Unit
of the University Hospital Maastricht was screened for those genotyped for the
AT1R A1166C polymorphism. Patients entered the study if they fulfilled all the
inclusion criteria: age between 18 and 80 years, Caucasian, hypertension
according to World Health Organization-International Society of Hypertension
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criteria", able to stop antihypertensive medication for 4 weeks. Exclusion criteria
were secondary hypertension, congestive heart failure (New York Heart
Association classes II through IV), hepatic (> Child-Pugh B) or renal insufficiency
(creatinine clearance <60 mL/min). Detailed evaluation of hormones and
endocrine metabolites was conducted if indicated. In case of clinical suspicion of a
renal artery stenosis, renal angiography was performed. Twenty-nine hypertensive
patients (15 AA and 14 CC) were selected matched for age, sex and body mass
index (BMI). All selected patients gave written informed consent to participate in
the study. The study was approved by the Medical Ethics Committee of the
University Hospital Maastricht.
Genetic analysis
DNA was extracted from whole blood with the use of the QIAamp' Blood Kit
(Qiagen Inc., Valencia, CA, USA). The AT1R A1166C polymorphism was genotyped
with means of mutagenically separated PCR, as described earlier.'
EXP3174 infusion protocol
All patients started with a low salt diet (55 mmol Na7day), subsequently followed
by a high salt diet (220 mmol NaVday), both with a fixed potassium intake of 80
mmol/day. Compliance with the diets was checked by measuring sodium,
potassium and creatinine output in two 24 hour urine collections obtained during
the last 2 days of the dietary period. Infusion experiments took place on the last
day of each salt diet. Antihypertensive medication had been stopped two weeks
prior to the start of the low salt diet and was continued during both salt diets.
Patients refrained from nicotine, alcohol, caffeine and caffeine-like substances
from 8:00 PM the evening before the measurements. Experiments started at 8:30
AM after an overnight fast and patients remained supine during the entire session.
In both arms an antecubital vein was cannulated with a 20G cannula. The cannula
in the right arm was connected to a 3-way tap for the infusion of EXP3174 and
para-aminohippurate (PAH)/inulin (for measuring renal hemodynamics), whereas
the cannula in the left arm was used for blood sampling. To ensure diuresis,
subjects consumed 200 mL of water every hour until the last blood samples had
been drawn. After a two-hour equilibration period, necessary to reach steady state
plasma concentrations of PAH and inulin, stepwise increasing doses (1.0, 3.0 and
10.0 ng/kg/min) of EXP3174 (active metabolite of losartan; generous gift of Merck
Sharp & Dohme, West Point, PA, USA) were administered. Each infusion step was
continued for 30 minutes to allow renal clearances to reach a new steady state.
Blood pressure and heart rate (HR) were measured at a 3-minute time interval and
after each infusion period blood samples were drawn for measurement of PAH,
inulin, hematocrit and plasma levels of Angll, active plasma renin concentration
(APRC) and aldosterone. Blood samples for measurement of angiotensin-
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converting enzyme (ACE) were drawn only at baseline. All samples were stored at -
80° C until assay.
Hemodynamic methods
Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean blood pressure
(MBP) and HR were measured by a semi-automatic oscillometric device (Dinamap
Vital Signs Monitor 1846, Critikon, Tampa, FL, USA). Pulse pressure (PP) was
calculated as the difference between SBP and DBP. Renal hemodynamics, i.e.
effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) were
measured as the clearance of PAH (Merck Sharp & Dohme, West Point, PA, USA)
and inulin (Inutest, Laevosan Gesellschaft, Linz, Austria) respectively, using the
continuous infusion method.'-' Both variables were corrected for body surface
area and expressed as mL/min/1.73 m'. Effective renal blood flow (ERBF) was
calculated using the formula: ERPF/(1-hematocrit). Filtration fraction (FF) was
calculated as GFR/ERPF. Renal vascular resistance (RVR) was calculated according
to the formula: (MBP/ERBF)-80,000 and expressed in dynes-sec-cm >.
Assay methods
Active plasma renin concentration (APRC) was measured by a two-site direct
immunoassay (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA)." For
measuring Angll, blood samples were collected in tubes containing an inhibitor
solution to prevent ;n w'fro generation and degradation of this peptide,'" and spun
immediately in a cooled centrifuge. Subsequently, the plasma was quickly frozen
in liquid nitrogen. Hereafter, Angll was determined by ' " I radioimmunoassay (RIA)
following extraction from plasma. Aldosterone was assayed by means of a solid-
phase protein binding RIA (Diagnostic Products Corporation, Los Angeles, CA,
USA).'* ACE, PAH and inulin levels were measured spectrophotometrically.'*'*
Intra- and interassaycoefficients of variation of all assays were <10%. All samples
from the same individual were assayed in a single run.
Platelet-binding studies
Platelet-rich plasma was obtained from 20 mL of venous blood (collected in a
sodiumcitrate containing glass tube) by centrifugation at 100g for 15 minutes at
room temperature. It was then washed with 20 volumes of cold Tris-buffered
saline (Tris-HCI 50 mmol/L, NaCI 100 mmol/L, NajEDTA 5 mmol/L, 0.05% BSA, pH
7.4) and centrifuged at 1000g for 15 minutes at 4C. After repeating washings and
centrifugations once more, platelets were resuspended in assay buffer. The
suspension platelet number was determined automatically in a Coulter counter
and the volume was adjusted to give a final platelet number of IOVUL.
Incubations were performed in a total volume of 250 jiL that included 100 |iL of
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platelet suspension. Saturation equilibrium binding studies were performed in the
presence of increasing concentrations of '"l-labeled Angll (0.040-1.000 nmol/L;
Amersham, Buckinghamshire, UK). Nonspecific binding was ascertained in the
presence of 10 (amol/L of unlabeled Angll. Incubation was performed for 90
minutes at 25 C in a shaking warm water bath. At the end of the incubation
period, 4 mL of ice-cold assay buffer was added to each tube and the platelets
were separated from the buffer by vacuum-filtration over GF/C Whatman filters
(Whatman, Maidstone, UK). Radioactivity of the GF/C filter was measured in a LKB-
Wallac gamma counter. The results of the saturation binding assays were analyzed
by Scatchard transformation of the data to calculate the /Co and the number of
sites Bm«.
Statistical analysis
Sample size was estimated on the basis of the variability of the assay methods as
derived from earlier studies. Of all measurements, assessment of ERPF has been
shown to be the one with the highest standard deviation (in our hands 6.4%). A
difference in ERPF > 13% can be detected in this study with a power of 0.8. Results
are expressed as means + standard error of the mean (SEM). To avoid the problem
of repeated measures, we used maximum responses (increase or decrease) during
EXP3174 infusion of each patient for statistical analysis. Because of small sample
sizes (n<20) non-parametric tests were used. A P-value of less than 0.05 was
considered to be statistically significant. Statistical analyses were performed using
SPSS 11.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Baseline characteristics of the two genotype groups are summarized in Tables
8.1-3. There were no significant differences in gender, age, body mass index (BMI)
and serum ACE concentration. During low salt diet CC patients showed a lower
GFR (P<0.05) and slightly lower ERPF (P=0.08) compared to AA patients. Although
compliance with the diet was not optimal, the expected shift in sodium excretion
when going from the low to the high salt diet was found in each patient. The
number of platelet AT1R binding sites (B,,,,,,) and Angll affinity (Ko) were
comparable for both genotype groups during both low and high salt.
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Table 8.1. Baseline characteristics.
Variable AA CC
Number (male/female) 15(8/7) 14(8/6)
Age.yeors 52 ± 3 55 ± 2
BMUg/m-' 27.2 ± I J 28-5 ±1.3
ACE.U/1 151 1 1 5 * 2
BMI: body mass index; ACE: angkttensin-converting enzyme.
Table 8.2. Baseline systemic, renal hemodynamic and humoral characteristics during low salt.
Variable A A C C
V, mmo//24rir 83 ±12 81 ± 13 <
MBP. mmHg 124 ± 4 122 ±5
ERPF,mi/m/n/».73frr' 373 ±24 307 ± 27
GFR.mCmin/J.7im* 114* 7 94 ± 5*
FF 0.3110.02 0.33 ±0.02
RVR. rfyn« MC-on' 16400 ± 1267 17756* 1741
APRC.mUA 14.7±2.3 15.8±2.3
Angll, pmofl 8.4 ±2.1 6.5 ±0.9
Aldosterone. nmol/I 0.21 ±0.03 0.26 ± 0.03
B^rmo/WO'ptofWws 5.86 ±1.36 4.27 ± 0.57
Ko.pmol/I. 672.0±211.5 615.9± 172.7
UNaV: urinary sodium excretion; MBP: mean blood pressure; ERPF: effective renal plasma flow; GFR:
glomerular filtration rate; FF: filtration fraction; RVR: renal vascular resistance; APRC: active plasma
renin concentration; Angll: angiotensin II; Bma«: maximum number of specific binding sites; KD:
equilibrium dissociation constant; *P<0.05 vs. AA.
Table 8.3. Baseline systemic, renal hemodynamic and humoral characteristics during high salt.
Variable AA CC
UN-V, mmo//24hr 147±14 172±15
MBP, mmHg 129 ± 5 120 ±3
ERPF, mt/m/n/;.73ny 370 ±33 299 ±25
GFR, ml/min//.73 m> 114 ± 7 98 ± 7
FF 0.33 ± 0 . 0 2 0.34 ±0 .02
RVR, dynes-sec-cm * 17810 ± 2138 17901 ± 1392
APRCmU/1 12.7 ± 2 . 3 12.0 ± 1 . 7
Angll,pmo//L 5 . 2 ± 1 . 2 5.6 ± 1.1
Aldosterone, nmo//L 0.19 ± 0.04 0.19 ± 0.03
B™,,frno//;0»p/afe/ets 6.40 ± 1.25 S.67±1.48
Ko,pmo/ /L 632.0 ±231.6 565.6 ±147.5
UNJV: urinary sodium excretion; MBP: mean blood pressure; ERPF: effective renal plasma flow; GFR:
glomerular filtration rate; FF: filtration fraction; RVR: renal vascular resistance; APRC: active plasma
renin concentration; Angll: angiotensin II; Bm«: maximum number of specific binding sites; KD:
equilibrium dissociation constant.
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Low so/f
There were no significant differences in responses for SBP (Figure 8.1), DBP (Figure
8.2), MBP and PP between the groups. CC patients showed a small, but significant
increase (5 bpm (7.9%)) in HR (P<0.05 vs. AA response; Figure 8.3). The absolute
increase in ERPF was 61 mL/min/1.73 nV in AA subjects, compared to only 29
mL/min/1.73 m-' in CC patients (P<0.01). After correcting for the lower ERPF at
baseline in CC patients, the blunted increase in ERPF in these patients was 12.9%
compared to 16.1% in AA patients (P=0.08; Figure 8.4). GFR showed no significant
change during EXP3174 infusion, but FF decreased by 14.0% in AA patients and by
9.0% in CC patients (P=0.05). RVR fell by 15.1% in AA patients compared to 7.5% in
CC patients (P=0.06 vs. AA response). APRC and Angll rose, and aldosterone fell to
a comparable degree in both groups. The time (i.e. dose of EXP3174) at which
maximum responses were found were comparable between both groups, and
were on average between 60 and 90 minutes for all variables.
H/gh so/f
Significant differences for blood pressure responses between the genotype
groups were found. On average SBP fell by 12 mmHg (6.6%) in the AA patients,
compared to only 2 mmHg (1.3%) in the CC patients (P<0.01; Figure 8.1). For DBP
these figures were 7 and 2 mmHg (6.7 and 2.4%), respectively (P<0.05; Figure 8.2)
and for MBP 10 and 2 mmHg (7.5 and 1.8%) (P<0.05). PP did not respond
differently between the genotype groups. HR increased in CC patients by 4 bpm
versus 2 bpm in AA patients (3.9 versus 7.0%) (P=0.06; Figure 8.3). The increments
in ERPF (Figure 8.4), GFR, APRC and Angll, as well as the decreases in FF, RVR and
aldosterone were not significantly different between the genotype groups. As
during low salt, the time at which maximum responses were found were
comparable between both groups, and were on average between 60 and 90
minutes for all variables.
bw«ft hlghMlt
i
W5 01
Figure 8.1. Maximum percentage change of SBP to infusion of EXP3174.
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Figure 8.2 Maximum percentage change of OBP to infusion of EXP3! 74.
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Figure 8.3. Maximum percentage change of HR to infusion of EXP3174.
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Figure 8.4. Maximum percentage change of ERPF to infusion of EXP3174.
Discussion
This study investigated the systemic and renal hemodynamic as well as humoral
responses to acute AT1R blockade with the active metabolite of losartan
(EXP3174) in relation to the AT1R A1166C polymorphism in essential
hypertensives. Patients were examined during both a low and high sodium diet in
order to allow evaluation of responses at different levels of activity of the renin-
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angiotensin system (RAS). Earlier work of our group revealed that CC patients have
an increased intrarenal Angll sensitivity during a high salt diet as compared to AA
patients.' Therefore, we anticipated that, at least during a high salt diet, C allele
carriers would also exhibit a potentiated responsiveness to ATI R blockade.
At baseline, in the low salt state, GFR and ERPF were lower while RVR tended to be
higher in CC patients compared to AA patients. At high sodium intake, similar
trends were observed, but differences were no longer statistically significant.
Miller et al. also found ERPF and GFR to be higher and RVR to be lower in AA
subjects during high salt diet when compared to the combined group of AC and
CC individuals.'" However, a comparable study of Hilgers et al. in male normo- or
mildly hypertensives could not confirm this." We recently completed a large
study in which we studied renal hemodynamics in 212 essential hypertensives on
a low salt diet. We were able to show that the AT1R C allele is independently
associated with reduced ERPF and GFR, and an increased FF."> These data indicate
that the decreased ERPF and GFR in C allele carriers is independent from sodium
status, suggesting a structural characteristic.
During the low salt period, the renal hemodynamic (ERPF, FF, RVR) effects of AT1R
blockade were blunted in CC patients as compared to AA patients, whereas the
systemic effects (blood pressure) were comparable. At high salt the opposite
(comparable renal hemodynamics and blunted systemic effects) was found. The
humoral effects (Angll, APRC and aldosterone) of AT1R blockade were as
expected, but showed no relationship with genotype during either diet. The
blunted renal hemodynamic effects in CC patients during sodium restriction are a
major finding of this study. At low levels of sodium intake higher circulating levels
of Angll, increased adrenal Angll sensitivity and decreased renal Angll sensitivity
are to be expected.'"™ In this state, the renovascular effects of AT1R blockade
should be at their maximum.'" The fact that CC subjects show blunted effects
upon ATI R blockade compared to AA subjects could theoretically be explained by
higher circulating Angll levels, greater sensitivity or affinity of the receptor for
Angll, or suboptimal receptor blockade by EXP3174 in these subjects. As Angll
levels were comparable for both groups during all EXP3174 infusion steps, the
latter two possibilities are more likely. In our earlier work on Angll infusions,' we
speculated that CC patients on a high sodium diet behave as if they are relatively
volume-overloaded in comparison to AA subjects. The present study which
examined the role of endogenous rather than exogenous Angll, corroborates that
notion if we assume that CC patients also had increased sensitivity or affinity for
intrarenal Angll at low salt intake. This could not only explain why basal renal
hemodynamics were significantly lower in CC patients than in AA patients on low
salt diet, but also why EXP3174 was not able to elicit a 'full' response in CC
subjects. Our findings at low salt could mean a functional 'overadaptation' to
sodium restriction, i.e. to retain as much sodium as possible. A second explanation
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could be that this is due to structural damage of the kidney by longstanding
exposition to increased intrarenal Angll activity.
In contrast to the renal hemodynamic effects, which were most pronounced
during the low salt diet, the systemic effects of ATI R blockade showed genotype-
related differences mostly during the high salt diet. This underscores the fact that
Angll has differential effects on the systemic and the renal vasculature. The finding
of a significant difference in blood pressure response during the high salt diet was
mainly caused by a more distinct blunted blood pressure decrease in the CC
genotype group during this diet compared to the low salt diet, as the blood
pressure response in AA patients was comparable at both salt diets. It seems
reasonable to assume that the blood pressure findings will be more distinct if a
better sodium-replete situation is obtained, as we did not succeed to study
patients with a mean 24 hour urinary sodium excretion of about 220 mmol/day.
The differences in HR response are remarkable, but consistent with our earlier
findings from the Angll infusion studies in which CC patients showed a decrease in
HR following administration of Angll.'' Whether the rise in HR is the cause of the
blunted decrease in blood pressure or an epiphenomenon cannot be concluded
from these data.
Miller et al. also found genetic differences in the response to AT1R blockade, but
the opposite of what we found: C allele carriers (AC and CC!) were the only ones to
show an effect of AT1R blockade, i.e. a decrease in MBP and increase in GFR."> As
their study is fundamentally different from ours, we can only speculate about this
discrepancy. Firstly, when acute effects of AT1R blockade are being studied it is
more appropriate to do this with an intravenous drug, rather than with an oral
prodrug. Since Miller and coworkers did not measure Angll levels after losartan
administration, we cannot be sure that they achieved the same amount of AT1R
blockade in the two genotype groups. Secondly, CC subjects were not studied as a
separate group but they were pooled with AC subjects. In fact, this combined
group existed of 29 AC and only 7 CC subjects. As the mode of inheritance of the
AT1R A1166C polymorphism is probably recessive,' the characteristics in this
pooled group are mainly caused by the A allele. Thirdly, only responses on blood
pressure and GFR were found, not on ERPF. Finally, their data were obtained only
during a high-salt diet. To the best of our knowledge no other studies are
available that examined renal function in the low salt state in relation to the ATI R
A1166C polymorphism.
In line with other observations," we found that aldosterone concentrations
decreased after losartan administration. However, we did not find any difference
between the genotype groups with respect to this effect. This finding supports
other studies that could not find differences in the genotype groups when Angll
was infused."' One could hypothesize, therefore, that the adrenal AT1R to some
extent is genetically different from the the renal ATI R.
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It remains elusive, why the C allele of the AT1R A1166C polymorphism is
associated with increased sensitivity to Angll and, in the end, an increased
incidence of cardiovascular disease.'*"** As we and others*' did not find
differences in the number of platelet AT1R binding sites (Bma«) and Angll affinity
(Ko), differences probably cannot be explained by the number and function of the
AT1R. On the other hand, one should realize that the platelet model is just a
surrogate model for the RAS in the systemic circulation, as well as in the kidneys
and adrenals. With a low number of AT1Rs"•" per platelet (about 4 to 6) the
limitations of this model in showing prominent differences in AT1R number and
function are clear. Because this polymorphism is located in the uncoding 3'-region
of the AT1R gene it could be in linkage disequilibrium with a coding mutation
nearby. However, Poirier et al. rescanned the AT1R gene, but did not find new
variants which could affect the regulation of the gene in response to Angll.*
Furthermore, the binding of AUF1, a protein that affects AT1R mRNA stability
through binding to AU-rich regions of the uncoding 3'-untranslated region of the
mRNA, is not affected by this polymorphism.'^
In this study only acute effects of AT1R blockade were studied. In a prospective
study in which ambulatory blood pressures were measured in AA and CC patients
that were treated with losartan-based therapy, we were able to confirm the
finding of a blunted blood pressure response in CC patients.^ One could
hypothesize that a group of approximately 10% of the essential hypertensive
patients (i.e. CC subjects) can be selected that should preferably not be treated
with ATI R antagonists.
In conclusion, we have found that in patients with the CC genotype of the AT1R
A1166C polymorphism renal function is impaired and systemic and renal
hemodynamic effects of ATI R blockade effects are blunted, compared to patients
with the AA genotype. In line with earlier studies this again confirms the concept
of increased Angll sensitivity in patients carrying the C allele of the AT1R Al 166C
polymorphism.
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Abstract
Clinical observations point towards heterogeneity in patients' responses to
antihypertensive drugs. In all likelihood, this is at least in part genetically determined. We
earlier showed that in patients with the CC genotype of the angiotensin II (Angll) type 1
receptor (AT1R) A1166C polymorphism blunted renal and systemic hemodynamic effects
can be found during acute blockade of the ATI R. The present study was conducted to
investigate whether blood pressure responses in CC carriers are also blunted during
chronic ATI R blockade.
After 3 weeks withdrawal of antihypertensive drugs, a 12-week losartan-based treatment
was started in 31 essential hypertensive patients genotyped for the AT1R A1166C
polymorphism (16 AA and 15 CC). Office (week 0, 2, 4, 6, 8, 12) and ambulatory (week 0, 6,
12) blood pressures were measured. The losartan dosage was increased and/or
hydrochlorothiazide was added when office blood pressures did not reach 140/90 mmHg.
All 31 patients finished the trial. Both genotype groups needed comparable treatment
changes during the trial to reach desired blood pressure goals. No differences in office
blood pressures were found between the two genotype groups. At week 12 a significant
blunted reduction in systolic (AA: 19.7±2.6%; CC: 14.1 ±1.4%; P<0.05) and diastolic (AA:
17.6±2.4%; CC: 11.1±1.7%; P<0.05) ambulatory daytime blood pressures were found in CC
patients compared to AA patients. Nighttime and 24 hour blood pressures showed the
same tendency, but were not significantly different.
This study shows that the blood pressure responses to chronic ATI R blockade are at least in
part genetically determined.
134
Introduction
One of the striking features of essential hypertension is the heterogeneity of
patients' responses to antihypertensive drugs. Recent data indicate that this is, at
least partly, genetically determined and that genetic polymorphisms in effector
systems may predict the responsiveness to pharmacological agents.'- An
outstanding example where this supposition could be tested is the interaction
between the polymorphisms of the angiotensin II (Angll) type 1 receptor (AT1R)
and the response to AT1R blockade. The gene coding for the AT1R has a
polymorphism (A1166C) in the 3'-untranslated region, which was found to be
associated with myocardial infarction,' hypertension/'' pregnancy-induced
hypertension,'' lacunar infarction,' and faster deterioration of renal function." We
showed that Angll sensitivity is also associated with this polymorphism, with C
allele carriers showing an increased renovascular sensitivity to Angll.* Very
recently, we found that CC subjects on a low salt diet have a blunted response of
blood pressure, effective renal plasma flow, filtration fraction and renal vascular
resistance to acute AT1R blockade as compared to AA patients, whereas at high
salt, this was only true for blood pressure.'" Whether these findings in the acute
situation are clinically relevant in terms of blunted blood pressure reduction with
chronic ATI R blockade in CC patients still remains unanswered. This prompted us
to conduct a study on the blood pressure reductions with losartan in hypertensive
patients with either the AA or the CC genotype. By selecting patients who were
homozygous for either the wild type or the mutant receptor gene, we aimed to
maximize the contrast between groups. As the clinical relevance was the main
incentive to conduct this study, we measured blood pressure both by means of
sphygmomanometry and by means of 24 hour ambulatory blood pressure
measurements (ABPM). Based on our earlier findings we hypothesized that C allele
carriers would exhibit a blunted response as compared to AA patients.
Methods
Study population
A genetic database of hypertensive patients from the Hypertension Research Unit
of the University Hospital Maastricht and from a general practice participating in
the Hippocrates Study" was screened for those genotyped for the AT1R A1166C
polymorphism. Patients entered the study if they fulfilled all the inclusion criteria:
either the AA (wildtype) or CC (mutant) genotype of the AT1R A1166C
polymorphism, age between 18 and 80 years, Caucasian, untreated blood
pressure between 140 and 210 mmHg systolic and/or 90 and 110 mmHg diastolic,
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able to stop antihypertensive medication for 3 weeks. Exclusion criteria were
diabetes, secondary hypertension, congestive heart failure (New York Heart
Association classes II through IV), hepatic (> Child-Pugh B) or renal insufficiency
(creatinine clearance <60 mL/min). Thirty-one hypertensive patients (16 AAand 15
CC) were selected matched for age, sex and body mass index (BMI). All patients
followed a washout period of their antihypertensive treatment for at least 3
weeks, at the end of which a 24 hour ABPM was executed. Hereafter, treatment
with losartan for 12 weeks was started. Patients were instructed to use a liberal salt
diet during the whole study. All selected patients gave written informed consent
to participate in the study. The study was approved by the Medical Ethics
Committee of the University Hospital Maastricht.
Blood pressure measurements
Office blood pressure measurements were obtained during the visits at week 0, 2,
4, 6, 8 and 12 of the study. Using a sphygmomanometer, three measurements
were performed at 2-minutes intervals after 10 minutes of rest in the sitting
position. All patients were seen by one of our group (L.H.H.). For analysis the mean
of these 3 office measurements were used. Hypertension was defined as systolic
blood pressure (SBP) >140 mmHg and/or diastolic blood pressure (DBP) >90
mmHg accord/ng to the European Society of Hypertension-European Society of
Cardiology 2003 Guidelines on Hypertension." Ambulatory blood pressure
readings were performed at week 0, 6 and 12 of the trial using the SpaceLabs
90217 device (SpaceLabs™, Redmond, WA, USA). Patients were monitored during
normal daily activity and recordings were obtained every 15 minutes during
daytime (7:00 AM to 11:00 PM) and every 30 minutes during nighttime (11:00 PM
to 7:00 AM). Blood pressure data were transferred into a personal computer and
analysed by the dabl ABPM program (ECF Medical Ltd., Dublin, Ireland) for the
following derivatives: time weighted mean blood pressure, load, leese, blood
pressure variability (standard deviation of mean blood pressure, coefficient of
variation, root mean square of successive deviations), number of load events,
number of leese events, maximum load duration, and maximum leese duration.
All these variables were calculated for the initial hour, daytime (defined as the
period from 9:00 AM to 9:00 PM less the initial hour), and nighttime (defined as the
period from 1:00 AM to 6:00 AM). Mean, load, and leese were also determined for
the entire 24 hour period. Lastly, the percentage dipping was calculated. All
analyses were applied to SBP, DBP, mean blood pressure (MBP), pulse pressure
(PP), and heart rate (HR), but only when data were valid (i.e. when MBP>0 and
SBP>MBP>DBP). For definition of these variables see appendix.
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Drug administration
Treatment with losartan 50 mg per day was initiated at baseline. At week 2, 4, 6
and 8 medication could be adjusted if office blood pressure did not reach the
following goals: S8P<140 mmHg and DBP<90 mmHg. Adjustments were executed
stepwise: step 2: losartan 100 mg per day; step 3: losartan 100 mg per day and
hydrochlorothiazide 25 mg per day; step 4: losartan 100 mg per day and
hydrochlorothiazide 50 mg per day. Serum creatinine levels were measured at
week 0 and 4 to rule out a possible decreased kidney function. Patients with levels
exceeding 150 nmol/L at week 4 were excluded from the trial.
Genetic analysis
DNA was extracted from whole blood with the use of the QIAamp' Blood Kit
(Qiagen Inc., Valencia, CA, USA). The AT1R A1166C polymorphism was genotyped
with means of mutagenically separated PCR, as described earlier."
Statistical analysis
Comparisons of means and proportions between the two genotype groups were
performed using the Mann-Whitney L/ and Chi-Square test, respectively.
Comparisons of drug effects within the groups during time were made using
Wilcoxon Signed Ranks test or Friedman test when applicable. The study had a
power of 0.8 to detect a difference in mean ambulatory 24 hour blood pressure of
>7% between groups. Results are expressed as means ± standard error of the
mean (SEM). A P-value of less than 0.05 was considered to be statistically
significant. Statistical analyses were performed using SPSS 11.0 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Baseline characteristics
Baseline characteristics of the two genotype groups are summarized in Table 9.1.
There were no significant differences in gender, age, BMI, waist/hip ratio, number
of smokers, office and ambulatory blood pressures, HR, and plasma creatinine.
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Table 9.1. Baseline characteristics of the study population.
Number, n (%)
Males/females, n
Age, years > •<<
BMI, Icg /m'
Waist/hip ratio
Smoking yes/no, n
Office SBP, mmHg '
Office DBP, mmHg
Office HR, beafs/m/'n
Daytime SBP, mmHg
Daytime DBP, mmHg
Nighttime SBP, mmHg
Nighttime DBP, mmHg
24 hour SBP, mmHg
24 hour DBP, mmHg
Creatinine,
16(51.6)
12/4
57 ± 3
26.2 ± 0.8
0.90 ± 0.03
4 / 12
176± 6
102 ± 4
76 ± 3
168 ± 5
103 ± 3
143 ± 4
85 ± 3
163 ± 5
99± 3
101 ± 7
CC
15(48.4)
8 /7
59 ±2
27.9 ± 0.9
0.91 ± 0.03
4/ 11
170±6
104 + 2
80 ±2
158±3
98 ±3
138±4
82 ±2
154 ±3
94±2
91 ±6
n: number; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR:
heart rate.
Treatment regimens
All 31 patients completed the 12 weeks of the trial. Treatment changes during the
trial were comparable between the groups (Table 9.2). The effective
antihypertensive regimen was reached at week 8 in all patients.
Table 9.2. Patient numbers with respect to treatment modalities during the trial.
teak
0
2
4
ft
8
12
LOS 50 mg
AA CC
16 15
1 2
1 2
1 2
1 2
1 2
LOSIOOmg
AA
15
1
1
1
1
CC
13
2
2
2
2
LOSIOOmg
HCTZ 25 mg
AA
14
5
4
4
CC
11
4
3
3
LOSIOOmg
HCTZ 50 mg
AA
9
10
10
CC
7
8
8
Total
31
31
31
31
31
31
LOS:toiartan;HCTZ:hydrochlorothiazide. .... . . ,_ . . , , ......... 4
Office blood pressure measurements
As shown in Figure 9.1, comparable decreases from week 0 to week 12 for both
office SBP (AA: from 176±6 mmHg to 140±5 mmHg, mean decrease: 20.1 ±2.5%,
P<0.0001; CC: from 170±6 mmHg to 136±3 mmHg, mean decrease: 19.4±2.0%,
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P<0.0001) and office DBP (AA: from 102±4 mmHg to 85±2 mmHg, mean decrease:
16.1 ±2.3%, P<0.0001; CC: from 104+2 mmHg to 86±2 mmHg, mean decrease:
16.1 ±2.4%, P<0.0001) were found. Office HR did not change significantly during
the 12 weeks in both genotype groups (AA: from 76±3 bpm to 76±3 bpm; CC:
from 80±2 mmHg to 77±2 mmHg).
180-
140
120-
500
so-
so
CC
4 6
Figure 9.1. Office SBP and DBP.
01
-20-
-25-
-»-AA
•••»••• C C
Figure 9.2. Change in daytime MBP. *P<0.05 vs. AA.
Ambulatory blood pressure measurements
At week 6 both genotype groups showed comparable decreases in daytime SBP
(AA: 14.6±2.0%; CC: 10.3±1.6%; P=0.10), DBP (AA: 10.2±2.0%; CC: 8.1 ±1.8%; P=0.44)
and MBP (AA: 11.2±2.0%; CC: 9.5±1.7%; P=0.52) compared to week 0. Decreases in
nighttime and 24 hour blood pressures from week 6 to week 0 were also
comparable between both genotype groups. Compared to AA patients CC
patients showed significantly blunted decreases from week 0 to week 12 in
daytime SBP (AA: 19.7±2.6%; CC: 14.1 ±1.4%; P<0.05), DBP (AA: 17.6±2.4%; CC:
11.1 ±1.7%; P<0.05) and MBP (AA: 20.2±2.4%; CC: 13.3±1.5%; P<0.05; Figure 9.2). No
differences at week 12 between the genotype groups were found during
nighttime and during 24 hours. At week 12, CC patients showed a small but
significant increase in daytime HR (from 77±3 beats/min to 81 ±3 beats/min,
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P<0.05 vs. week 0), whereas AA patients showed no significant change (from 78±3
beats/min to 78±3 beats/min, P=0.96). Changes in blood pressures and HR from
week 6 to week 12 were not significantly different between the genotype groups.
Pulse pressure, load, leese, blood pressure variability, number of load and leese
events, maximum load and leese duration, and percentage dipping were not
significantly different between the genotype groups during the 12 weeks of the
study.
Discussion
Earlier work of our group revealed that patients with the CC genotype of the ATI R
A1166C polymorphism have an increased intrarenal Angll sensitivity as compared
to AA patients,' and show blunted systemic and renal hemodynamic responses to
acute ATIR blockade.'" As these studies only focussed on acute hemodynamic
effects, the question remained if these findings can be extrapolated to the daily
clinical situation. This prompted us to evaluate the blood pressure responses to
chronic AT1R blockade with losartan during a trial of 12 weeks duration in patients
with the AA and CC genotype of the the AT1R A1166C polymorphism.
Both genotype groups showed comparable changes in drug regimen during the
12 weeks ot the trial it office blood pressure goals (SBP<140 mmHg and DBP<90
mmHg) were not reached. During these 12 weeks all 31 patients (16 AA and 15CC)
showed a significant decrease (*15-20%) in office SBP and DBP, which was not
significantly different between the genotype groups. With respect to ambulatory
blood pressures a significant difference in the fall of daytime blood pressures (SBP,
DBP, and MBP) was found between the genotype groups with a blunted response
in CC patients at week 12. These findings are completely in line with our study on
the effects of acute ATIR blockade. The discrepancy in this trial between office
and ambulatory blood pressure findings once again illustrates the superiority of
ABPM, even though office blood pressure measurements in this study were
obtained according to a standard protocol by one investigator.
One could argue that the blood pressure differences found may not solely be
ascribed to diminished responsiveness to ATIR blockade in CC patients. Adding
hydrochlorothiazide, however, activates the renin-angiotensin system (RAS) and
therefore potentiates the blood pressure lowering effects of losartan. As, in our
theory, CC patients have an increased sensitivity to Angll, further activating the
RAS (by means of a diuretic) does not improve the blood pressure lowering
effects of losartan in these subjects, in contrast to AA patients where losartan
treatment will be further potentiated. As the treatment regimens used during the
12 weeks were nearly identical in both groups, and since known confounders (e.g.
renal function, smoking, etc.) of the blood pressure response were similar in both
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groups, we can safely conclude that the blunted response in CC patients to
losartan-based treatment is related to the genetic mutation of these subjects.
As we only tested losartan, we cannot rule out that our findings are a specific drug
effect rather than a class effect. It would be interesting, therefore, to repeat this
study with other ATI R antagonists which produce more extensive blockade of the
AT1R.
The differences in HR response are remarkable, but consistent with our earlier
findings. In our earlier Angll infusion study, CC patients showed a decrease in HR
following administration of Angll.'' In line with this observation, our study with
acute AT1R blockade revealed an increase in HR.'" Thus, in three separate studies
we have shown the same phenomenon in CC patients. Whether the rise in HR is
the cause of the blunted decrease in blood pressure (i.e. exaggerated
baroreceptor response) or an epiphenomenon (e.g. more diastolic left ventricular
dysfunction) cannot be concluded from these data.
Besides increased Angll sensitivity/"" we recently showed that the AT1R A1166C
polymorphism is associated with lower glomerular filtration rate and effective
renal plasma flow, and increased filtration fraction.''' This indirectly suggests that
the C allele is associated with (longterm) increased sensitivity to, or activity of,
Angll. Others showed increased vascular responsiveness of coronary and internal
mammarian arteries to different stimuli in patients carrying the C allele."''" Thus,
lucic is yiuwiny eviUence li idi Ine V. dncie niUeeU is dsauOcueU wiln inciedscO
Angll sensitivity with respect to the AT1R A1166C polymorphism. It remains
elusive, why the C allele of the AT1R A1166C polymorphism is associated with
increased sensitivity to Angll and, in the end, an increased incidence of
cardiovascular diseased *•" *> As we'° and others" did not find differences in the
number of platelet AT1R binding sites (Bmax) and Angll affinity (KD), differences
probably cannot be explained by the number and function of the AT1R. On the
other hand, one should realize that the platelet model is just a surrogate model for
the RAS in the systemic circulation, as well as in the kidneys and adrenals. With a
low number of AT1 Rs" ^  per platelet (about 4 to 6) the limitations of this model in
showing prominent differences in AT1R number and function are clear. Because
this polymorphism is located in the uncoding 3'-region of the ATI R gene it could
be in linkage disequilibrium with a coding mutation nearby. However, Poirier et al.
rescanned the AT1R gene, but did not find new variants which could affect the
regulation of the gene in response to Angll.3° Furthermore, the binding of AUF1, a
protein that affects ATI R mRNA stability through binding to All-rich regions of the
uncoding 3'-untranslated region of the mRNA, is not affected by this
polymorphism.^'
As this 'chronic' study lasted only 12 weeks, more extended studies are needed to
find out if the blunted decrease in blood pressure lasts for longer time periods. It is
possible that with time compensatory mechanisms fade out the differences.
When, however, the blunted response in CC patients is sustained, one could
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hypothesize that a group of approximately 10% of the essential hypertensive
patients (i.e. CC subjects) can be selected in which antihypertensive treatment
should preferably not be initiated with ATI R antagonists. : ^ .
In conclusion, we have found that in patients with the CC genotype of the AT1R
A1166C polymorphism ambulatory blood pressure responses to losartan-based
treatment are blunted, compared to patients with the AA genotype. In line with
earlier studies this again confirms the concept of increased Angll sensitivity in
patients carrying theCalleleof the AT1R A1166C polymorphism.
M2
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Appendix
' " ' ' • • » i j "
Time weighted mean blood pressure:
ABPMs consist of samples taken over 24 hours. However they are not always taken
at regular intervals (e.g. a patient might accidentally or deliberately take an extra
reading or a reading might be missed). To calculate the relevant mean over a
certain timeframe this must be taken into account. Each reading therefore
represents a timeframe from halfway from its preceding reading to halfway to its
succeeding reading. As for the first and last readings of each timeperiod this will
give errors, the software program uses a frequency of one reading every 30
minutes (0.556 kHz) to also calculate these timeframes. Missed readings are dealt
with by allowing compensation for singletons. The maximum weight for one side
(to preceding or succeeding reading) is therefore the period.
Load:
Area of the curve above an upper limit of normality (daytime: 135/90, nighttime:
120/70) expressed as a percentage of the area of the curve above an average of
normality (daytime: 122/78, nighttime: 105/60) where values below the upper
limit are regarded as being at that limit.
Leese:
Area of the curve below a lower limit of normality (daytime: 110/66, nighttime:
90/50) expressed as a percentage of the area of the curve below an average of
normality (daytime: 122/78, nighttime: 105/60) where values above the lower limit
are regarded as being at that limit.
Number of load events:
Distinct occasions when curve goes above normal.
Number of leese events:
Distinct occasions when curve goes below normal.
Maximum load duration:
Longest period when curve is continuously above normal.
Maximum leese duration:
Longest period when curve is continuously below normal.
Percentage dipping:
(daytime value less nighttime value)/(daytime value)-100.
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Introduction
Hypertension is a rather symptomless disorder with a growing incidence,
especially in the developed and developing world. Acting as the most important
risk factor worldwide for mortality, it in fact is a silent killer.' The majority of
patients with hypertension (*95%) suffer from primary or essential hypertension,
meaning that we do not know the exact cause of their hypertension. What we do
know, is that this multifactorial disorder is caused by heterogeneous genetic and
environmental factors. Accumulating evidence shows that the kidney plays a
central role in the pathophysiology of essential hypertension. The renin-
angiotensin system (RAS) is its most important regulator system that modulates
both renal hemodynamics, i.e. glomerular filtration rate and renal blood flow, as
well as tubular function. The importance of this system in the pathophysiology of
essential hypertension is nicely illustrated by genetic linkage studies, showing that
some of the genes (angiotensinogen (AGT), angiotensin-converting enzyme (ACE),
and angiotensin II type 1 receptor (AT1R)) encoding the different proteins of the
RAS, are potential candidate genes in essential hypertension. Angll is the effector
hormone of this system and genes involved in its generation and effect seem to
play a prominent role in the genetics of essential hypertension.
Genetic aspects of hypertension
Chapter 2 provides an overview of the genetic aspects of both monogenic and
essential hypertension. As twin and adoption studies in the past already indicated,
the genetic heritability in blood pressure resemblances is substantial: between 25-
65%. Pickering and Platt debated in the 1960s the distribution of blood pressure in
the population. While Pickering argued that blood pressure like other traits such
as height or weight is continuously distributed, Platt believed that the distribution
was bimodal. Nowadays, the polygenic model of Pickering has been widely
accepted as the best model explaining the blood pressure distribution. The major
gene that should explain the bimodal distribution of blood pressure in Platfs
model seems not to exist; instead, the evidence is growing that multiple genes are
involved each having a modest effect on blood pressure. Although the genetic
component of blood pressure heritability is substantial, environmental factors
cannot be ruled out. The actual blood pressure of a subject is the resultant of a
very complex play between many genetic, environmental and interacting factors.
To understand the contemporary epidemic outbreak of hypertension in the
developed and developing world, some evolutionary aspects of blood pressure
regulation need to be emphasized. Several studies indicate that our entire world
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population is belonging to a small sub-Saharan African founding population that
replaced all other hominoids. This implies that there is substantial sharing of
alleles, including those responsible for common diseases. It has been
hypothesized that until the industrialization, that dramatically changed our way of
living with regard to physical activity and dietary patterns, there was no
evolutionary selection pressure to adapt our genes. Due to the irregular
availability of food, short periods of feast alternated with relatively longer periods
of hunger. These circumstances selected thrifty genes in our African founders. The
thrifty-genotype hypothesis implies that the genetic basis of contemporary
modern diseases such as obesity, hypertension and diabetes mellitus is not to be
found in recent mutations or genetic defects, but rather lies in the conservation of
the ancestral version of the relevant genes.
Three different approaches for the study of genetics in hypertension are practiced:
studies on rare genetic syndromes, linkage studies and association studies. In the
last years, most progress in the study of genetic aspects of hypertension has been
made by meticulously studying the several monogenic or Mendelian forms of
hypertension. Almost all syndromes (glucocorticoid-remediable aldosteronism,
apparent mineralocorticoid excess, hypertension exacerbated in pregnancy,
Liddle syndrome, pseudohypoaldosteronism type II) have been clarified at the
molecular level. Not surprisingly, in all these syndromes the molecular defect is
causing an increased sodium and volume reabsorption, thereby again illustrating
the importance of the kidney in the pathophysiology of hypertension. Only one
monogenic syndrome, hypertension with brachydactyly, still has to be clarified.
Although the genes involved in these syndromes typically impart very large
effects on blood pressure, the genes involved in essential hypertension mostly
show modest effects. The extensive search for these genes revealed linkages with
quantitative trait loci on almost all chromosomes. Especially chromosomes 2, 3,
and 7 repeatedly showed evidence for linkage with hypertension. Candidate
genes that showed significant linkage are AGT, u-adducin, ACE, and AT1R. The
M235T polymorphism in AGT, insertion/deletion (I/D) polymorphism in ACE, and
A1166C polymorphism in AT1R frequently showed positive associations with
hypertension, although opposite associations have been reported as well.
Finally, this chapter gives an overview of the RAS as we know it today. Briefly, by
cleaving AGT renin generates angiotensin I (Angl), which is then converted by ACE
to Angll. This effector hormone Angll, by stimulating the ATI R, produces amongst
others vasoconstriction, sodium retention, and stimulation of cellular proliferation.
It is now becoming more clear that besides the circulating RAS, tissue RAS is at
least as important in Angll generation. Furthermore, new angiotensins (Anglll and
AnglV) and new receptors (AT2R and AT4R) have been discovered, although the
exact functions of these new team players are not yet completely understood.
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RAS polymorphisms and blood pressure
Taking the obvervations into account described above, we decided to focus on
the role of the ACE I/D and AT1R A1166C polymorphisms in modulating the
effects of Angll on the kidney and, indirectly, blood pressure.
In chapter 3 the results are described of a study in healthy normotensives In
which we investigated the associations of the ACE I/D and AT1R A1166C
polymorphisms with blood pressure. The rationale of this study was that most
data with regard to the potential hypertensive effect of genetic polymorphisms,
alone or in combination, have been obtained in selected populations, which are
potentially confounded by referral bias. Furthermore, in most studies dealing with
the effect of genetic polymorphisms on blood pressure, results may have been
influenced by pre-existing cardiovascular morbidity and antihypertensive
treatment. Therefore, the present study aimed to assess the effect of the two
aforementioned polymorphisms and their interaction on blood pressure in
healthy normotensive subjects who were drawn from a primary care practice. This
cross-sectional study included 198 healthy subjects. To minimize blood pressure
variability just one investigator measured blood pressure in a standardized way. It
was found that the ACE D allele was associated with increased systolic blood
pressure (SBP) and diastolic blood pressure (DBP). SBP (but not DBP) was highest
in the CC genotype group of the AT1R A1166C polymorphism. No synergistic
effect of the ACE D and AT1R C alleles on blood pressure was found. This study
thus confirmed an association of the ACE I/D and AT1R A1166C polymorphisms
with blood pressure, although a synergistic effect of both polymorphisms on
blood pressure does not seem to be present.
In chapter 4 we addressed the same issue as discussed in chapter 3, but now we
focused at a highly selected hypertensive population. We hypothesized that data
concerning the associations of the ACE I/D and ATI R A1166C polymorphisms with
hypertension are conflicting because most studies investigated the qua//fof/Ve
phenotype (hypertension), rather than the quanf/faf/Ve phenotype (the level of
blood pressure). Furthermore, most studies have focused on office blood
pressures only. We therefore studied both office and 24 blood pressure profiles in
348 hypertensive patients. Office blood pressure did not differ between the
various ACE or AT1R genotype groups. However, ambulatory blood pressure
(systolic, diastolic, and mean) and blood pressure load were increased in ACE D
allele carriers. The AT1R A1166C polymorphism showed no consistent association
with blood pressure or blood pressure load. We concluded that frequent
measuring of blood pressure by means of ABPM is crucial to find an association of
the ACE D allele with various aspects of blood pressure.
Are chapter 3 and 4 examples of two of the many association studies that we saw
the last decade in the genetic research in hypertension? We think not, but let us
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first set out the problems that are seen in genetic association studies in complex
diseases like essential hypertension.
The first results of new associations usually show positive findings with impressive
figures. For instance, the initial data with respect to the association between the
ACE I/D polymorphism and myocardial infarction showed odds ratios >3.0 (with
wide confidence intervals)', whereas a meta-analysis later indicated that it is
probably more around 1.5.' Findings in these mostly small studies were often not
replicated in larger, better designed studies. This has led to considerable
scepticism against association studies. This, in our view, is only partly justifiable. Of
course, studies need to be adequately powered to find positive (or negative)
associations. In fact, a power calculation published in the manuscripts should help
the reader interpret the results. Larger studies that followed at a later stage,
mostly rejected earlier reported positive findings/'' These mega-studies, with
sometimes > 10,000 patients included, have one big disadvantage: due to their
sizes they only are able to study associations with end-points (death, myocardial
infarction, etc.). However, in the complex diseases that are studied it is somewhat
illogical to study these 'distal phenotypes'. Many interacting factors between gene
and end-point cloud the true genetic effects. Thus, our message is rather to study
associations between genetic polymorphisms and intermediate phenotypes (e.g.
renal plasma flow, immediate responses to pharmacological agents, etc.) in
adequately powered studies. In such studies, large sample sizes usually are not
necessary.
The functional aspect of a gene variant is perhaps the most important issue, and
certainly the most underappreciated one, of association studies. The question is
whether or not a certain polymorphism a) may alter the transcription, translation,
composition or function of the gene product, or the regulation of these processes,
and b) may do so in a manner that could plausibly be related to the phenotype
(i.e. the disease or symptom) that it is associated with. Gambaro et al. have
highlighted the example of the ACE I/D polymorphism which has been associated
with dozens of the most complex phenotypes imaginable, whereas only a few
studies have investigated whether or not the polymorphism is related to altered
conversion of Angl to Angll/- As genotyping nowadays is quite easy and cheap to
execute, there is a real risk that many association studies will be performed which
explore genotype frequencies in data sets (available from earlier studies) with
multiple insufficiently defined phenotypes. The chance of finding spurious
associations is substantial when many phenotypes are included in such studies.
Thus, an association study should only be performed when a clear a priori
hypothesis has been formulated.
Although it looks trivial, more attention should be paid to the fype of phenotype
that will be studied, as well as the qua//ry of phenotyping. The many association
studies in essential hypertension deal with either hyperrens/on as a phenotype,
which is a dichotomous variable, or b/ood pressure as a phenotype, which is a
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continuous trait. As probably many genes influence blood pressure over the
whole continuum, it seems wise to use only blood pressure as the phenotype to
study. With respect to the quality of phenotyping, most studies used office blood
pressure measurements. Although easy to perform, there is no doubt anymore
that this way of measuring blood pressure has some major shortcomings
compared to e.g. ambulatory blood pressure measurements: substantial intra- and
interobserver variability, digit preference and observer bias, and the possible
white-coat effect.' In a complex disease like essential hypertension the genetic
heritability is rather low,* meaning that differences between the wild-type and
mutant allele, if associated, will only be a few mmHg. So, investigators studying
the association of a certain polymorphism with hypertension should decide to a)
study large populations with rather easy-to-perform phenotyping of moderate
quality (e.g. office blood pressure measurements by just a few investigators), or b)
study smaller populations with high quality phenotyping (e.g. ambulatory blood
pressure measurements). The sizes of the populations studied depend on
statistical power calculations.
The association of the ACE I/D polymorphism with hypertension varies between
different populations. The general idea is that a positive association with a certain
phenotype should be reproducible in a different ethnic population (i.e. on a
different genetic background) to confirm that the genotype-phenotype
relationship really exists. However, we should realize that a certain polymorphism
can be associated with a particular phenotype in one ethnic population but not in
another. It is not likely that hypertension is a disorder to which the same genes
contribute in every population. Analogous to this is the finding that people from
recent African descent (Afro-Americans, Carribbeans) more often show a salt-
sensitive type of hypertension, compared to Caucasians. Different genes may
predispose to the phenotype of hypertension in different populations. The key
point is that the finding of an association between genotype and phenotype is
generally strengthened if the association under investigation can be reproduced
in a second sample with a different ethnic background, but that it is not
necessarily weakened if the association cannot be confirmed.
Sharma and Jeunemaitre recently proposed clear, stringent criteria for high-
quality positive and negative association studies that, when adhered to, will
greatly enhance the quality of future studies.' The association studies as described
in chapter 3 and 4 had clear a priori hypotheses, were well-powered for their study
goals, used office blood pressure measurements by one investigator in the
normotensive study group and ambulatory blood pressure measurements in the
hypertensive study groups, and focused at a quantitative rather than a qualitative
trait.
So what to decide about the association of the ACE I/D polymorphism and blood
pressure? In general, we may conclude that studies in different populations give
divergent results. The clearest association of the ACE I/D polymorphism with
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blood pressure is repeatedly found in African populations or those of recent
African descent. In Caucasian and to a lesser extent Asian populations the
association is weaker, and predominantly present in males, as our study also
showed.
ACE I/D polymorphism and Angll generation
Although there is now substantial evidence available for a positive association of
the ACE I/D polymorphism with blood pressure and, mainly, atherosclerotic
complications, it is still unknown whether higher circulating ACE levels in D allele
carriers of the ACE I/D polymorphism lead to enhanced formation of Angll.
Therefore, we conducted an ;n wrro study, described in chapter 5, in which the
plasmatic conversion of Angl over time in relation to the ACE I/D polymorphism
was investigated. The results show that the ACE DD genotype, at least at low
plasma concentrations of Angl, is associated with a slower conversion of this
peptide, compared to the II and ID genotype groups. Adding an extra amount of
Angl to the plasma, however, abolishes the differences between the genotype
groups.
We know from phylogenic molecular biology that the absence (i.e. 'deletion') of
the /Wu element in the human genome is the ancestral state, whereas the
presence (i.e. 'insertion') of the >4/u element at a particular chromosomal site
reflects a single, unique event in human evolution. Once inserted at specific
chromosomal locations most /Wu elements do not appear to be subject to loss or
rearrangement, making them stable genetic markers.'" This means that the ACE
DD genotype, with the highest serum ACE levels, represents the ancestral
situation. As chimpanzee, the last hominoid that diverged from man, are lacking
the A/u element the insertion in the ACE gene occurred at most about 7 million
years ago." This finding fits well with the fact that people from (recent) African
descent have the highest frequency of D alleles,'^ wheras Asian people (that are
most distinct from our African ancestors) have the lowest frequency.'*
We can only speculate why during evolution of man serum ACE levels had to be
lowered. Originally, the RAS is a volume-regulating, rather than a pressure-
regulating system. Therefore, one could hypothesize that in the ancestral situation
thrifty genes were necessary to retain volume and salt in times where continous
supply of these essentials was not possible. A slower Angl-ll conversion, as we saw
In DD subjects, fits in this theoretical framework because slower Angl-ll conversion
provides for longer duration of salt-retaining effects via Angll and aldosterone.
These volume- and salt-retaining mechanisms may have resulted in somewhat
higher blood pressures. But as we concluded before, the blood pressure
increasing effects of the DD genotype are just minor. During evolution the
volume-dependency became less important due to cultivation of man which
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guaranteed a more continous supply of volume and salt. In this way pressure-
regulating systems probably became more important and the RAS had to be set
to a lower level. One way of doing so could have been to reduce serum (and
tissue?) ACE levels. In a salt-rich environment as we are faced with today, disposal
of sodium becomes much more important than retention of this electrolyte. In this
theory, one could envisage that under conditions where sodium intake greatly
exceeds the physiological needs or where the renal excretory capacity of the
kidney is impaired, other mechanisms have to be recruited to get rid of the
surplus. This could be, for instance, a rise in pressure. Thus, salt-sensitivity of blood
pressure may not be a disorder in its own right but rather an adaptive
phenomenon, necessary to maintain sodium balance. In this theory, salt-related
increases in pressure would be more likely to occur in II subjects because they are
probably operating at a lower setpoint. In the literature, there is indeed some
evidence that salt sensitivity is associated with the ACE I allele." "
As our study focused only on circulating ACE, we do not know whether the Angl-ll
conversion by vascular- and tissue-ACE is also slower in DD subjects. Theoretically,
it could even be that a higher c/'rcu/afing ACE compensates for decreased vascu/ar-
and/or r/ssue Angl-ll conversion.
RAS polymorphisms and renal function
As described earlier, the RAS plays a prominent role in the regulation of renal
function. In chapter 6, we describe our study of renal function in 212 well
characterized essential hypertensives with respect to the ACE I/D and AT1R
A1166C polymorphisms. The results show that the AT1R C allele is independently
associated with reduced effective renal plasma flow (ERPF) and glomerular
filtration rate (GFR), and increased filtration fraction (FF). No significant
interactions between the AT1R C allele and known determinants of renal function
(age, gender, body mass index, blood pressure) were present. On the other hand,
no differences in renal hemodynamics with respect to the ACE I/D polymorphism
were found. Lastly, interactions of the AT1R C and ACE D alleles such as the ones
which have previously been reported could not be confirmed for the phenotypes
studied here. Thus, our findings show that the AT1R C allele is a new, unknown,
independent determinant of renal function.
AT1R A1166C polymorphism and Angll sensitivity
As the results of chapter 6 indicate that the Angll related effects are more
prominent in AT1R C allele carriers, we then decided to test the hypothesis that
this polymorphism is associated with increased Angll sensitivity. To this end we
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studied renal hemodynamic and humoral responses to Angll in essential
hypertensive patients during a high sodium diet, as in these circumstances the
effects of exogeneous Angll are most prominent. Our data, described in chapter
7, show that patients with the AT1R CC genotype display an exaggerated
response of GFR, ERPF and renal vascular resistance to Angll at a low dose of 0.3
ng/kg/min, but not at the higher doses employed. In addition, we found that CC
patients, in contrast to the others, respond to Angll with an overall decrease in
heart rate. Thus, except for the changes in heart rate, phenotypic differences
between the groups were observed only at the lowest dose when plasma levels of
Angll remain within the physiological range. Because responses to Angll during
the supraphysiological doses of 1.0 and 3.0 ng/kg/min were comparable between
the genotype groups, our data indicate that sensitivity, but not reactivity to Angll
is increased in CC patients. These findings are in line with observations by others
showing increased vascular responsiveness of coronary and internal mammarian
arteries, to different stimuli in patients carrying the C allele.
In the following studies, described in chapters 8 and 9, we were interested
whether the increased Angll sensitivity in AT1R C allele carriers also has clinical
implications with respect to pharmacotherapy. In chapter 8 we describe a study
in which we investigated the systemic and renal hemodynamic, as well as humoral
responses to acufe AT1R blockade with the active metabolite of losartan
(EXP3174) in relation to the AT1R A1166C polymorphism in essential
hypertensives. Patients were examined during both a low and high sodium diet in
order to allow evaluation of responses at different levels of activity of the RAS. We
found that blood pressure responses to EXP3174 during low and high salt diet
were significantly blunted in CC patients compared to AA patients. During low salt
both the increase in ERPF and the decrease in FF were significantly blunted as well
in CC patients compared to AA patients. These findings indicate that, at least in
the acute setting, ATI R blockade is less efficient in AT1R CC patients.
The data presented in chapter 8 raised the question whether these findings can be
extrapolated to the daily clinical situation. This prompted us to evaluate the blood
pressure responses to chronic AT1R blockade with losartan-based therapy during
a trial of 12 weeks duration in patients with the AA and CC genotype of the
A1166C polymorphism. The results, laid down in chapter 9, showed that
comparable changes in drug regimen were needed to reach office blood pressure
goals (SBPs140 mmHg and DBP<90 mmHg). During these 12 weeks all patients
showed a significant decrease (=15-20%) in office SBP and DBP, which was not
significantly different between the genotype groups. With respect to ambulatory
blood pressures a significant difference in the fall of daytime blood pressures (SBP,
DBP, and mean blood pressure) was found between the genotype groups with a
blunted response in CC patients at week 12. These findings are completely in line
with our study on the effects of acute ATI R blockade.
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The results presented in chapter 8 and 9 show a blunted effect of ATI R blockade
by losartan in ATI R C allele carriers. This finding is supported by a study of Diez et
al.'* They showed that left ventricular chamber stiffness remained unchanged in
ATI R C allele carriers after 1 year treatment with losartan, whereas it decreased in
AA hypertensives.
Evidence is now accumulating that the C allele of the ATI R AH 66C polymorphism
is an independent cardiovascular risk factor."'» But it still remains unclear how
this epidemiological finding can be explained in a pathophysiological way. As
Angll is the effector hormone of the RAS one could hypothesize that higher
plasma Angll, increased sensitivity for Angll by the AT1R, or increased density of
the AT1R are possible explanations. Then, how are one (or more) of these
functional alterations linked with this genetic noncoding mutation? Is the A1166C
polymorphism in linkage disequilibrium with a coding mutation nearby or in the
promoter? We will discuss each of these possibilities.
We (chapter 8) and others'"' showed that plasma Angll levels are not significantly
different between the genotype groups. Whether this is the same at the tissue
level is unknown. As is seen often in negative feedback systems (chronic) increases
of one component will lead to decreases of its controlling components, thereby
ultimately resetting the system. In our study, as described in chapter 8, no
differences as well in renin levels between AA and CC patients could be found.
This is confirmed in the study of Miller et al.™ So, from these data we should
conclude that the enhanced Angll related effects in C allele carriers cannot be
explained by increased plasma levels of one of the RAS components.
As we showed in chapter 7 the AT1R A1166C polymorphism is associated with
increased Angll sensitivity, but not reactivity. This was predominantly found in the
renal vascular bed, although the decrease in heart rate suggests that a partly
systemic response is present as well. Others showed increased vascular
responsiveness of coronary and internal mammarian arteries to different
vasoconstrictor stimuli, including Angll, in patients carrying the C allele.''' " One
study demonstrated an increased vascular sensitivity of isolated mesenteric
arteries of C allele carriers to prostaglandin F(2alpha), but not to angiotensins.^"
Hilgers et al. did not find differences in Angll response with respect to the AT1R
Al 166C polymorphism." The discrepancies of this study with our findings could
be explained by the short-term infusion of relatively high Angll doses (0.5 and 1.0
ng/kg/min for 15 minutes). As this evidence clearly indicates that increased Angll
sensitivity is associated with the AT1R A1166C polymorphism, the exact
pathophysiological mechanism remains unclear. Is the AT1R itself more sensitive
for its agonist, or are the number of ATlRs upregulated in C allele carriers? To
answer these questions AT1R binding studies are useful.
Although, it is difficult to study /n wVo AT1R density, ex wVo platelet binding
studies are an accepted model.^s As we describe in chapter 8, and confirmed by
Paillard et al.," no differences in the number of platelet AT1R binding sites (Bmax)
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between AA and CC patients are present. These findings are compatible with the
equal plasma levels of Angll that are found, as described above. Indirect evidence
further indicates that the number of ATlRs indeed is not upregulated in carriers
with the CC genotype, as the increased responsiveness to Angll is not masked by
the increase in ATI Rs due to ACE inhibition." This is of interest because it provides
the hypothesis that CC patients may still increase their response to Angll, even
under circumstances that by themselves cause increased Angll responsiveness. As
these data suggest that not the number of ATlRs is increased in C allele carriers,
we hypothesize that the explanation lies in an increased Angll sensitivity of the
AT1R itself. However, the same platelet AT1R binding studies as described above,
could not show differences in Angll affinity (KD) of the AT1R. Although we should
conclude from the platelet binding data that the number and function of the ATI R
is comparable between the genotype groups, one should realize that this model is
just a surrogate model for the systemic RAS, as well as for the local RAS in the
kidneys and adrenals. The AT1R probably is not an important receptor for the
platelet, as is illustrated by the low number of ATI Rs"-*' per platelet (about 4 to 6).
So, although this is the best tool we have to estimate /n wVo AT1R density and
Angll affinity we should be careful by extrapolating findings to the systemic and
local RAS. Our AT1R blockade data (chapters 8 and 9) further support the
hypothesis of an increased agonist responsiveness of the ATI R in C allele carriers.
The AT1R antagonist losartan is less effective in blocking the receptor due to the
increased agonist-ligand interaction in C allele carriers compared to A allele
carriers.
The AT1R Al 166C polymorphism is located in the 3'-untranslated region (3'-UTR)
of the gene. In this part of a gene mRNA stability is regulated. It is hypothesized
that these regions play a role in changing gene expression in cardiovascular
pathophysiology.'-' The binding of AUF1, a protein that affects AT1R mRNA
stability through binding to AU-rich regions of the 3'-UTR, is not affected by this
polymorphism." Newly identified polymorphisms in the AT1R gene that might
explain the associations found with the C allele are particularly worthwhile for
further characterization when 3 conditions are met: linkage disequilibrium with
the ATI R Al 166C polymorphism, a similar or stronger interaction with the disease,
and location in a region that would suggest a functional role. As the promoter of a
gene is important in gene function regulation, several studies searched for new
polymorphisms in the promoter of the AT1R gene. Several new polymorphisms
have been found, mostly in linkage disequilibrium with each other, but not with
the A1166C polymorphism in the 3'-UTR.*«" One study showed a weak linkage
disequilibrium between the mutant A allele of the G-2228A promoter
polymorphism and the mutant C allele of the Al 166C polymorphism.** However,
in this study no association of any of the alleles with hypertension could be found.
To conclude, the noncoding AT1R A1166C polymorphism is an independent
cardiovascular risk factor. (In)direct evidence indicates that increased levels of
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renin and Angll or upregulated ATlRs in C allele carriers are probably not the
pathophysiological explanation. The more logical explanation is a functionally
altered AT1R, leading to an increased Angll responsiveness. However, the hard
evidence is still lacking. At the molecular level, no new coding polymorphisms
have been found yet that are in complete linkage disequilibrium with the A1166C
polymorphism, nor is the mutant C allele of this polymorphism associated with an
altered AT1R mRNA stability.
Perspectives for future research
Although essential hypertension is the most important risk factor worldwide for
mortality, our knowledge of its pathophysiology is just poor. The genetic
component in essential hypertension is substantial, and so are probably the
number of genes that are involved. Association studies will be needed for
discovering new potential candidate genes. Each of these genes have small effects
(just a few mmHg) on blood pressure in the general population, making the
quality criteria of the study designs very important. If studies adhere to these
stringent criteria, their results, both positive and negative (!), are useful for our
understanding of the pathophysiology of essential hypertension. Nowadays, most
association studies focus on one or just a few polymorphisms with respect to
hypertension. Future association studies will focus on the combination of multiple
polymorphisms. These studies need inclusion of thousands of subjects. As
discussed above, the quality of phenotyping in such large studies is potentially at
risk. The quality and quantity of genotyping is already improving at high speed
with the introduction of micro-array facilities. The information that will be gained
in this way (multiple genotypes of multiple phenotypes in thousands of patients)
will be enormous and hard to decipher. This work will be the field of
bioinformatics, a new scientific branch that will show a rapid grow in the next
coming years. As large studies are needed for future association studies,
international cooperation between research groups seems a logic development.
This, however, may introduce a decrease in homogeneity of the study population,
and therefore may lead to false negative conclusions. Associations of
polymorphisms with blood pressure are not, as we have recently learned, present
in all different populations. So, as nowadays essential hypertension is not
exclusively a risk factor for mortality in the Western world, genetic studies in other
populations are also important as well. The last decade association studies mainly
focussed at the distal phenotype hypertension or blood pressure. Future studies
will focus more at intermediate phenotypes as RAS activity, sympathetic nerve
activity, endothelial function, etc. As these are more proximal phenotypes, smaller
study populations can be used.
159
Chapter 10
Besides bioinformatics, some other rather new sciences will be 'booming' the
coming years and will be important for a complete understanding of the
(patho)physiology from gene to blood pressure. Genes are translated to proteins,
which eventually will cause an effect, eg. rise in blood pressure. This is the field of
proteomics: identifying and quantifying these proteins, and determine their
localization, modifications, interactions, activities, and, ultimately, their function.
Understanding the exact route from genotype to phenotype creates potential
levels of pharmacological intervention, thereby modifying the phenotype. Lastly,
the area of pharmacogenetics, in which the responses to pharmacotherapy with
respect to genetic determinants are studied, will learn us more about the
interindividual differences in blood pressure responses to antihypertensives.
The first steps in understanding the complex mechanisms that are involved in
blood pressure regulation have been made. Many more more steps will follow the
coming years.
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Essential hypertension is a common disorder, which affects 25-30% of the adult
population, and up to 60-70% of those beyond the seventh decade of life.
Although seemingly symptomless it is in fact a silent killer, because it is by far the
most important risk factor worldwide for total mortality. Although the clinical
implications of hypertension are substantial our understanding of the disorder is
strikingly low. The majority of patients with hypertension (*95%) suffers from
primary or essential hypertension, which is an euphemism for not knowing the
exact cause of the increased pressure. It is widely believed that essential
hypertension is a multifactorial disorder caused by heterogeneous genetic and
environmental factors.
Accumulating evidence shows that the kidney plays a central role in the
pathophysiology of essential hypertension. The reninangiotensin system (RAS) is
the principal hormonal system that modulates both renal hemodynamics, I.e.
glomerular filtration rate and renal blood flow, as well as tubular function.
Angiotensin II (Angll) is the effector hormone of this system and genes involved in
its generation and effect (angiotensinogen (AGT), angiotensin-converting enzyme
(ACE), and angiotensin II type 1 receptor (AT1R)) seem to play a prominent role in
the genetics of essential hypertension. The mutant D allele of the ACE
insertion/deletion (I/D) polymorphism is associated with higher circulating serum
ACE levels and therefore, at least in theory, generates more Angll causing higher
blood pressures and an increased incidence of cardiovascular disorders. On the
other hand, the mutant C allele of the AT1R A1166C polymorphism is associated
with a higher incidence of cardiovascular abnormalities and there is data to show
that the interaction of Angll with the AT1R is altered due to this polymorphism.
Taking these observations into account, our research has focused on the role of
these polymorphisms in modulating the effects of Angll on the kidney and,
indirectly, blood pressure.
Genetic aspects of hypertension
Chapter 2 provides an overview of the genetic aspects of both monogenic and
essential hypertension. As twin and adoption studies in the past already indicated,
the genetic heritability in blood pressure resemblances is substantial: between 25-
65%. The evidence is growing that multiple genes are involved each having a
modest effect on blood pressure. Although the genetic component of blood
pressure heritability is substantial, environmental factors cannot be ruled out. The
actual blood pressure of a subject is the resultant of a very complex play between
many genetic, environmental and interacting factors.
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Whereas in earlier times hypertension was rarely seen, we are now faced with an
epidemic outbreak in the developed and developing world. The thrifty-genotype
hypothesis implies that the genetic basis of contemporary modern diseases such
as obesity, hypertension and diabetes mellitus is not to be found in recent
mutations or genetic defects, but rather lies in the conservation of the ancestral
version of the relevant genes. These genes in our contemporary environment of
high salt and carbohydrates intake explains the increasing incidence of these
diseases.
In the last years, most progress in the study of genetic aspects of hypertension has
been made by meticulously studying the several monogenic or Mendelian forms
of hypertension. Almost all these monogenic syndromes have been clarified at the
molecular level. Not surprisingly, in all these syndromes the molecular defect is
causing an increased sodium and volume reabsorption, thereby again illustrating
the importance of the kidney in the pathophysiology of hypertension. Although
the genes involved in these syndromes typically impart very large effects on blood
pressure, the genes involved in essential hypertension mostly show modest
effects. The extensive search for these genes revealed linkages with quantitative
trait loci on almost all chromosomes. Candidate genes that showed significant
linkage are AGT, u-adducin, ACE, and AT1R. The M235T polymorphism in AGT,
insertion/deletion (I/D) polymorphism in ACE, and A1166C polymorphism in AT1R
frequently showed positive associations with hypertension, although opposite
associations have been reported as well.
RAS polymorphisms and blood pressure
Taking the obvervations into account described above, we decided to focus on
the role of the ACE I/D and AT1R A1166C polymorphisms in modulating the
effects of Angll on the kidney and, indirectly, blood pressure.
In chapter 3 the results are described of a study in healthy normotensives who
were drawn from a primary care practice, in which we investigated the
associations of the ACE I/D and AT1R A1166C polymorphisms with blood pressure.
It was found that the ACE D allele was associated with increased systolic blood
pressure (SBP) and diastolic blood pressure (DBP). SBP (but not DBP) was highest
in the CC genotype group of the AT1R A1166C polymorphism. No synergistic
effect of the ACE D and AT1R C alleles on blood pressure was found. In chapter 4
we addressed the same issue as discussed in chapter 3, but now we focused at a
highly selected hypertensive population. We hypothesized that data concerning
the associations of the ACE I/D and AT1R A1166C polymorphisms with
hypertension are conflicting because most studies investigated the qua//faf<Ve
phenotype (hypertension), rather than the quonf/fof/Ve phenotype (the level of
blood pressure). Furthermore, most studies have focused on office blood
pressures only. We therefore studied both office and 24 blood pressure profiles in
348 hypertensive patients. Office blood pressure did not differ between the
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various ACE or AT1R genotype groups. However, ambulatory blood pressure
(systolic, diastolic, and mean) and blood pressure load were increased in ACE D
allele carriers. The AT1R Al 166C polymorphism showed no consistent association
with blood pressure or blood pressure load. We concluded that frequent
measuring of blood pressure by means of ambulatory blood pressure
measurement is crucial to find an association of the ACE 0 allele with various
aspects of blood pressure.
ACE I/D polymorphism and Angll generation
Although there is now substantial evidence available for a positive association of
the ACE I/O polymorphism with blood pressure and, mainly, atherosclerotic
complications, it is still unknown whether higher circulating ACE levels in D allele
carriers of the ACE I/D polymorphism lead to enhanced formation of Angll.
Therefore, we conducted an <n wfro study, described in chapter 5, in which the
plasmatic conversion of Angl over time in relation to the ACE I/D polymorphism
was investigated. The results show that following the immediate conversion of
Angl, a secondary phase of slow conversion is demonstrable. While the initial
phase does not differ between the three genotype groups, the slow conversion of
Angl does, with the lowest conversion occurring in DD patients. The difference
can be overcome at higher prevailing concentrations of Angl.
RAS polymorphisms and renal function
As described earlier, the RAS plays a prominent role in the regulation of renal
function. In chapter 6, we describe our study of renal function in 212 well
characterized essential hypertensives with respect to the ACE I/D and AT1R
Al 166C polymorphisms. The results show that the AT1R C allele is independently
associated with reduced effective renal plasma flow and glomerular filtration rate,
and increased filtration fraction. No significant interactions between the AT1R C
allele and known determinants of renal function (age, gender, body mass index,
blood pressure) were present. On the other hand, no differences in renal
hemodynamics with respect to the ACE I/D polymorphism were found. Lastly,
interactions of the AT1R C and ACE D alleles such as the ones which have
previously been reported could not be confirmed for the phenotypes studied
here. Thus, our findings show that the AT1R C allele is a new, unknown,
independent determinant of renal function.
ATI R Al 166C polymorphism and Angll sensitivity
As the results of chapter 6 indicate that the Angll related effects are more
prominent in AT1R C allele carriers, we then decided to test the hypothesis that
this polymorphism is associated with increased Angll sensitivity. Our data,
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described in chapter 7, show that theC allele of the AT1R A1166C polymorphism
is associated with increased sensitivity, but not reactivity to Angll. In the following
studies, described in chapters 8 and 9, we were interested whether the increased
Angll sensitivity in AT1R C allele carriers also has clinical implications with respect
to pharmacotherapy. We were able to show a blunted effect of both acute
(chapter 8) and chronic (chapter 9) AT1R blockade by losartan in AT1R C allele
carriers.
Evidence is now accumulating that the C allele of the AT1R A1166C polymorphism
is an independent cardiovascular risk factor. It still remains unclear how this
epidemiological finding can be explained in a pathophysiological way. We
showed that both plasma renin and Angll levels are not significantly different
between the genotype groups. Indirect evidence from platelet binding studies
indicated that also number of AT1R binding sites, or an increased Angll sensitivity
of the AT1R itself are not plausible explanations.
In chapter 10 the results of the studies mentioned above are discussed in light of
the current literature. Lastly, we discuss the perspectives for future reseach in the
field of genetics of hypertension.
168
Samenvatting
170
Samenvatting
Samenvatting
Essentiele hypertensie (=verhoogde bloeddruk) is een veel voorkomende
aandoening, welke bij 25-30% van de volwassen populatie voorkomt, en zelfs bij
60-70% van de mensen ouder dan 70 jaar. Alhoewel het een symptoomloze
aandoening lijkt te zijn, is het in feite een stille moordenaar, omdat het wereldwijd
verreweg de belangrijkste risicofactor is voor totale mortaliteit. Ondanks de
klinische implicaties van hypertensie, is ons begrip van deze ziekte opvallend
gering. In het merendeel van de patienten met hypertensie (*95%) is sprake van
primaire of essentiele hypertensie, wat een eufemisme is voor het niet kennen van
de exacte oorzaak. Het wordt algemeen aangenomen dat essentiele hypertensie
een multifactoriele aandoening is, veroorzaakt door heterogene genetische en
omgevingsfactoren.
Er is toenemend bewijs dat de nieren een centrale rol spelen in de pathofyslologle
van essentiele hypertensie. Het renine-angiotensine systeem (RAS) is het
hormonale systeem dat zowel de renale hemodynamiek (glomerulaire
filtratiesnelheid en renale doorbloeding), als de tubulaire functie beinvloedt.
Angiotensine II (Angll) is het effector-hormoon van dit systeem en de genen welke
betrokken zijn bij zowel de produktie als effecten van dit hormoon
(angiotensinogeen (AGT), 'angiotensin-converting enzyme' (ACE), angiotensine II
type 1 receptor (AT1R)), lijken een prominente rol te spelen in de genetische
aspecten van essentiele hypertensie. Het mutante D-allel van het ACE
insertie/deletie (I/D) polymorfisme vertoont een associatie met hogere
circulerende serum ACE-waarden en kan derhalve, althans theoretisch, leiden tot
een grotere productie van Angll, hetgeen op den duur hogere bloeddrukken en
een toegenomen incidentie van cardiovasculaire aandoeningen tot gevolg heeft.
Daarnaast is er het mutante C-allel van het AT1R A1166C polymorfisme, hetgeen
ook geassocieerd is met een toegenomen incidentie van cardiovasculaire
afwijkingen. Het is vooralsnog onduidelijk of de interactie van Angll met de ATI R
veranderd is door dit polymorfisme. Dit hiaat in onze kennis vormde de aanleiding
voor ons onderzoek: wat is de rol van deze polymorfismen in het moduleren van
de effecten van Angll op de nier en, indirect, de bloeddruk.
Genetische aspecten van hypertensie
Hoofdstuk 2 bevat een overzicht van de genetische aspecten van zowel
monogene als essentiele hypertensie. Uit vroegere tweeling- en adoptie-studies is
gebleken dat de genetische overerving van bloeddrukovereenkomsten
substantieel is: ongeveer 25-65%. Er is toenemend bewijs dat multipele genen
hierbij betrokken zijn, met elk slechts een gering effect op de bloeddruk. Hoewel
de genetische component bij de overerving van bloeddruk aanzienlijk is, spelen
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omgevingsfactoren ook een grote rol. De eigenlijke bloeddruk van een persoon is
de resultante van een complex spel tussen vele genetische, omgevings- en andere
factoren. Waar hypertensie in vroegere tijden zelden werd gezien, worden we nu
geconfronteerd met een epidemie in zowel de westerse als de
ontwikkelingslanden. De 'thrifty-genotype' (=zuinig genotype) hypothese houdt
in dat de genetische basis van hedendaagse moderne ziekten, zoals obesitas,
hypertensie en diabetes mellitus niet verklaard kan worden door recente mutaties
of genetische defecten, maar door de 'conservering' van zogenaamde betrokken
oergenen. Verondersteld wordt dat deze genen in onze hedendaagse omgeving
met een hoge inname van zout en koolhydraten de oorzaak zijn van een
toenemende incidentie van deze ziekten. De afgelopen jaren is de meeste
vooruitgang in de studie van genetische aspecten van hypertensie geboekt door
het nauwgezet bestuderen van monogene of Mendeliaanse vormen van
hypertensie. Bijna alle bekende monogene syndromen zijn inmiddels tot op
moleculair niveau opgehelderd. Niet onverwacht, veroorzaken al deze moleculaire
defecten een toegenomen zout- en volumereabsorptie, daarbij nogmaals het
belang van de nier in de pathofysiologie van hypertensie onderstrepend. Hoewel
de genen betrokken bij deze monogene syndromen erg grote effecten op de
bloeddruk uitoefenen, hebben de genen die betrokken zijn bij essentiele
hypertensie een meestal veel geringer effect. De uitgebreide zoektocht naar deze
genen Met koppelingen zien met zogenaamde 'quantitative trait loci' (^genetische
locus waarvan wordt aangenomen dat het continu verdeelde kenmerken zoals
bloeddruk, cholesterol, etc. bepaald) op bijna alle chromosomen. Kandidaatgenen
welke een significante koppeling hebben laten zien met hypertensie zijn AGT, a-
adducine, ACE, en AT1R. Het M235T polymorfisme bij AGT, insertie/deletie (I/D)
polymorfisme bij ACE, en A1166C polymorfisme bij AT1R hebben herhaaldelijk
positieve associaties met hypertensie laten zien, alhoewel negatieve associaties
ook gerapporteerd zijn.
RAS polymorfismen en bloeddruk
De waamemingen, zoals hierboven beschreven, inachtnemend, besloten wij ons
te richten op de rol van de ACE I/D en AT1R A1166C polymorfismen in het
moduleren van de effecten van Angll op de nier en, indirect, de bloeddruk.
In hoofdstuk 3 worden de resultaten beschreven van een studie in gezonde
normotensieven, gerekruteerd uit een huisartsenpraktijk, waarin we de associaties
van de ACE I/D en AT1R Al 166C polymorfismen met bloeddruk onderzochten. Wij
vonden dat het ACE D-allel samenhing met een verhoogde systolische en
diastolische bloeddruk. Systolische bloeddruk (maar niet diastolische bloeddruk)
was het hoogste in de CC-genotype groep van het AT1R Al 166C polymorfisme. Er
werd geen synergistisch effect van de ACE D- en AT1R C-allelen op de bloeddruk
gevonden. In hoofdstuk 4 keken we naar hetzelfde vraagstuk als besproken in
hoofdstuk 3, maar nu in een sterk geselecteerde hypertensieve populatie. Wij
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veronderstelden dat onderzoeksresultaten betreffende de associaties van de ACE
I/D en AT1R A1166C polymorfismen met hypertensie zo tegenstrijdig zijn, omdat
de meeste studies het /cwa//far/eve fenotype (hypertensie), in plaats van het
kwonf/faf/eve fenotype (de hoogte van de bloeddruk) onderzochten. Verder keken
de meeste studies naar alleen spreekkamerbloeddrukken. Wij onderzochten
derhalve zowel spreekkamer- als 24-uurs ambulante bloeddrukmetingen in 348
hypertensieven. Spreekkamerbloeddrukken verschilden niet tussen de
verschillende ACE of AT1R genotype-groepen. Ambulante bloeddrukken
(systolisch, diastolisch, en gemiddelde) en bloeddruk-'load' (=percentage van
bloeddrukwaarden boven een normaal gemiddelde) waren daarentegen
verhoogd in ACE D-allel dragers. Het AT1R A1166C polymorfisme liet geen
consistente associatie met bloeddruk of bloeddruk-'load' zien. Wij concludeerden
dat herhaaldelijk meten van de bloeddruk, zoals met ambulante 24-uurs
metingen, cruciaal is om een associatie van het ACE D-allel met verschillende
bloeddrukaspecten te vinden.
ACE I/D polymorfisme en Angll-vorming
Alhoewel er thans meer bewijs aanwezig is voor een positief verband tussen het
ACE I/D polymorfisme en de bloeddruk of atherosclerotische complicaties, is het
nog steeds onbekend of hogere circulerende ACE-waarden in D-allel dragers van
het ACE I/D polymorfisme tot een toegenomen vorming van Angll leiden. Wij
hebben daarom een /n v/rro studie verricht, beschreven in hoofdstuk 5, waarin de
plasma-conversie van Angl gedurende de tijd in relatie tot het ACE I/D
polymorfisme bestudeerd werd. De resultaten laten zien dat na een eerste, snelle
conversie van Angl, een tweede fase van langzame conversie optreedt. Terwijl de
eerste, snelle, fase niet verschillend is tussen de drie genotype-groepen, is de
tweede, langzame conversie van Angl dat wel, met de traagste conversie in DD-
patienten. Het verschil kan opgeheven worden door hogere Angl-concentraties
aan het begin van de conversie.
RAS polymorfismen en nierfunctie
Zoals eerder beschreven, speelt het RAS een prominente rol in de regulatie van de
nierfunctie. In hoofdstuk 6 beschrijven wij een studie waarin wij gekeken hebben
naar de nierfunctie in 212 goed gekarakteriseerde essentieel hypertensieven in
relatie tot de ACE I/Den AT1R A1166C polymorfismen. De resultaten laten zien dat
het AT1R C-allel onafhankelijk geassocieerd is met een afgenomen doorbloeding
en filtratiesnelheid, en een toegenomen filtratiefractie. Er waren geen significante
interacties tussen het AT1R C-allel en bekende determinanten van nierfunctie
(leeftijd, geslacht, Quetelet-index, bloeddruk). Daarentegen konden geen
verschillen in renale hemodynamiek gevonden worden met betrekking tot het
ACE I/D polymorfisme. Tenslotte konden geen interacties tussen de AT1R C- en
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ACE D-allelen, zoals die eerder beschreven zijn, gevonden worden voor de
fenotypes welke hier bestudeerd zijn. Onze bevindingen laten dus zien dat het
AT1R C-allel een nieuwe, nog onbekende, onafhankelijke determinant van de
nierfunctie bij hypertensie is.
AT1R A1166C polymorfisme en Angll-gevoeligheid
Aangezien de resultaten van hoofdstuk 6 lieten zien dat de Angll-gerelateerde
effecten prominenter zijn in AT1R C-allel dragers, besloten wij de hypothese te
testen dat dit polymorfisme geassocieerd is met een toegenomen Angll-
gevoeligheid. Onze gegevens, beschreven in hoofdstuk 7, laten zien dat het C-
allel van het AT1R A1166C polymorfisme geassocieerd is met een toegenomen
gevoeligheid, maar niet reactiviteit, voor Angll. In de studies hierna, beschreven in
hoofdstukken 8 en 9, waren wij geinteresseerd of de toegenomen gevoeligheid
voor Angll in AT1R C-allel dragers ook klinische implicaties heeft met betrekking
tot farmacotherapie. Wij zagen een afgenomen vermogen in ATI R C-allel dragers
de AT1R te blokkeren met losartan, in zowel de acute (hoofdstuk 8) als chronische
situatie (hoofdstuk 9).
Het bewijs stapelt zich nu op dat het C-allel van de AT1R A1166C polymorfisme
een onafhankelijke cardiovasculaire risicofactor is. Het blijft echter nog steeds
onduidelijk hoe deze epidemiologische bevinding vanuit pathofysiologisch
oogpunt verklaard kan worden. Wij konden aantonen dat zowel plasma-renine en
Angll niet significant verschillen tussen de genotype-groepen. Indirect bewijs uit
bloedplaatjesbindingstudies toont aan dat ook het aantal AUR-bindingsplaatsen,
of een toegenomen Angll-gevoeligheid van de AT1R zelf, geen plausibele
verklaringen zijn.
In hoofdstuk 10 worden de resultaten van de studies zoals hierboven besproken
bediscussi£erd in het licht van de huidige literatuur. Tenslotte bediscussieren wij
de perspectieven voor toekomstig onderzoek in het veld van de genetica van
hypertensie.
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En dan het dankwoord. Wetende dat dit het best gelezen onderdeel van het
proefschrift zal worden, vergroot dit de druk om niemand te vergeten. Op het
moment van schrijven van het dankwoord, heb ik in gedachten alle mensen laten
passeren die me al die jaren geholpen hebben. Ik realiseer me nu des te meer dat
een promotie-onderzoek echt teamwerk is, wat met de hulp van velen tot stand
komt.
Beste Luc Snoeckx, ik begin mijn dankwoord bij jou. Als tweedejaars student
kwamen Jos Webers en ik (na een zorgvuldige consultatie van ook andere
capaciteitsgroepen) tot de conclusie dat jij de beste persoon was om ons de
beginselen van het wetenschappelijk onderzoek bij te brengen. Een artikei en een
studentenprijs waren het resultaat. Jouw enthousiasme, maar ook je didactisch
talent, hebben toen bij mij de vonk doen overslaan en me laten inzien dat
onderzoek leuk en verslavend kan zijn. Dank voor al je tijd en moeite die je in ons
gestoken hebt.
Promoveren is niet alleen een paar artikelen schrijven en bundelen in een boekje.
Het is ook een opleiding tot wetenschappelijk onderzoeker. Ik mag me gelukkig
prijzen dat ik, gesteund door mijn (co)promotor, mijn periode in Maastricht niet
alleen met het onderzoek direct gerelateerd aan mijn boekje bezig heb hoeven
zijn. Door het mee helpen opzetten van andere onderzoeken, het Cardiovasculair
Genotyperingslab en het Cardim-databestand heb ik de diverse facetten van het
doen van wetenschappelijk onderzoek kunnen meemaken.
Mijn promotieonderzoek begon met het genotyperen van monsters in het
laboratorium van de pathologie onder leiding van Mat Daemen. Beste Mat,
aanvankelijk was je nauw betrokken bij het onderzoek, je had het immers samen
met Peter opgezet, later liet je me meer en meer los toen je merkte dat een en
ander goed op de rails stond. Dank voor je betrokkenheid en aansturing in het
begin. Dank ook aan Monique Verluyten die me alle principes van het
genotyperen bijbracht en aan de analisten Loes van Eijk en Petra Aarts die veel
monsters verwerkt hebben.
Frank Soomers en Jelle Stoffers: klein zijn we begonnen met 2 prikdagen in jullie
huisartsenpraktijk in Kerkrade. Dit was het begin van de Kerkrade Risk Study, later
omgedoopt tot de Socrates-studie. Goed om te zien dat dit nu is uitgebouwd tot
een groot onderzoek waarin op diverse manieren door diverse capaciteitsgroepen
gekeken wordt naar de cardiovasculaire aandoeningen in jullie praktijk. Ik ben blij
dat de vruchten van dit onderzoek hebben geleid tot een eerste artikei zoals
beschreven in hoofdstuk 3 van dit proefschrift. Verder was een aantal van jullie
patienten bereid tot meerdere onderzoeken in Maastricht, die over het algemeen
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veel van hen vroegen. Dank voor jullie hulp hen te selecteren en te vragen om
medewerking.
Ik heb mij vrijwel al die jaren wel omringd geweten door een of meerdere
studenten die mij geholpen hebben. Allen veel dank daarvoor! Harriet
Vreugdenhil: jij was de eerste student en hebt mij mede de principes van werken
in een DNA-lab bijgebracht. Het verdere genotyperen is mede gedaan door
Vanessa van Empel, Remy Bemelmans en Lisa Tans. Drie studenten hebben veel
tijd en moeite gestoken in een onderzoekslijn samen met de Cardiologie: Mireille
Emans, Bianca Bendermacher en Ruben de Boer. Ondanks dat de onderzoeken
waar jullie mede aan geholpen hebben niet in dit boekje zijn terug te lezen, is
jullie inzet zeker niet voor niets geweest. Ik heb in ieder geval erg prettig met jullie
samengewerkt. Pascal Franssen heeft veel werk verzet in het kader van de ABPM-
studie in Rotterdam. Iris Zwaan, de resultaten van je wetenschapsstage hebben
mede geleid tot die beschreven in hoofdstuk 4. Dank voor je inzet. En dan Leon
Henskens (met een accent aigu boven de e!). Jij was de constante factor de laatste
jaren. Je zorgvuldigheid en tomeloze inzet leidden ertoe dat ik, controlfreak als ik
soms kan zijn, blind aan jou dingen kon overlaten. Het onderzoek beschreven in
hoofdstuk 9 is wel het beste voorbeeld: nagenoeg zelfstandig door jou gedaan.
Grote klasse! Alleen jouw voorkeur voor de componistenfamilie Strauss staat
diagonaal tegenover die van mij, maar daar valt mee te leven. Ik ben daarom blij
dat Je een van m/jn paranymfen wilt zijn. Ik wens je a<fe succes toe in je eigen
onderzoek.
Diverse onderzoeken heb ik gedaan in samenwerking met collega-onderzoekers.
Een onderzoek met de groep van Louis Peeters en Marc Spaanderman van de
Gynaecologie en Obstetrie leidde tot interessante bevindingen over de rol van
RAS-polymorfismen bij pre-eclampsie. Helaas is het ons (nog) niet gelukt de rest
van de wereld te overtuigen van deze bevindingen. Ook werden er onderzoeken
met de cardiologie opgezet. Ik heb prettig samengewerkt met de cardiologen
Pieter Doevendans, Ebo de Muinck en Frits Bar. In het kader van de ABPM-studie
werd samenwerking aangegaan met Ad Dees, internist, uit het Ikazia Ziekenhuis in
Rotterdam. Dank voor de aangeleverde patienten. De goede samenwerking met
Nijmegen, middels de persoon van Bart Veldman, leverde interessante
bevindingen betreffende het ecNOS-polymorfisme en een artikel op. Ook heb ik
prettig samengewerkt met de groep van Rick Grobbee en Yvonne van der Schouw
uit Utrecht. Professor Redon: thank you for your willingness to share some of your
DNA-samples with us.
Toen de aantallen van te genotyperen monsters in de duizenden gingen lopen
werd het tijd om een eigen lab hiervoor te gaan opzetten. De analisten Michael
Geurts en later ook Danielle Bisschops hebben dit belangrijke werk keurig gedaan.
Hetzelfde lab herbergde het lab Klinische Farmacologie waar Jet Bost nauwgezet
honderden monsters angiotensine I en II heeft bepaald. Alles onder leiding van
Paul Schiffers. Jullie alien bedankt!
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Het opzetten van een groot databestand waarin alle data van onze
onderzoeksgroep gekoppeld werden was een andere grote uitdaging. Het
uiteindelijke Cardim (cardiovascular database internal medicine) is met name door
onze data-typiste Stella Brand een succes geworden. Stella, ook jij wordt
gekenmerkt door een tomeloze inzet en ijver, maar bovenal nauwkeurigheid. En
als je denkt dat ergens een foutje gemaakt is, neem je 'gewoon' weer de hele
dataset door. Ook kon ik bij herhaling aankomen met weer een nieuwe deadline
die gisteren reeds verlopen was. Veel van de data in dit proefschrift zijn mede
door jouw werk onttrokken uit stoffige klappers en succesvol gekoppeld aan de
nieuwste verkregen data. Heel veel dank daarvoor.
De infusiestudies werden verricht op het Circulatietaboratorlum door Monlque
Fuss. Monique, jij zag me als studentje komen, nu alweer 10 jaar geleden. 'Weer zo
een die komt en gaat' dacht je misschien, maar ik bleef hangen. Jouw jarenlange
ervaring met vooral klaringsstudies waren een belangrijke constante factor. Wat Ik
altijd in jou gewaardeerd heb is dat je duidelijk laat merken als je het ergens niet
mee eens bent. Een eigenschap die ik zeer kan waarderen. Waar je ook bij
herhaling duidelijk in was, is mijn toekomst. Volgens jou is er goud te verdienen
met een commercieel cardiovasculair kliniekje net over de grens op Dults
grondgebied. Als mede-aandeelhouder zag je dit wel zitten. Ik vrees voor je dat Ik
dit nog even wil uitstellen.
Mijn collega-onderzoekers Esther Beeks, Kim van der Zander, Thomas Wierema,
Marieke van Onna, Sergio Rodrfguez, Marrigje Nabuurs en Claudia de Haan dank ik
voor de prettige en gezellige samenwerking. Een aantal is reeds gepromoveerd,
van de rest komen de boekjes op korte termijn af. Esther: wij hebben veel kamers
door de gebouwen heen gedeeld en doordat een aantal onderzoeken in elkaar
overliepen veel samengewerkt. Frustraties deelden we ook gezamenlijk, maar
gelukkig: gedeelde smart is halve smart. Ik wens je veel succes met je laatste
loodjes. Claudia: jij zag jezelf niet zo als collega-onderzoeker ('oh dat onderzoek, ik
zie wel'), maar was de drijvende kracht achter het Circulatielab. Je bent een
fantastische regelaar en dacht altijd actief mee hoe mijn onderzoeken ingepast en
uitgevoerd konden worden op het Circulatielab. Ook buiten het werk is er een
vriendschappelijk contact ontstaan. Ik waardeer het dat je je organisatorische
talenten tot het einde toe hebt willen gebruiken door mijn paranymf te zijn.
De overige collega's van het lab, Dorien Bleeker en Boy Houben, dank ik voor het
verrichten van diverse hand- en spandiensten. Monique Lahaye, dank voor de
secretariele ondersteuning.
Tiny Wouters: geroemd in al vele dankwoorden. Nu ik zelf met je heb
samengewerkt kan ik de lofzang alleen maar bevestigen. Je bent een noeste
werker en offerde veel vrije tijd (zelfs vakantie!) ten behoeve van de layout van
mijn proefschrift op. Een prettige bijkomstigheid is dat je net zo'n perfectionist
bent als ik en dat maakt samenwerken prettig! Veel dank.
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Dank ook aan leden van de beoordelingscommissie onder voorzitterschap van
Prof.dr. Struijker Boudier. Met name ook dank aan de externe leden van de
commissie, Prof.dr. Navis en Prof.dr. Danser, beiden met een indrukwekkende
staat van dienst in het onderzoeksveld van genetische polymorfismen van het
renine-angiotensine systeem. Met Prof.dr. Vlietinck en Prof.dr. Daemen heb ik al
prettig mogen samenwerken. Ik ben blij dat u beiden zitting hebt willen nemen in
de commissie.
Dan mijn copromotor en promotor. Bram Kroon, als copromotor was je direct
betrokken en verantwoordelijk voor het onderzoek. Onze gezamenlijke
toevoeging aan de onderzoeksgroep van Peter was het begin van het genetisch
onderzoek binnen deze groep. Samen hebben we veel verschillende
onderzoekslijnen op- en uitgebouwd. Ik ben blij dat je me de ruimte gaf dingen
op te zetten, maar me er tevens op wees dat het proefschrift niet te veel
ondergesneeuwd mocht worden. Ik heb prettig met je samengewerkt en kijk uit
naar mijn komende opleiding binnen het aandachtsgebied Vasculaire
Geneeskunde. Peter de Leeuw, jij bent de beste promotor die een promovendus
zich kan wensen. Je bent meer dan de promotor die op afstand de voortgang van
het onderzoek volgt. Je bent betrokken, enthousiast en laagdrempelig. Altijd als ik
gefrustreerd raakte door bepaalde onderzoeksuitkomsten of door de zoveelste
'onterechte' afwijzing van een artikel wist jij door een paar simpele, geniale
vuoTjientfn win u* u<iid ceni A> le aridiy^erer) ot feeh en anaer zo te rormuieren
mij weer hoop te geven. Met veel plezier kijk ik terug naar de twee schrijfweken
die we in je buitenverblijf in de Ardeche hebben doorgebracht: de perfecte balans
tussen ideaal klimaat, wetenschappelijke produktie, de 'cuisine ardechoise' en af
en toe een goede greep uit je wijnkelder.
Uiteraard ook een dankwoord voor mijn ouders: jullie hebben me altijd alle
kansen geboden om me te ontwikkelen. Dat dit boekje uiteindelijk tot stand is
gekomen is mede jullie resultaat. Ik hoop dat we nog lang in goede gezondheid
met elkaar mogen doorbrengen.
Lieve Helga, aan jou draag ik dit boekwerk op. Als iemand mijn oprechte dank
verdiend ben jij het wel. Al die jaren met een partner grotendeels werkend op
afstand van huis, deadline na deadline, en veel gezamenlijke vrije tijd die
opgeofferd werd ten behoeve van het proefschrift: jij hebt het allemaal doorstaan.
Fantastisch en bewijzend dat onze band sterk is. Na deze moeilijke jaren gaan we
het straks zeker rustiger krijgen met Ruben en ons aanstaand kindje.
Lieve Ruben, jij bent het mooiste wat me in mijn leven is overkomen en nog elke
dag overkomt, mijn achilleshiel. Jouw aanwezigheid maakt al het andere relatief.
Ik zie uit naar al de dingen die we samen nog gaan beleven. Als eerste binnenkort
een broertje..., of een zusje!
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Wilko Spiering werd op 23 oktober 1971 in Arnhem geboren. In 1990 behaalde hij
het VWO diploma aan het Christelijk Lyceum te Arnhem. Datzelfde jaar werd
gestart met de studie geneeskunde aan de Rijksuniversiteit Limburg te Maastricht,
waar hij in 1995 het doctoraalexamen (met genoegen) en in 1997 het artsexamen
(met genoegen) behaalde. Tijdens de studie werden studentassistentschappen
gelopen op de afdelingen Fysiologie (Prof.dr. L.H.E.H. Snoeckx) en Interne
Geneeskunde (Prof.dr. J.P. van Hooff en Prof.dr. P.W. de Leeuw). Van 1997 tot 2000
was hij Assistent In Opleiding (AIO) aan de vakgroep Interne Geneeskunde,
Cardiovascular Research Institute Maastricht (CARIM), Universiteit Maastricht
onder leiding van Dr. A.A. Kroon en Prof.dr. P.W. de Leeuw. Van 2000 tot 2001 was
hij medisch coordinator van het onderzoeksproject Hypertensie en Cognitie van
de vakgroepen Interne Geneeskunde en Neuropsychologie van het Academisch
Ziekenhuis Maastricht (Prof.dr. P.W. de Leeuw en Dr. M.P.J. van Boxtel). In april
2001 werd begonnen met de opleiding Interne Geneeskunde in het Academisch
Ziekenhuis Maastricht (opleider Prof.dr. H.F.P. Hillen). Sinds 1 oktober 2003 wordt
zijn opleiding voortgezet in het Catharina-ziekenhuis Eindhoven (opleider Dr. B.
Bravenboer). Per 1 april 2005 zal hij starten met het aandachtsgebied Vasculaire
Geneeskunde. Hij is getrouwd met Helga Fokkema en samen hebben zij 1 zoon:
Ruben.
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